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ABSTRACT 
in recent years, researchers have demonstrated that the saponins derived 
from the bark extract of the South American tree, Qui!laja saponaria Molina, 
possess an exceptionally potent immune stimulating capability. This has kindled 
much interest in their potential development as immuno- adjuvants. These saponins 
have also been shown to play a very important role in the formation of immune 
stimulating complexes (ISCOMs), which are a specific type of antigen/adjuvant 
delivery system consisting of a cage-like structure made up of a Quillaja saponin, 
cholesterol and phospholipids in a 1:1:1 ratio. The purified fraction of the bark 
extract, known as Quii-A, has been shown to contain more than 60 saponin 
compounds. The structures of several of these have been reported, while some 
have only been partially characterized. While the use of Quii-A as an adjuvant is 
well established in veterinary medicine, its use in humans has not been achieved 
due to its toxicological effects and the fact that its composition can not be 
standardized from batch to batch. Adjuvant research has become very important 
for the successful development of modern subunit vaccines as these vaccines do 
not elicit an immune response sufficient to grant an adequate protection to the 
subjects when administered alone. 
In this research saponin compounds from Qui I-A, a commercially available 
bark extract of Quillaja saponaria Molina, were separated, purified and structurally 
characterized. The biological activity of the individual compounds or fractions 
ii 
isolated to near purity have also been investigated. Compounds characterized that 
had novel structures were screened for possible adjuvant properties and compared 
with other compounds of known structures. 
Preliminary High Performance Liquid Chromatography (HPLC) separation of the 
extract Qui I-A by gradient elution using an ammonium acetate (1 0 
mM)/acetonitrile/water solvent system on C5 reverse phase high performance 
liquid chromatography (RP- HPLC) column has resulted in the purification of a 
saponin compound having a molecular weight of 1560 m/z. Mass spectrometric 
analyses, which included utilization of techniques such as collision induced 
dissociation and tandem mass spectrometry, afforded a proposal of the molecular 
structure and fragmentation pattern of this compound designated QF-23. Large 
scale separation of the material Quii-A over fifty HPLC runs has enabled the 
acquisition of five more fractions in pure or near pure form, including two that are 
documented to have been previously isolated by other researchers, as well as a 
sufficient amount of pure compound QF-23 to facilitate the performance of nuclear 
magnetic resonance experiments (NMR) to confirm the structure of this compound. 
Liquid Chromatography/ Electrospray Ionization- Mass Spectrometry (LC/ESI-MS) 
has been employed to investigate further and more specifically the elution 
characteristics and composition of the crude materia! Qui I-A. The results of this 
experiment has shown Qui I-A to be a highly complex mixture of saponins and non-
saponin components which have a tendency to co-elute. Over 80 HPLC peaks were 
iii 
detectable by means of a photodiode array detector. Solid phase extraction 
technique was capable of eliminating some materials from Quii-A. 
Biological investigation of some saponin fractions revealed a fraction that 
had considerably lower in vitro toxicity to mouse monocytes than the other fractions 
tested, while the toxicity of QF-23 was found to be moderate and comparable to 
that of the well-established QS-21. In vitro studies have shown the compound QF-
23 to be capable of stimulating mouse monocytic cells to produce the cytokine IL-1 
alpha, thus suggesting that it may have immune-adjuvant properties. 
iv 
Structure of Quillaja sapon1ns 
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Chapter 1: Introduction 
Quillaja is a genus of plants belonging to the family Rosaceae. It is native to 
the South American countries of Bolivia, Peru and Chile. Plants of this genus 
contain saponins, that have the characteristics of soap, and have been used by the 
native peoples to wash clothes. Hence, the name Quillaja, derived from the native 
word for "to wash", que/lean, was given to the genus. The saponins derived from 
these plants have found important uses in a considerable number of industries: 
pharmaceutical, veterinary (vaccines), food, cosmetics, agriculture and so on 
(George, 1965; Birk 1969; Bamford, 1980; 1988; Price eta!., 1987; Chavali and 
Campbell, 1987; Chavali et a/., 1987; 1988; Hostettmann and Marston, 1995; 
Anaguade , 1999). Recently, these saponins have attracted a great deal of interest 
from researchers because of their immuno modulatory activity and potential use as 
vaccine adjuvants in humans (Chavali and Campbell, 1987; Chavali et al., 1987; 
1988; Bamford, 1980; 1988; 1992; Ahmeida, 1992; Audibert and Lice, 1993; 
Behboudi et al., 1995; 1997; 1999). They have been shown to have potent immuno 
stimulatory activity inducing both the humoral and cell mediated responses (Chavali 
and Campbell 1987; Chavali et a!., 1987; 1988; Bamford, 1980; 1988; 1992; 
Ahmeida, 1992; Audibert and Lice, 1993; Behboudi eta!., 1995; 1997; 1999). They 
are also used as major components of immune stimulating complexes (ISCOMs) 
which are highly efficient delivery systems for antigen and adjuvant in vaccine 
1 
administration (More in eta/., 1984; 1998; Ronnberg et al., 1995). The saponins are 
most abundant in the Quillaja saponaria Molina species (Wallis, 1967; McClintock, 
1984; Price et.al., 1987; Chavali eta!., 1987). 
The need for the use of co-immune stimulators (adjuvants or co-adjutants) 
in the administration of certain vaccines, particularly those produced through 
attenuation and other methods (for example, those that result in the so called 'killed 
vaccines') has long been recognised as a result of the weak immunogenecity of the 
resultant antigen (Dalsgaard, 197 4 ). In modern days, this problem has been 
accentuated even further by the new methods of vaccine development which result 
in highly purified antigens that are even weaker immunogens. These subunit 
vaccines are favoured over the conventional whole organism vaccines because 
they are capable of inducing highly specific and required immune responses (Vogel 
and Powell, 1995; Gizurason, 1996). A number of adjuvants are available for use 
in veterinary vaccines, but the choice is limited to one when it comes to adjuvants 
approved for human use (Audibert and Lice, 1993). For many years Quiffaja 
saponins have found extensive use in veterinary vaccines. Human applications 
have greatly been hampered by their toxicity. A commercially available Quillaja 
saponin extract has been demonstrated to be a mixture of over 60 compounds that 
are difficult to separate (van Setten and van Werken, 1999). Fractionation and 
structural elucidation of these components, as well as structural/function studies, 
may facilitate the discovery of a nontoxic, adjuvant active component that may be 
suitable for human use. 
2 
1.1. Botanical information 
1.1.1 The Genus Quillaja 
As previously mentioned, the genus Quillaja, also natively called Quillaia or 
Quillaiae, belongs to the family Rosaceae (suborder:- Rosineae, order: -Rosales, 
grade: - Archichymadeaceae, subphylum:- Dicotyledons, phylum: - Angiospermae; 
flowering plants ). The family consists of about 100 genera and over 2000 species. 
Members of this family usually contain saponins and cyanogenetic glycosides, 
which yield hydrocyanic acid under enzymatic influence. The plants normally have 
simple or compound leaves. Trees of this genus are well known for their saponin 
constituents. The genus Quillaja consists of only four species, namely; Q. saponaria 
Molina, Q. poeppigii, Q. smegmadermos de Candolle, and Quillaja selloniana also 
known as Fontenellea braziliensis (Wallis, 1967; Grieve, 1995). The species of this 
genus that has been of enormous interest is the Q. saponaria Molina species, as 
it is the major source of the saponins found to have a profound immunological 
activity. 
1.1.2. Quillaja saponaria Molina 
The Quillaja Saponaria Molina species was first described botanically and 
named in 1782 by a Chilean Jesuit named Juan Ignatius Molina. As mentioned 
earlier, he adapted the name of the genus 'Quillaja' from the local names 'qui!lal 
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or 'cul!ay, themselves derived from the Chilean word 'quillean' meaning 'to wash'. 
He selected 'saponaria' as the species name because of the soap-like property of 
the bark (Mclintock, 1984)1. 
The tree of Quillaja saponaria Molina, also known as Panama Wood, 
Soapbark Tree, Quillaia, Quillayor Cullay, (Wallis, 1967; Trease and Evans, 1996; 
Grieve, 1995) is a large tree (about 18 m high (Figure 1 )), indigenous to Chile, 
Bolivia and Peru. Its bark has been long used by the native peoples for washing silk 
and wool. It was known to the Europeans in the early part of the 18th century but 
was not regularly imported until 1857 when it was sent to France under the name 
Bois De Panama indicative of the route by which it was sent. Since 1878, the tree 
has been introduced into India and California for medicinal and industrial purposes; 
the constituents were used in the cosmetic, pharmaceutical, and food industries as 
well as for agricultural and veterinary purposes. This soapbark tree is oak-like and 
evergreen. Its leaves are alternate, simple, oval, shallowly and remotely toothed, 
and one to two inches long. The leaves have short petioles while the flowers are 
greenish yellow when open and somewhat less than an inch across. They have five 
spreading sepals and petals, and ten stamens arching upwards. The fruits split at 
maturity into five spreading seed pods, each about half an inch long, opening along 
1 Molina was born in Chile in 1737 and lived there until1768 when he was expelled together with other Jesuits 
by the Spanish Monarch, Carlos Ill. He then settled in the city of Bologna, Italy until his death in 1829. In 
1782, Molina published a classic work on the geography and the natural and civil history of Chile. In this work 
he described for the first time many Chilean plants among which was Quilfaja saponaria. This work was first 
published in Italian, but it has since been translated into other European languages (Mclintock, 1984). 
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one side with numerous winged seeds (see Figure 1 ). 
The tree flowers and fruits from September to December (Mclintock, 
1984).The inner bark foams like soap when crushed and mixed with water. It was 
imported into Europe during the last century as an emulsifier, and for the less 
important use of producing froth on stale beer (Mclintock, 1984). The bark 
constitutes about 38 - 44% of total dry mass of the tree (Plato eta!., 1986}. 
1.1.3. Pharmacognosy of the bark drug 
The commercial bark consists almost entirely of phloem and is 100 X 20 X 
0.6 em in dimensions. it is brownish or yellowish in colour and has reddish-brown 
or blackish-brown longitudinal striations. The inner surface is yellowish brown and 
fairly smooth. The bark has a splintery fracture that separates into laminas. Minute 
glittering points of calcium oxalate can be seen sometimes with the naked eye, but 
are obvious on the smooth inner surface of the bark and on the fractured laminated 
surface when viewed with a lens. The bark is almost odourless but its powder is 
very sternutory (extremely irritating to the nostrils and fauces, causing prolonged 
fits of sneezing), and has an unpleasantly acrid and astringent taste. The powder 
froths abundantly when shaken with water and it yields a pale straw-coloured 
tincture (Wallis, 1967; Trease and Evans, 1972; 1996). Microscopical examination 
of a transversed section of the bark reveals a chequered appearance of medullary 
rays, cris-crossed by alternating bands of lignified and non-lignified phloem. The 
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Figure 1: A picture of the Qu/1/aja saponarta Molina trH. (Courtesy of 
Dr. Martin Gardner of the Royat Botanic Garden, Edinburgh, UK.) 
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phloem is tortuous and often accompanied by small groups of rectangular sclereids 
(Wallis, 1967; Trease and Evans, 1972; 1996). The histological characteristics of 
the bark are well described in detail in Wallis (1967). 
1.2. Constituents of Quillaja saponaria Molina 
The chief constituents of the soap bark tree are saponins found mainly in the 
inner bark. Upon hydrolysis, the saponins yield the principal sapogenin, quillaic 
acid ( hydroxygypsogenin) and gypsogenin. The total concentration of saponins in 
the tree is 9- 1 0%. The bark also contains sugars, starch, calcium oxalate, and 
uronic acid. 
Presently, there is not much information available about the composition of 
Quillaja saponins. A number of these saponins have been structurally 
characterised, such as QS-111, QS-21, QS-7, QS-18 (see Figures 2 and 3 on page 
10 and Table 1 on page 11 ). But there are still some 50 compounds whose 
structural identities are not yet known (van Setten et a!., 1995). The difficulty in 
separation is postulated to be attributable to the formation of mixed micelles 
comprised of the different saponin species in aqueous solution, which prevents 
effective separation (Kensil, 1996). 
The saponins and other constituents, as extractable material in water 
(ethanol or water /ethanol mixture), constitute 20- 25% of the weight of the bark. 
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The saponins themselves are estimated to constitute 5% of the bark weight and 
20% of the total extractable material. The rest of the extractables are tannins and 
phenolic compounds separable from the saponin extract (Qui-A) via dialysis, gel 
filtration and dialfiltration (Kensil, 1996). A typical analysis of the commercially 
available Quillaja extract powder (Quii-A) reveals the following content: moisture 
5.0%, protein 0.5%, fat 0.4%, fibre 0.3%, ash 2.5%, carbohydrates (including 
saponins) 91.3% (Anagaude, 1999). 
1.2.1. Saponin constituents of Quillaja saponaria Molina 
Definition 
Saponins are high molecular weight compounds of natural origin found 
mainly in higher plants and belong to a group of compounds known as glycosides 
that consist of a sugar portion and a non-sugar portion in their molecular structures. 
The non-sugar portion of glycosides is called the aglycone, and in most saponins 
it has soap-like characteristics from which the term saponin was derived. The 
aglycone of saponins may have a triterpene or a steroidal skeleton and is 
synthesised from squalene by the plant. 
Many saponins have a hemolytic activity as well as the following 
characteristic properties that are also used for their identification and 
characterisation: bitter taste, forms stable foams in aqueous solutions, high toxicity 
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to fish and amphibians, and may form molecular complexes with cholesterol and 
other hydroxy steroids. However, a great deal of variability exists in these properties 
between saponins from various sources, and not all the saponins necessarily 
possess these properties (Birk, 1969). For these reasons, saponins are now 
defined on the basis of their molecular structure, such as triterpene glycosides or 
steroidal glycosides (Hostettman and Marston, 1995). The aglycone of the saponin 
molecule is also called the genin or sapogenin, and the terms monodesmosidic, 
bidesmosidic and tridesmosidic are used to describe the number of sugar chains 
attached to the aglycone, being one, two, and three, respectively. Oligosides refer 
to glycosides containing more than three to four monosaccharides (Hostettmann 
and Marston, 1995). Quillaja saponin is a mixture of acylated triterpenoid 
oligogiycosides (acylated saponins) (Higuchi et al., 1987). 
Saponins are widely distributed throughout the plant kingdom and have been 
identified in at least 400 species belonging to more than 80 different families. Some 
saponin containing plants are found as components of the human diet while others 
are found in animal feed. Saponins have been found in various parts of the plants, 
e.g., leaves, stems, roots, bulb blossom, bark, and fruits. They have been found to 
be localized in organelles which have high metabolic turnover rate such as the 
mitochondria, the chloroplasts, the hypocotyl and the cotyledon (Anisimov and 
Chirva, 1980, Taniyama eta/., 1988). This gave the impression that they may be 
important constituents with some physiologically significant role, perhaps the 
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regulation of the metabolism and the overall development of the organism 
(Anisimov and Chirva, 1980). A long standing theory that helps to explain their 
presence in plants, which can be as high as 30 % in some species, is that they 
protect the plant against fungal attack, suggested from the observation that there 
is often an increase in saponin content of the part of the plant undergoing microbial 
attack (Defago, 1977; Hostettman and Marston, 1995). Saponin concentrations in 
plant structures have been found to depend also on the environmental 
temperatures and vegetative period of the plant: e.g., flowering, fruit bearing etc. 
(Birk, 1969). Quillaja saponins occur in the inner bark of the Quillaja saponaria 
Molina tree and other species of the genus Quillaja ( Korbert, 1887; Wallis, 1967; 
Mclingtock, 1984; Trease and Evans, 1996). 
History 
The saponins contained in the bark of Quillaja saponaria Molina have been 
studied for a long time, in fact since as far back as 1903 (Labriola and Deulefeu, 
1969). The isolation of Quil!aja saponin was reported for the first time in 1887 and 
to this day Quillaja saponin has proven to be a complex and poorly separable 
mixture. Some of the very early scientists that studied the Quil!aja saponin were 
Windaus eta!., who were the first to isolate the aglycone by acid hydrolysis in 1926 
(Windaus et al., 1926 in Labriola and Deulefeu, 1969). The aglycone was later 
named quillaic acid by Elliott eta!., 1939 (Labriola and Deulefeu, 1969), who also 
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determined its correct formula as C30H460 5. In the early works with Quillaja saponin, 
D-galactose was the only other product identified by hydrolysis, besides the 
aglycone, (Labriola and Deulefeu, 1969). In 1969, Libroala and Deulefeu partially 
described the structure of the prosapogenin. 
1.2.2. The Chemistry of the Qulllaja saponins 
Methods of extraction, Isolation, purification and quantification of the 
saponins 
Dalsgaard in 1970, employed dialysis, ion exchange and gel filtration 
chromatography (precoated silica gel layers developed with n-butanol, 96% ethanol 
and ammonia solution in the ratio 3:6:5 as the mobile phase) to the Quillaja extract 
to produce the product he named Qui I-A. The extract was obtained from 5g of the 
quilleae cortex extracted with 50ml of distilled water stirred vigorously for three 
hours at room temper_ature, clarified by means of a Buchner funnel filtration followed 
by centrifugation at 800rpm for 15 min (Dalsgaard, 1970). Higuchi et al. (1987 and 
1988) extracted saponins from the Quillaja bark using methanol and achieved 
purification through droplet counter current chromatography and reverse phase 
column chromatography. For the production of a good quality extract Steinbeck, 
et al. (1995) recommended the use of the bark from young trees, as it was found to 
be less heterogenous. Kensil et al. (1991) isolated QS-21, -18, -17 and -7 (see 
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Figures 2 and 3 and Table 1 for structures) by silica chromatography from a water 
extract of Quillaja bark. The resulting products consisted of one peak each when 
analysed by reverse phase HPLC (White et a!., 1991 ). Using these 
chromatographic techniques, which utilised organic solvents, they separated 
saponin mixtures into 28 fractions. Four of these were tested and were found to 
have adjuvant activity (Kensil eta!., 1991 ). The reverse phase HPLC method of 
separation and purification (purification is achieved by repetitive injection of 
separated samples until a single peak is obtained, showing the presence of only 
one ion by mass spectrometry) was first applied by Kersten eta!. in 1988. This is 
the method now favoured by most researchers, presumably because of its simplicity 
and relative effectiveness. In 1998, Thompson found . that a C5 reverse phase 
column gave better separation than a C8 column, for a commercial Quillaja saponin 
extract called Spikoside. 
The structure of the Quillaja saponaria Molina saponins 
Quillaja saponins are didesmosidictriterpenoid oligoglycosides, which means 
that they are glycosides having multiple sugar chains attached at two different 
positions to an aglycone with a triterpenoidal skeleton. The aglycone is qui I laic acid 
(3~-16 a -dihydroxy-23-oxolean-12-en-28-oic acid) and the sugars are attached 
at its C3 and C28 positions (see Figure 2, A typical molecular structure of Quillaja 
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saponins). The sugar at C3 is ether bound while the one at C28 is ester bound 
(Figure 2, A typical molecular structure of Quillaja saponins). Two structural 
features distinguish Quillaja saponaria saponins from saponins of other plant 
species. One is that they have an aldehyde group attached to the C4 position of the 
triterpene structure (see Figure 2) and the other is that some contain a fatty acid 
moiety at R3 (Figures 2 and 3) (Kensi! eta!., 1995; van Setten and van de Werken, 
1996). 
The common molecular structure of the Quillaja saponaria Molina saponins 
is described in Figure 2 and Table 1 presents a compilation of some of the 
structures reported thus far. 
Structures of other compounds containing a rhamnose joined to the 
glucoronic acid rather than a xylose in forming the trisaccharide of the C-3 carbon 
have recently been reported (van Setten and van de Werken, 1996; Nord and 
Kenne, 1999). Lately, QS-21 has been demonstrated to isomerize into a 
regioisomer, which differs from the parent molecule at the position of attachment of 
the fatty acyl moiety to ~-D-fucose sugar, as it can either be attached to the 3rd or 
4th hydroxyl group (see Figure 2, page 14). The major isomer QS-21A has the fatty 
acyl moiety attached to the fucose at the 41h hydroxyl group (Jacobson eta!., 1996). 
The ratio of these isomers at equilibrium is 1 :20 (Jacobson eta!., 1996). 
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Table 1: Structures of some characterized Quillaja saponins. 
1. DS-1 and DS-2 were described by Highuchi eta!. in 1987 
2. QS-111 was described by Highuchi et al. in 1988. 
3. The compounds QS-7, QS-17, QS-18 and QS-21 were described 
by Kensil eta/. in 1991. 
4. H PLC fractions 1- 4 were characterized in 1995 (together with 
some forty or so others) by van Setten et a!. 
5. The structure of compound S2 was suggested by Nord and 
Kenne in 1999. 
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Table 1: Structures of some characterized Quillaja saponins. 
(Refer to structures in Figures 2 and 3) 
Saponin R1 R2 Rs R4 X 
DS-1 apiose -H -H absent absent 
DS-2 apiose glucose -H absent absent i 
QS!II apiose glucose Figure 3 rhamnose absent 
QS-7 apiose/xylose glucose CH3CO- absent absent 
(proposed 
structure) 
QS-17 apiose glucose Figure 3 rhamnose absent 
QS-18 apiose glucose Figure 3 -H absent 
QS-21 apiose -H Figure 3 -H absent 
HPLC fraction 1 
-H hexose -H absent C8H120 5 
HPLC fraction2 
-H -H -H absent CaH120s 
HPLC fraction 3 pentose hexose -H absent C8H120 5 
HPLC fraction 4 pentose -H -H absent CaH120s 
Compound -H -H Figure 3 -H absent 
S2 
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Methods employed in the structural elucidation of saponins from 
Qui/laja saponaria Molina 
A typical mass spectrometric analysis would use tandem mass spectrometry 
as applied by Schopke eta!. (1996) on triterpenoid saponins of Bellis annua. In the 
structural elucidation of saponins, issues that might be addressed can be broken 
down as follows: (1) the determination of the structure of the aglycone; (2) the 
composition and frequency of the monosaccharides in the carbohydrate moiety; (3) 
the nature of the linkages of the monosaccharides to one another; ( 4) the anomeric 
configuration of each glycosidically linked monosac-charide; and, (5) the location 
of the carbohydrate moiety on the aglycone. 
A schematic representation of the molecular structural elucidation of 
saponins as recommended by Hostettetmann and Marston (1995) is depicted in 
Diagram 1. 
The specific structural features that need to be determined are shown in 
Table 2, adapted from the review of van Setten and van de Weaken ( 1996) on the 
molecular structures of saponins from the Quillaja saponaria. The monomer 
mapping method has recently been developed by van Setten and van de Werken 
who applied it to 50 Quillaja Saponins (van Setten & van de Werken, 1994; van 
Setten et al., 1995).The diazomethane degradation is thought to proceed through 
an epoxide intermediate, as studied by Higuchi et a!. (1988). Several cleavage 
reactions need to be performed to obtain partially overlapping products. The data 
from these products, in comparison with the NMR data of the intact product, may 
lead to establishment of the ways in which the reaction products are linked in the 
original compound. 
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Diagram 1. Structure elucidation of saponins (Hostettmann& Marston, 1995) 
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Table 2: Specific structural features to be determined in structural elucidation 
of Quil!aja saponins. 
Structural feature Technique 
Molecular weight - FAB-MS, El-MS 
Monomer composition - Acid hydrolysis & TLC or GC/MS 
- monomer mapping 
Primary sequence of 28-0 bound - FAB-MS/MS 
glycocyl moiety -Partial acid catalyzed cleavage & 
identification of saccharide products 
by methylation analysis and/or TLC 
Branching Pattern of 28-0 bound -FAB-MS/MS 
glycocyl moiety -Partial acid catalyzed cleavage & 
identification of saccharide products 
by methylation analysis and/or TLC 
Anomeric Configurations 1H and 13 C NMR 
Absolute Configuration GC/MS after derivatization with a 
chiral agent 
Acyl Moiety (non carbohydrate 1H and 13C NMR, FAB-MS, El-MS, 
moiety) MS/MS 
Aglycone El MS, IR, 'H and 13C NMR, TLC 
Binding position to aglycone 1H and 13 C NMR 
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One major problem with this approach is the risk of side reactions which may lead 
to production of molecules difficult to correlate to the original structure.The 
procedure for the alkaline hydrolysis is best described by Higuchi eta/. (1987). Of 
the two methods employed, the one recommended by van Setten and van de 
Werken is the concentrated ammonia/methanol mixture 1:3 v:v reaction, as the 
reagents can be simply removed by evaporation (van Setten & van de Werken, 
1996). Through this reaction, the sugars located in the R4 portion of the structure, 
and the fatty acid present in the molecule can be identified and the decacylsaponin 
can be characterized. Basic hydrolysis cleaves the more sterically hindered ester 
formation at C-28 to yield the 3-0 glycoside, generally referred to as the 
prosapogenin. 
Acid catalyzed cleavage reactions are also described in detail by Higuchi et 
a/. (1987). These reactions yield the aglycone. Presently up to four different 
aglycones have been isolated from Qui/laja saponaria Molina, three of which have 
already been characterized as qui !laic acid, gypsogenin and gypsogenic acid (van 
Setten & van de Werken, 1996; Varshners et a/., 1985). There are two other 
important reactions which have been described and used by Higuchi eta!. (1987) 
to describe the sugar types and linkages. These are partial acid catalyzed cleavage 
and methylation analysis. These methods are also described by Hostettemann and 
Marston (1996). Kensil eta!. (i 992) also applied the method of methylation analysis 
to Quillaja saponin, however, van Setten and van de Werken (i 996) recommended 
the use of the method as described by Biermann in the Analysis of Carbohydrates 
by GLC (Biermann, 1988) as it results in only one partially methylated alditol 
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acetate (PMAA) product per monosaccharide (van Setten & van de \Nerken, 1996). 
Monomer mapping has recently been applied to 50 saponin components of Qui I-A 
which were found to consist of pairs. Intra pair differences were shown to occur 
within the 3-0 bound glycosyl moiety, interchanged pentose and rhamnose, while 
inter- pair differences existed in the 28-0 bound glycosy! moiety (van Setten et af., 
1995). 
Stability of Quillaja saponins and the extract of Quillaja saponaria Molina 
The saponins of Quilfaja saponaria Molina have been shown to isomerize at 
the fucose site. This isomerization involves the hydroxyl groups attched at positions 
C3' and C4' (Figure 2, page 14 and Table 1, page 15). The group attached at this 
position, C4' (which is in many saponins the fatty acyl domain, while in others it can 
only be a methyl group, or even a hydrogen atom as is the case in the compounds 
DS-1 and DS-2) migrates between the two hydroxyl groups in aqueous solution 
(Kensil et al., 1995b; Kensil eta!., 1996; van Setten and van de Werken, 1996). 
Base catalyzed deacylation was found to be the major degradation reaction of the 
Quillaja saponin QS-21, and solutions of this compound are reported to be most 
stable at pHs between five and seven. Kensil eta!. (1995a) and Cleland et at 
(1996) have extensively studied the stability of QS-21 in vaccine formulation with 
the MN rgp 120 HIV-1 subunit vaccine. They found that the storage of QS-21 in 
aqueous solutions resulted in the interconversion of the QS-21 molecules into its 
two isomers designated QS-21A and QS-21 B, both of which however are 
immunologically active. The compound was found to be most stable in its micellar 
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form, presumably due to the fact that the labile ester linkage bond becomes buried 
in the hydrophobic micellar environment. The maximum stability was found at a pH 
of 5.5, which is unusual as esters are usually less stable at lower pHs. The 
formulation that gave a shelf-life of over two years was 500mg/ml QS-21 in 20 mM 
sodium succinate and 150mM sodium chloride, buffered at pH 5.5. 
Ester hydrolysis results in the loss of adjuvant properties (Kensil eta/., 1992) 
making it essential that before administration of the vaccine the QS-21 molecule 
must maintain its intact structure (Cleland et al., 1996). The storage requirements 
for the commercially available preparations such as Quii-A, ISCOPREP-7.0.3™ and 
Stimulon are outlined in Vogel and Powel, 1995. 
1.3. Pharmaceutical applications of Quillaja saponaria Molina 
According to the literature, the use of Quillaja bark and its saponin can be 
traced as far back as the eighteenth century, when the native people took 
advantage its soap like properties and used it to wash their bodies and clothes. The 
saponin had an advantage over the true soaps because it was harmless to the 
fabrics and their colours, rendering it the best choice for silks, wools and sensitive 
skin. This property was later exploited by the American manufacturers who 
produced saponin containing soaps for use on sensitive skin. Quillaja saponins also 
have a very healthy stimulating action on the skin, and for this reason saponin 
soaps have been widely available in America for washing, shaving, shampooing 
and baths, for many years (Korert, 1911 ). Even to date Quillaja saponins are 
included in shampoos, liquid detergents, toothpastes and other cosmetic 
preparations (Tanaka eta/., 1996). 
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Another early use of Qui!faja saponins was in the food industry where they 
have been added to soft drinks to slow the loss of effervescence after opening, and 
to stale beer to make it lively and drinkable again. (Korbert, 1911; Birk, 1969; 
McClintock, 1984; and Price et af., 1987). In the United States, the United Kingdom 
and some other countries, the addition of the extract of the Quillaja saponaria 
Molina to foodstuff has been at times illegal (Steinbeck eta/., 1995; Grieve, 1995). 
Control was imperative because of the potential hazardous and toxic effects of 
these extracts. At present, the extract has been categorized as 'generally 
recognized as safe' (GRAS) by the U.S. Food and Drug Administration (title 21 CFR 
172-51 0/FEMA no. 2973}, and has now found applications in other food stuff such 
as milkshakes, cream sodas, mousses, cocktail mixes, and as a tasteless and 
odourless preservative, because of its antioxidant property. (Makkar, 1998; 
Anagaude, 1999; Garuda, 1999). 
The historical pharmaceutical application of the Quillaja bark extract was as 
an emulsifying agent for tars and volatile oils (Wallis, 1967). Presently, it is being 
used, to some extent, as an antioxidant (Anagaude, 1999). Therapeutically, the 
soap bark has a long tradition of use as a treatment for chest problems. It has been 
employed for the treatment of bronchitis, especially in the early stages of the illness 
and works through increasing the amount of the respiratory tract fluid which in turn 
results in the clearing of the phlegm through coughing (expectorant action). It is not 
recommended for a dry cough, but gargles of warm salt solution with 1 0-20 drops 
of Quiflaja extract have been employed in dry throat catarrh as a liquifying 
expectorant (Korbert, 1911 ). Other therapeutic uses of the Qui!laja extract and its 
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saponins include, stimulant, mucosal irritant, nauseant, antihemorrhoidal, (in 
ointments), treatment of dandruff (as a constituent in dandruff shampoo), 
anti-inflammatory, antimicrobial, antihypercholesterolemic agent, astringent, 
anthelmintic (the tape worm is forced to lose its hold when it comes into contact with 
the saponin and it is then removed by the purgative action of the saponin), 
treatment for dermatosis, promotion of hair growth, prevention of tooth decay and 
halitosis (by inclusion in mouth washes), and so forth. It is presently being 
developed for use in humans as an immune stimulant. Its use in this regard is now 
well established in veterinary medicine, while the use of the extract in human 
vaccines does not yet comply with the requirements for medical products because 
the composition of the extract cannot be standardized from batch to batch. It has 
also been reported to cause toxicological effects in humans, such as; I iver damage, 
respiratory failure and gastro-intestinal irritation (Kobert, 1911; Wallis, 1967; 
Dalsgaard, 197 4; 1978; Oakenful, 1981; Maharaj et a!., 1986; Kersten, 1988; 
Dalsgaard et a!., 1995; van Setten et a/., 1995; van Setten and van de Werken 
1996; Anagauda, 1999). 
The Quillaja bark extract has lately received a considerable amount of 
attention from several groups of researchers for various novel applications. The 
extract has been proposed to decrease the ammonia level in the atmosphere; to 
suppress or stimulate microbial growth; to increase the binding of ammonia during 
ammoniation of straw and soil; to reduce odours from cattle manure in dairy barns; 
as livestock feed additives to reduce rumen motility and improve nutrient absorption 
that could be beneficial in fattening livestock and cholesterol reduction in the 
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animals; in waste purification and treatment applications, where the saponins would 
increase microbial reactions in both aerobic and anaerobic systems, enhance the 
biodegradation of oils and fats and enhance oxygen transfer (Price et al., 1987; 
Crober et al., 1991; Wallace eta!., 1994; Rouchi, eta!., 1 995; Makar 1996; Sen et 
a!., 1998; Anagaude, 1999). Quillaja saponins have also found use in photographic 
materials, in photosensitized film as a surfactant, and in the manufacture of high 
temperature oils (Prado eta!., 1986; Tanaka eta!., 1996). 
Physicochemical properties of the saponin constituents 
Quillaja saponin is an off-white powder that provokes sneezing. Upon being 
tasted, it first has a sweet taste and then becomes bitter. It is water soluble and 
produces a stable foam at high aqueous dilutions. Quillaja saponins are highly 
soluble in aqueous solutions of pH 5 and above and less soluble in solutions of 
lower pH due to their acidic moiety (glucuronic acid) (van Setten, 1996; Kensil, 
1996). The commercial saponin is obtained from the Quillaja bark and is usually a 
mixture of qui I laic acid and Qui!laja sapotoxin though frequently it also includes a 
non-toxic modified quillaic acid, produced during the preparation. Quillaic acid, 
C19H300 10, has been obtained as a colorless, amorphous powder that is highly 
sternutatory (sneeze provoking). Its aqueous solution is acidic and has an acrid 
taste. When boiled in mineral acids it yields Quillaja sapotoxin, galactose and 
another sugar that is non-fermentable and is dextrorotatory (believed to be a 
mixture of glucuronic acid and xylose). Quillaja sapotoxin, C17H260 10, is also 
colorless, amorphous, sternutatory and acrid (Wallis, 1967). 
Saponin mixtures in suspension have stabilizing properties (van Setten, 
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1996) and membrane permeation enhancing properties that make them ideal for 
components in devising drug delivery systems. This has been demonstrated with 
delivery of insulin and amino glucoside antibiotics by nasal and ocular routes, both 
of which can be presently only administered by intravenous and intramuscular 
routes (Recchia eta!., 1995). The semi-synthetic Quillaja saponin DS-1 (having the 
fatty acyl portion removed) has been found to be more effective in drug delivery 
than the crude saponaria mixture (Pillion eta!., 1995; 1996). DS-1 has also been 
studied in intestinal drug transportation and been found to be a good candidate as 
an absorption enhancing agent that can be co-formulated with orally delivered 
biopharmaceuticals, especially those presently presenting absorption difficulties 
(Chao et al., 1998). 
1.4. Immunological properties of Quillaja saponaria Molina 
Saponins from Quil/aja saponaria Molina have been identified as potent 
adjuvants and have been studied most thoroughly in the form of Quii-A. This 
saponin mixture has been shown to augment antibody responses to both T-
dependent and T-independent antigens and to produce antigen specific helper T-
iymphocyte activity and memory ( Frebbe and Mullen, 1986; Wu, 1982). Since their 
discovery, saponins were extensively studied to determine their general 
characteristics and properties. In addition to these, numerous other in vitro and in 
vivo studies were carried out to determine the biological effects of the different 
saponins. It was found that most of the biological activity of the saponins arose from 
their surface activity and their ability to form complexes with steroids and proteins 
(Burkey, 1996). It was during early studies that the adjuvanticity of saponins was 
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discovered in France 1930 (Galea, 1932; Rielriu eta!., 1936; Bamford eta!., 
1992 ). The adjuvanticity was believed to be at least in part due to the combination 
of the surface and cholesterol binding activity of the saponins (van Setten and van 
de Werken, 1996), which results an initial effect on the mucosal immune system 
of secretion of mediators ( cytokines) into the circulation. The mediators then initiate 
a multiple of cellular events that results in an enhanced immune response (Chavali 
eta/., 1987; 1988). 
Co-adjutants (Adjuvants} 
A number of viral antigens, such as the foot-and-mouth virus, were found to 
have very low antigenicity when used alone. This could be attributed to several 
factors. For example, in the case of the foot-and-mouth virus, the low antigenicity, 
which is an apparent contradiction given its high molecular weight if compared to 
other strong antigens, such as diptheria toxin (which are smaller), was attributed to 
the homologous nature of this virus. In addition, the foot-and-mouth virus acquires 
host antigens during infection which renders the virus less virulent. As a result of 
these factors, the foot-and-mouth virus has low antigenicity, necessitating the use 
of co-adjutants such as aluminum hydroxide. Some high molecular weight 
carbohydrates possess very high antigenicity. Saponins, which are high molecular 
weight compounds that include carbohydrate moieties, possess high antigenicity 
because oftheir heterogeneity, in addition to their high molecular weights (Espinet, 
1951 ). Espinet, in 1951, reported the results of some studies involving saponins 
(including Quillaja saponins) as immune stimulants for the foot- and- mouth vaccine 
26 
(Espinet, 1951 ). However, saponins had been in use as co-adjutants in veterinary 
vaccines, such as those for pleuro-pneumonia, rinderpest, sheep pox virus, etc., 
long before Espinet's foot-and-mouth experiment (Espinet, 1951 ). 
In 1970, Dalsgaard demonstrated the superiority of Quillalja saponins as 
adjuvants over other saponins available commercially (Dalsgaard, 1970) and in 
197 4 he purified a substance from the extract of Qui!laja saponaria Mol ina that had 
improved adjuvant activity in the foot-and-mouth disease vaccination with fewer 
side effects in the animals immunised. He named it Qui!-A (Dalsgaard, 197 4). 
The structure of the sapogenin (aglycone) of Quillaja saponins have 
previously been partially described by Labriola and Deulefeu in 1969 (also refer 
sections 1.2.1. pages 9 and 1 0 and 1.2.2. page 19) . 
In 1984, Morein and his co-workers reported the use of Quii-A (then 
commercially available as Spikoside and lscotec AB) in immune stimulating 
complexes, abbreviated ISCOMs, which they demonstrated to possess a potent 
immune stimulating capability with fewer side effects when administered to large 
animals (Morein, 1984). However, these ISCOMs were found to be highly toxic to 
mice (Kensil eta/., 1991, Simms eta!., 1997; 1998). 
In one study the antigenic protein concentration in the ISCOMs was found 
to influence the immunological activity of the ISCOMs in an inverse relationship 
(Kersten eta!., 1988b). Chavali and Campbell (1987) specifically demonstrated the 
capability of Quillaja saponins to evoke a very strong immunocompetence 1n 
animals when administered with antigens, rendering protection of up to 1 00% 
mice with rabies vaccine administered orally). They observed an induction of 
cytotoxic T -lymphocyte activity and a potent memory response, in addition to an 
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enhanced humoral response (measured by lgG antibody titre), when the antigen 
was administered in conjunction with Quillaja saponins. Interestingly, they also 
reported an induction of an increased and prolonged activity of natural killer cells 
(non-specific immunity) in mice fed saponin alone. Also, they reported an induction 
of substances they termed soluble factors that are known to be cytokines, and that, 
these soluble factors had regulatory activities on the activation, proliferation and 
differentiation of the lymphocytes (Chavali and Campbell, 1987a; 1987b; Chavali 
eta!., 1987; 1988). 
The need for adjuvants 
It has generally been observed that the ingestion of inactivated or killed 
infectious agents does not always result in an immune response, and if an immune 
response is elicited, most of the time it will be weak and mainly humoral rather than 
cellular (Ogra eta/.,1980; Genco eta/., 1983). Still, some antigens are naturally 
very poor immunogens when administered on their own, and need to be 
administered in conjunction with certain substances that can boost their immune 
response. In the early years few substances were known to potentiate the immune 
response of antigens. Known adjuvants included aluminium hydroxide, oil emulsion 
adjuvants such as, Freund's Complete Adjuvant (FCA) and Freund's Incomplete 
Adjuvant (FIA) (Freund, 1956; Hebert, 1967; Bamford, 1980), formal, a lipoid amine 
designated CP 20.96, muramyl dipeptide, and liposomes (Espinet, 1951; Anderson 
eta!., 1983; Genco eta!., 1983; Leclerc et al., 1985; Tauban eta/., 1983). Even 
then, the use of these substances was not without limitations. They had variable 
responses ranging from moderately effective to ineffective, depending on the 
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antigen used and the mode of delivery. Some of them, e.g. FCA and FIA, also 
demonstrated such undesirable reatogenic effects that their use even in animals 
is presently questionable (Gupter eta! 1993). FIA in particular has been noted to 
cause carcinogenicity in mice ( Potter and Boyce, 1962; McCardle, 1964; Muray et 
al., 1972). FCA have also been shown to generate auto-immune responses in some 
cases because of its capability to stimulate systemic immune responses (Gupta and 
Siber, 1995). 
Aluminium compounds were the first adjuvants described in 1926. These 
adjuvants have the shortcomings of not being active with many antigens and 
stimulating mainly humoral immune responses (Audibert and Lice , 1993). They 
however remain the safest and only licenced adjuvants for human use (Powell and 
Newman, 1995). Recently, the development of highly purified subunit vaccines has 
made the research on adjuvants an imperative part of vaccine development, 
because of the weak immunogenicity of these vaccines (Pietrobon and Kanda, 
1992). To date, more than 80 substances with adjuvant properties are either 
available for use or being investigated. A compendium of them has been compiled 
by Vogel and Powell (Vogel and Powell, 1995). Among the most recently introduced 
adjuvants are cytokine adjuvants (Gu eta!., 1991; Brewster eta/., 1991; Hora eta!. 1 
1992;), muramyl dipeptide adjuvants (Allison and Byars, 1992), and saponin 
adjuvants (Clark eta!., 1991; Gupta eta/. 1 1993; Bussiere eta!., 1995). 
Saponin adjuvants 
Since the discovery of their adjuvanticity in 19301 saponins found extensive 
use as adjuvants in parenterally administered veterinary vaccines. Some of the 
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veterinary vaccines which saponin adjuvants have been employed include foot-
and-mouth desease vaccine, rabies vaccines, antimalarial vaccines, and vaccines 
for babesiasis and triponomiasis (Espinet, 1951; Schneider et a/.1971; Dalsgaard, 
1970; 197 4; 1978; Wictor eta!., 1973; Strobbe eta!., 1976; Black, 1977; Solyom et 
a!., 1980; McColm eta!., 1982; Soulebout eta!., 1985; Bamford et a/., 1988). The 
superiority of saponins as adjuvants over other adjuvants such as aluminium 
hydroxide, formal, etc. has been demonstrated by Espinet (1951 ), Rivenson (1958), 
Schneider and Benge!sdorf ( 1963), Strobbe et ai. ( 1964 ), Black ( 1977) and other 
researchers. Dalsgaard (1970) has shown that Quillaja saponins are better 
adjuvants than other saponins. Campbell et af. (1985) and Maharaj eta!. (1986) 
investigated the expansion of the use of saponin adjuvants (including Quillaja 
saponins) in oral vaccines. They used an oral rabies vaccine on mice. The immune 
response induced by Quillaja saponins has been reported to be very strong. QS-21, 
one of the purified Qui!laja saponins, has been found to induce the production and 
to enhance the immunological response up to 11 fold in some mice infected with a 
polysaccharide antigen, E. Coli 055:B5 Polysaccharide (White et af, 1991 ). 
Maharaj et al. (1986) observed a much higher antibody titre that lasted for at least 
six months with an oral rabies vaccine administered in conjunction with Quilfaja 
saponin, even longer than when the vaccine was administered intraperitoneally. 
The antibody titre was found to be even higher when saponin was given hours 
before the antigen. As adjuvants, saponins, including Qui!laja saponins, have been 
found to stimulate the production of complement fixating antibodies (Strobbe, i 973). 
Frebbe and Mullen (i 986) have extensively studied the responding cell population 
to the immune stimulation induced when Quii-A is used as an adjuvant. In 1992, 
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Newman demonstrated that QS-21 elicits both heightened antibody and MHC class 
I restricted cytotoxic T-lymphocyte responses (Soltysik eta!., 1993; Kensil eta!., 
1991; Newman et a!., 1992). QS-21 has aiso been demonstrated to increase 
antibody titre to cancer antigens, rendering it of considerable potential as a cancer 
vaccine adjuvant (Soltysik eta!., 1993). It has been shown to induce the production 
of a required immune response. QS-21 induced the production of major 
histocompatibility complex (MHC) class I restricted cytotoxic T-lymphocytes (CTL) 
(also known as cluster of differentiation antigen S (CDS+) T-lymphocytes) where 
initially only MHC class II restricted (CD4+) T-lymphocytes were induced. A typical 
immune response experienced with soluble proteins such as the HIV-1 subunit 
vaccine was used to demonstrate this effect. The induction of CDS+ cytotoxic T -cell 
immune response provides longer lasting protection than when only CD4+ T -helper 
cells are induced (Wu eta/., 1992; Akashi eta!., 1990). In addition, the enhanced 
proliferative response produced when formulations containing QS-21 were used 
was found to be virus group specific (a very important issue especially in the 
development of HIV-1 vaccines because of its genetic variability). The introduction 
of virus group specific responses was found only when QS-21 was the adjuvant 
(Wu et al., 1992). 
To date, protective immunity has been attained for a variety of antigens 
including viruses, bacteria, mycoplasma and parasites. Table 3 gives a list of 
examples of antigens that have been experimented with in the studies of the 
adjuvanticity of Quillaja saponins. 
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Table 3: Various antigens whose immune responses have so far been 
potentiated by the use of the saponins of Quillaja Saponaria. 
Class of Type of Disease it Animal Results 
antigens antigen causes model obtained and 
used references 
Anthrax vaccine anthrax cattle, sheep, enhanced immunity 
goats 
(Espinet, 1951) 
pleuro-pneumonia pleuro-pneumonia cattle, sheep, protective immunity 
goats, attained 
(Espinet, 1951) 
Veterinary Rinderpest vaccine rinderpest acrid wild animals protective immunity 
antigens attained (Espinet, 1951) 
(Almost all of the Foot-and-mouth foot-and-mouth cattle protective immunity 
vaccines fisted vaccine attained 
here are used (Espinet, 1951) 
practically) 
Rabies vaccine rabies red-fox, cats, protective immunity 
(parenteral) dogs, mice attained 
(Espinet, 1951) 
Oral rabies vaccine rabies mice enhanced immunity 
(used only with 1 00% protection 
experimentally) (Maharaj et ai., 1986) 
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E coli 018 sepsis, traveler's Mice greatly enhanced i 
polysaccharide diarrhoea, urinary immune response 
(has very low tract infections (11fold) 
antigenicity and no production of 
response in children) additional isotypes. 
(White et al., 1991) 
Neonatal meningitis respiratory enhanced immune 
a subunit vaccine infections response 
(Couhgiin et al., 
1995) 
Human Influenza virus strain influenza mice enhanced immune PR-8 response 
antigens even so when QS-21 
is in iscom 
form.lltoxic effects 
(All human nlocal irritation 
vaccines are still (Ronberg et al., 
only 1995) 
experimental) 
HIV-1 HIV/AIDS, mice enhanced response 
(a subunit antigens viremia group specific 
gp120 and p24) response 
(Wu, 1992) 
Hemagglutinin, encephalitis mice (Morein, et al., 1998) 
measles virus 
Immune-affinity lethal infection mice (Morein, et al., 1998) 
purified protein 
Trypanosoma cruzi 
Herpes simplex Virus herpes simplex mice and enhanced 
-Type1 guinea pigs immunogenecity and 
(detergent-solubilized excellent protection 
subunit antigen) against systemic or 
local challenge 
(Erturketal., 1991) 
Fusion protein, encephalitis mice (Morein, et al., 1998) 
measles virus 
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ISCOMs ( Immune stimulating complexes) 
iSCOMs are a specific type of antigen/adjuvant containing structures that 
were first described by Morein eta!. (1984). They may be regarded as a delivery 
system of antigen and adjuvant, created to make antigens optimally immunogenic 
by presenting the adjuvant and the antigen in the same particle, thus reducing the 
amount of antigen and adjuvant required for efficiently enhancing the immune 
response. The antigen and the adjuvant are presented in the most physically 
immunogenic form (several copies of the antigen/adjuvant are presented in a sub-
microscopic particle that resembles particles of an infectious agent). Because of the 
uniformity of the particles, the antigen is targeted to lymphatic organs and cells 
(More in eta/., 1998). 
The ISCOM structure is composed of a Quillaja saponin (or some other 
saponin) matrix, cholesterol and phospholipids in a molar ratio of 1:1:1. The Quilfaja 
saponin forms micelles at its critical micelle concentration of 0.03%. When in 
micelle form the saponin avails hydrophobic regions for interaction with membrane 
proteins of the antigens and forms complexes with them. The final resultant 
structure is cage-like, has a diameter of about 35 to 40 nm and is made up of 
ringlike subunits 12 nm in diameter. The structure is physically stable and can be 
frozen, freeze-dried and suspended in various buffers. 
ISCOMs were found to be at least ten times more potent as adjuvats than 
lipid micelles formed by membrane proteins alone. The antigen in the ISCOM must 
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have a hydrophobic domain; it can be an envelope protein of a virus, a cellular 
membrane protein, a peptide domain or many other antigens. A variety of viral 
antigens have been used in ISCOM formation and they include influenza virus 
rabies virus, herpes simplex virus, HIV-1 virus, and so forth. Different ratios of 
antigen to saponin have been shown to have different effects on the immune 
response and on the size of the ISCOM. 
Other species containing immunologically active saponins 
It is worth noting that the adjuvant activity is not entirely confined to Quillaja 
saponins alone. It has also been reported in saponins of other genera, among 
which are Gypsophila and Saponaria genera. These saponins are structurally 
related to Quillaja saponins (Price eta!., 1987), including the presence of branched 
sugar chains at positions three and 28, which are hypothesised to be very important 
for adjuvant activity (Bamford eta/., 1992). Two of the adjuvant active saponins from 
Gypsohila have been separated, purified, and partly structurally characterized. 
Glycyrrhizic acid, a glycoside from Glycyrrhiza gfabra L. (Leguminosae) has been 
demonstrated to possess a more profound in vitro immunomodulatory activity than 
Qui!Jaja saponins (Chavali et a!., 1987). Recently, separation of some adjuvant 
active saponins from the root of Polygala senega L. found in the prairies of the 
Canadian province of Saskatchewan has been reported. The authors reported the 
toxicity of these saponins, measured by lethality in mice, to be less than that of 
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Qui I-A at the same dose (Estrada eta!., 2000)0 However, they still have not proved 
the usefulness of this saponin in ISCOM technologyo 
Pharmacological properties and toxicity of the Quillaja saponlns 
Saponins in general are powerful irritants, local anaesthetics and muscular 
poisonso Due to their local irritant properties when injected hypodermically they 
cause intense pain and when applied to the nose they cause sneezingo They cause 
vomiting, diarrhoea, and gastroenteritis when taken orally in large doses. Local 
application can be harmful to the motor and sensory nerves and may cause a 
condition of the muscles known as rigour mortis, in which the muscles become 
brittle and structurelesso Poisoning which can lead to death, has symptoms like 
headache, vertigo, vomiting, hot skin, rapid and feeble pulse, progressive muscular 
weakness, and finally coma (Grieve, 1999). Saponins combined with lipids 
(cholesterins and the lecithins) in equimolar concentrations loose their toxicity 
thereby rendering them more useful. However in this state they still exert their 
hemolytic activity on erythrocyteso The lipid membrane of the red blood cells 
develops holes and leak out hemoglobin. The amount of hemolysis, however, is 
only a physical measurement and is not indicative of the systemic toxicity of the 
saponin, as other factors such as phagocytosis, absorbability, gastric 
decomposition, and plasma cholesterol neutralization play a role in the overall toxic 
effect of a saponin (Kobert, 1911 )0 This statement holds true for Quilfaja saponins 
as well (Kensil, 1996). 
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Kensil et a!. (1991 ), have studied the toxic and hemolytic activity of the 
Quillaja saponins. They measured toxicity in terms of lethality to mice. They found 
that Quii-A was lethal to mice at concentrations of 100-125 micrograms/kg body 
weight. The purified saponin QS-18 was the most lethal (at concentrations of 25 
micrograms/kg body weight). It is also the most abundant in Quii-A. QS-21 and 
QS-7 had a large minimum toxic concentration(mtc)/minimum inhibitory 
concentration(mic) or minimum effective concentration(mec) ratio (mtc/mic (mec) 
ratio also known as therapeutic index (TI)). QS-21 was found to be the most 
hemolytic, while QS-7 was the least hemolytic. No correlation was found between 
hemolytic activity, lethality, and adjuvant activity. QS-21 which has higher hemolytic 
activity than QS-18 is comparatively less lethal to mice. In a study of toxicity and 
side effects of adjuvant formulations conducted by Simms eta!. (1997; 1998), in 
their research of immune responses induced by different adjuvants administered 
with the herpes virus type-1 subunit vaccine, out of about five different adjuvants 
lethality was observed only in a group of mice receiving ISCOMs. In other words, 
ISCOMs were found to be the most toxic adjuvants in this experiment utilizing this 
particular animal model. However this was not the case when guinea pigs were 
used (Simms et al., 2000; 2002). It is therefore quite apparent that the toxicity of 
the saponin adjuvants is an issue of great concern in the development of saponins 
as commercial veterinary and human vaccine adjuvants. However, other studies 
have been conducted which did not show any significant toxic effects in short-term 
feeding studies in rats (Gaunt eta/., 1974) and long term toxicity studies in mice 
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(Phillips eta/., 1979). The toxicity has been found to be less when the saponins are 
administered orally rather than parenterally. 
Saponin safety by oral route has been evaluated on food grade Quillaja 
extracts. No carcinogenic effects or change in mortality rate were observed in these 
studies. Only a decrease in weight gain and antihypercholesterolemic effects were 
observed. The decrease in weight gain was attributable to some extent to the 
unpalatability of the saponin extract treated food. However, it is believed that the 
cumulative amount of the saponin to be used in immunization would be much lower 
than the concentration used in toxicity studies and that the two issues mentioned 
earlier (decreased weight gain and anti hypercholesterolemic effects) would not be 
a problem at all (Kensil, 1996). 
Local reactogenicity in parenterally administered vaccines with Quillaja 
saponins has been observed but disappears after about two weeks 
postimmunization. Incorporation into ISCOMs considerably reduces systemic 
toxicity and local irritation. Still a tremendous reduction in toxicity has been 
observed with lscoprep 703, a fractionated Quillaja saponin (Sjolander et ar, 1997; 
Coulter et a/1998). Safety studies in these saponins are stili being carried out, and 
the latest reports on this subject are showing promising results (Sjolander eta/., 
1997; Coulter eta! 1998; Deliyannis et ar, 1998; Verschoor et ar, 1999; Harrison 
et al., 1999). 
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Non=immunological studies involving Quillaja saponins 
Several other studies involving Quil!aja saponins have been carried out. 
Another saponin study demonstrated that Quillaja saponins from various 
commercial sources differed in their biological activity, with respect to their 
modulation of microbial growth in natural and artificial fermentation; this was 
measured by their effects on the growth of E. coli (Sen eta!., 1998). 
One such study reported an observed drug interaction between Quillaja 
saponins and a compound abbreviated TET (tetradine), which is a calcium ion 
antagonist of Chinese herbal origin (Leung et al., 1997). TET has been 
demonstrated to have antihypertensive and antisilicotic effects in experimental 
models and clinical trials (Gao eta/., 1965; Qian eta!., 1983; Leung eta!., 1988). 
TET was found to enhance membrane permiabilization effects of the Quiilaja 
saponins. 
Other studies involved the exploration of the micellar properties of Qui!laja 
saponins in order to provide information for utilization as emulsifiers and to 
investigate the potential role of Quilfaja saponins in the development of micellar 
based extraction process for the removal of cholesterol from milk (Mitra and 
Dungan, 1997) and for lowering plasma cholesterol levels in humans and animals. 
Studies on rumen fermentation and Quillaja saponins are geared towards 
investigating the ammonia-binding effects of the saponins, which can be beneficial 
in alleviating the problem of ammonia emissions from excreta (Markar and Becker, 
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1997). Scientists point out that addition of saponins to animal feed will alter rumen 
fermentation, promote higher animal production and reduce environmental 
pollution by lowering the emission of polluting gases like carbon dioxide, methane 
and ammonia (Markar et at., 1998). The potential applications of Quiffaja saponins 
and other saponins for this purpose is currently being investigated. 
Mechanism of action 
Surface activity and cholesterol binding activity are in part responsible for the 
adjuvanticity (van Setten and van de Werken, 1996; Hostettman and Marston, 
1995). The enhancement of the immune responses by Quillaja saponins in oral 
vaccines (oral rabies vaccine as the model) was postulated by Maharaj eta/. (1986) 
to be a result of: protection of the antigen from degradation by digestive enzymes; 
complexing with the enzyme to present it in a more immunologically active form; 
and, stimulation of the interaction of the antigen with the lymphocytes by increasing 
the permeability of the intestinal membranes. 
A detailed overview of the studies on the mechanism of action of Quillaja 
saponins has been carried out by Kensil (1996). A summary of this overview is 
given below. Quillaja saponins do not cause the formation of a depot of antigen, as 
is proposed as one of the mechanisms of action of other adjuvants like FlA. Instead, 
studies have shown that the Quillaja saponins act by increasing the following: the 
lymphocyte homing to injection site (free saponin); attraction of polymorphonuclear 
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cells to the injection site (ISCOMs); interferon gamma and interleukin-2 production; 
and, MHC class II expression on macrophages and antigen processing and 
presentation by macrophages. Researchers including Strobbe eta!. (1973), Wu et 
al. (1992), Soltysik eta!. (1995), and van Setten and van de Werken (1996), have 
in the course of their studies of the Quillaja saponins suggested mechanisms of 
action of these compounds that corresponded to the ones mentioned in the 
summary above. The recent studies of Hoshi and his co-workers (1999), on this 
subject and the review of Morein (1998), emphasize the increased cytokine and 
chemokine production to be responsible for the enhanced immune responses 
induced by the Quillaja saponins. These findings have been confirmed by other 
researchers (Spickler and Roth, 2003; Francis et a!., 2002 and McCiuskie and 
Weeratna, 2001; Rao and Gurfinkel, 2000; Oda eta!., 2000 and Ragupathi eta!., 
2000). 
Cytokine induction by Quiliaja saponins 
The development of an effective immune response involves the lymphoid 
cells, the inflammatory cells and the hematopoetic cells. The complex interactions 
among these cells are mediated by a group of low molecular weight regulatory 
proteins or glycoproteins, collectively designated as cytokines. These substances 
are secreted by white blood cells and various other cells in response to a number 
of stimuli. These cytokines assist in regulating the development of the immune 
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effector cells, while others possess direct effector functions of their own. In general, 
cytokines serve as messengers of the immune system (Goldsby eta/., 2000). The 
cytokine interleukin-1 is the first cytokine released by activated macro phages in the 
response to antigens. 
An effective immune response requires mainly two major groups of cells: 
lymphocytes and antigen presenting cells (APCs). B-lymphocytes and T-
lymphocytes are the two major populations of the lymphocytes. While the B-
lymphocytes can recognize antigen on its own through their B-cell receptors, the 
T-cell receptors can recognize only antigen that is bound to cell membrane proteins 
called Major Histocompatibility Complex (MHC). MHC molecules that function in this 
antigen presentation event are polymorphic glycoproteins found on cell membranes 
and are divided into two major classes: class I MHC molecules, expressed by nearly 
all nucleated cells, and class II MHC molecules, expressed only by antigen 
presenting cells. Antigen presenting cells include macrophages and monocytes: 
(macrophage precursors), 8-cell lymphocytes, dendritic cells and various other 
cells. 
The effects of adjuvants, including Quillaja saponins, on the two major 
populations of the lymphocytes (the 8-lymphocytes (8-cells) and the T-lymphocytes 
(T-cells)) have been studied to a great extent by different researchers. The recent 
studies are those as mentioned in: Spickler and Roth, 2003; Ghosh eta!., 2002; 
Qiao et al., 2003; Marchand et al., 2003; Francis eta!., 2002; Marcian eta!., 2002; 
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Lunden et a!., 2002; Liu eta/., 2002; Huber et a!., 2002; Paykari et a!., 2002; 
Slingluff eta!., 2001; Berndart eta!., 2001; Diwan eta!., 2000; Hu eta!., 2001; 
Evans et al., 2001; Shu eta!., 2001; Rao and Gurfinkel, 2001; Boyaka eta!., 2001; 
Hancock eta/., 2000., da Fonseca eta!., 2000; Shu et a!., 2000; Sabbatini et a!., 
2000; Behboudi et a!., 1999; Sjolander and Cox, 1998; Cox et at., 1998; Moore et 
a!., 1999; Sjolander eta!., 1998; and many others. 
Two well defined sub-populations ofT-cells are well recognized: T-helper 
(Th) cells that generally display CD4 molecules on their membrane, and T -cytotoxic 
(Tc) cells that generally display CD8 molecules on their membranes. A third type 
ofT-cells, T-suppressor (Ts) cells, have been previously postulated, however, 
recent evidence suggests that it may not be distinct from the Th and Tc sub-
populations (Goldsby eta!., 2000). A Th-cell recognizes only antigen bound to the 
MHC class II molecule and upon activation it secretes various cytokines which then 
play an important role in the activation of B-cells, T -cells, macrophages and various 
other cells that take part in the immune response including non-specific effector 
cells called natural killer (NK) cells. Tc-cells on the other hand are activated by 
antigen bound to MHC class I molecules and upon activation they proliferate and 
differentiate into cytotoxic T -lymphocytes (CTL) whose vital function is in monitoring 
the cells of the body and directly eliminating any virus infected cells, tumor cells, 
cells of a foreign tissue graft, or any other cells that display antigen. 
Differences in the cytokines produced by Th- cells result in different types 
of immune responses. A Th-1 response produces a cytokine profile (IL-2, IFN-y, 
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TNF-!3) that supports mainly the following biological activities: inflamation; Th and 
Tc- cell proliferation, NK and CTL activity, inhibition of viral replication; activation 
of macrophages, increased expression of class I and class I! MHC molecules; 
induction of class switch to lgG2a antibodies by proliferating B-ceils and blockade 
of IL-4 induced class switch to igE and lgG1 antibodies; increased phagocytosis 
and cytotoxicity and reduced Th-2 activity. A Th-2 response on the other hand 
produces a cytokine profile of !L-4, IL-5, IL-6, and IL-1 0, which in turn supports the 
following biological functions, B-cell proliferation and differentiation; class switch 
to lgG1 and lgE antibodies; lgA production; eosinophil growth and differentiation; 
plasma (a B-lymphocyte) cell production; antibody secretion; suppression of 
cytokine production by macrophages and therefore indirect reduction of cytokine 
production by Th-1 cells, and down regulates class II MHC expression by antigen 
presenting cells. 
The cytokine IL-1 is mainly secreted by monocytes, macrophages, B-cells 
dendritic cells, endothelial cells and other cell types, and its activity is on the Th-
cells; (co-stimulation of activation), B-cells (promotion of maturation and clonal 
expansion), NKcells (enhanced activity), macrophages and neutrophils (increases 
chemotactic attraction), and so forth. Hence, the measurement of the IL-1 induction 
activity of a substance is a very good indicator of its immunological activity.Studies 
on the cytokine induction properties of the Quilfaja saponins have been carried out 
by various researchers, and the general belief is that they are able to induce both 
Th-1 like and Th-2 like responses, sometimes even equally (Sjolander eta!., 1998; 
Sasaki et al., 1998; Simoes eta!., 1999; Smith eta!., 1999; McNeal et ar, 1999; 
Gosh eta!., 2002). 
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1.5, Other studies performed on the saponins of Quillaja saponaria 
Molina 
It appears that since 1996, much of the work done in relation to Quil!aja 
saponins was that concerning their immunostimulatory activity and ISCOM 
formation. Only a few structure elucidation or structure function relationship studies 
have been encountered (Steinbeck eta!., 1995; Ronberg eta!., 1995; Kensil eta!., 
1996; So eta!., 1997; Nord and Guo eta!., 1998; Kensil eta!., 1998; Kenne, 1999; 
Nyberg et af., 1999). 
Structure/function relationship studies 
The early studies in structure activity relationship performed on QS-21 
revealed that the aldehyde group at the C4 position in the triterpene was important 
for adjuvant activity and that it may actually be important for the adjuvanticity. 
Modifications at the carbonyl group of the glucunonic acid did not abolish the 
antibody stimulating activity. However, the required dose was raised substantially. 
The induction of cellular immunity was lost in most of the derivatives of the 
glucononic acid I (Soltysik eta/., 1995). 
Studies have shown that DS-1, a deacylated saponin from Qui!Jaja 
saponaria, differing from QS-21 only by not having the fatty acyl moiety, was 
inactive as an adjuvant (Kensil et a!., 1992), suggesting the possibility of the 
adjuvant activity of QS-21 residing within the fatty acid domain. However, Kensil et 
a/. (1996) isolated this moiety and evaluated it for adjuvanticity. The fatty acyl 
moiety was found to be inactive as an adjuvant, leading to the conclusion that the 
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acyl moiety was essential for the adjuvant activity but was not sufficient on its own. 
The positioning of this acyl moiety was shown not to be crucial by Cleland eta!.. 
(1996) who demonstrated that the domain in QS-21 underwent reversible migration 
from the 4-hydroxyl group of the fucose to the 3-hydroxyl group and that both 
isomers were biologically active. 
Immunological studies 
There has been a considerable number of studies on the immune stimulating 
activity of the Quiflaja saponins. Most of the studies conducted used the saponins 
in ISCOM form as it was the form reported to elicit larger immune responses at 
minute concentrations of the saponins and, as a consequence, with minimal or no 
toxic effects in the model animals (Morein eta/., 1984). In most studies ISCOMs 
were found to have a much higher immune stimulating activity than other adjuvants 
such as Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvant (FIA), 
allum adjuvant and so forth (Leenaars eta/., 1994; Steineker et al., 1995; Gupta and 
Siber, 1995; Rubbuelo eta/., 1995; Sjolander eta/., 1996; Hoshi eta!., 1998; Jiang 
et a!., 1999; Simms et a!., 1997). Interestingly, the non-ionic surfactant vesicle 
(NISV) delivery system, an adjuvant system described by Brewer eta!. (1992), was 
found to induce greater lymphoproliferative responses than ISCOMs. However, 
ISCOMs have been found by other researchers to be superior in eliciting protective 
immunity (De!iyannis eta!., 1998; Cox et af., 1998; da Fonseca eta!., 2000; 
Stittelaar eta!., 2000). 
In almost all the antigens tested with ISCOMs, the isotypes mostly produced 
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were lgG1 and lgG2a, indicating both Th-1 and Th-2 responses (Kenney eta!., 
i 989; Ahmeida eta/., 1991; ten Hagen eta!., 1993; Hassan eta!., 1996; Sjolander 
eta!., 1996; 1997a; 1997b; 1999; Francis eta/., 2002; Connolly and Hill, 2002; 
Qiao et al., 2003). However, some lgG2b and lgG3 antibodies are produced with 
some antigens, like influenza virus but not in large quantities, indicating the 
presence of some degree of Th-2 response for these antigens (Lovgren, 1988; 
Vi!lacres-Erikson, 1992; Sjolander, 1996). lgG2a antibodies are very important in 
viral and parasitic infections as they activate complement, induce antibody 
dependant cellular toxicity and have been reported to have the greatest antigen 
neutralising capacity (Spiegelberg eta!., 197 4; Kipps eta!., 1984; Coultier eta!., 
1987; Hassan et a!., 1996; Sjolander et a!., 1996). ISCOMs are very efficient in 
inducing the proliferation and differentiation of 8-cells that secrete antigen specific 
lgG antibodies (Antibody Secreting Celis). These ASCs were found to be localised 
in several organs including the draining lymph nodes, spleen and the bone marrow 
and were also found to persist for a long time. In addition, the 8-cell memory 
induced by ISCOMs was found to be very potent (Hoglund eta!., 1989; Classen and 
Osterhause, i 992; Sjolander eta/., 1996). 
In addition to induction of humoral immune responses the administration of 
antigens in ISCOMs has been found to affect the resulting immune response in 
other aspects including activation of regulatory T-helper cells as demonstrated by 
the production of IL-2 and IFN-y (Th-1 response) (Villacres-Erikson eta!., 1992; 
Valensi eta/., 1994; Fossum et al., 1994; Sjolander eta/., 1997a; 1997b), induction 
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of cytotoxic CD8+ lymphocytes (Takashi eta!., 1990; van Binnendijk eta/., 1992; 
Lipford eta!., 1993), and induction of the activity of natural killer (NK) cells which 
is observed when Quiflaja saponins are administered alone (Chavali and Campbell, 
1987). !SCOMs have also been demonstrated to enhance the surface expression 
of MHC class II molecules on Antigen Presenting Cells (APCs) (Takas hi eta., 1990; 
van Binnendijk eta!., 1992). Studies have shown that the T -cell memory response 
induced by ISCOMs was also very potent (Sjolander eta!., 1997a). The saponins 
up-regulated the Th-1 and Th-2-like responses equally (joint responses) (Jiang et 
a/., 1999). In one study, Dotsika et a!., ( 1997), demonstrated that responses 
generated by ISCOMs can be manipulated by altering the composition of the 
triterpenoid saponin in the IS COM, and that the levels of the saponin in the ISCOM 
can determine the type ofT- cell response produced, whetherTh-1-like or Th-2-like 
(that is humoral or cell mediated responses). 
Latest developments in the research on the saponins of Quillaja 
saponaria Molina 
It has recently been reported that an ISCOM formulation containing a 
mixture of fractions A and C (QH-A and QH-C), previously fractionated through 
reverse phase HPLC by Ronberg eta!., (1995), has highly promising properties of 
an ideal adjuvant. The formulation designated QH-703 (ISCOPREP 7.0.3™), 
consists of 70% QH-A and 30% QH-C, and lacks QH-8, the fraction found to be the 
most toxic of the three. The formulation was found to have strongly similar adjuvant 
properties compared to the semi-purified Qui I-A but without the toxic effects of the 
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Qui I-A. Interestingly, the major factor of this formula (QH-A) was initially thought to 
be immunologically inert, but it turned out to be a potent inducer of T -cell 
proliferation and production of the type ! cytokines. It was found that the QH-A I 
QH-C ISCOMs induced higher levels of lgG2a antigen specific antibodies than 
those induced by QH-C ISCOMs on their own. Fraction QH-C has been 
demonstrated to strongly induce the production of lgG2a antibodies, which is 
indicative of a Th-1 response, and the production of the cytokines IFN-y, TNF- ~. 
1 L-2, and IL-3 (Johansson eta!., 1999). ISCOPREP 7.0.3™ has been developed 
for human use and is presently undergoing clinical evaluation (Viliacres-Eriksson 
eta!., 1997; Behboudi et at., 1996; Sjolander eta/., 1997; Behboudi et al., 1997; 
Johansson eta!., i 999). 
More structural characterization of Quillaja saponins is being carried out. The 
latest encountered is that of Nord and Kenne eta!. (1999), who separated and 
characterized six fractions using mass spectrometry (MS), NMR and chemical 
methods. The latest number of saponins reported to be detected by MS from the 
Quillaja saponin bark is 60 (van Setten eta!., 1998). Behboudi eta!. (1999) have 
demonstrated that the Quillaja saponins stimulate BandT -cell responses differently 
and to various degrees (i.e., T-h1 and Th-2 responses). The fraction QH-A is a 
potent stimulator ofT -cell responses while fraction QH-C primarily stimulated B-cell 
responses. As such, it would be possible to develop vaccine formulations with 
defined characteristics according to a particular need. QH-A, QH-B, and QH-C are 
Quillaja saponin fractions which have been clinically and functionally defined. Their 
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use in ISCOMs has been extensively studied and a combination of QH-A and QH-C 
in influenza vaccine is currently under Phase 1 and Phase 2 clinical studies for 
humans (Romberg eta!., 1995: Romberg eta/., 1997). QH-B and QH-C have strong 
adjuvant activity but they are also highly toxic, QH-B being the most toxic. 
Modification of the carbohydrate chain of QH-B was performed in an attempt to 
investigate the possibilities of the reduction in toxicity of this compound. The 
outcome was that the toxicity was reduced by this modification (carried out by 
oxidation with periodate) but so also was the adjuvanticity (Romberg eta!., 1997). 
The modified products, although they retained the cholesterol binding capacity, 
formed saponin-lipid complexes uncharacteristic of ISCOMs. 
Furrieret a/. (2002) have investigated (with positive outcomes) the possibility 
of intestinal activity of Qui I-A ISCOMs in modulating local innate immune responses 
and antigen uptake. They used the protein antigens, ovalbumin, delivered orally. 
While losef eta!. (2002) evaluated the systemic and intestinal antibody secreting 
cell responses and protection of a recombinant RFVP2/WaVP6 rotavirus-
like-particle (2/6VLP) oral vaccine using ISCOMs in a gnotobiotic (Gn) pig model 
of human rotavirus (HRV) disease. The 2/6VLPs adhered to the ISCOM-matrix 
(2/6VLP-ISCOM) and were antigenic, but they failed to induce protection. However, 
when combined with attenuated (Att) HRV for oral priming, the 2/6VLP-ISCOM 
vaccine was effective as a booster and induced partial protection against virulent 
Wa HRV. 
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Bungener eta!. (2002) and Chen et a/. (2002) have reported studies in 
which other means of antigen presentation for the purposes of vaccine development 
were investigated and in which ISCOMs were included in the evaluative studies of 
these methods against others. Both groups of researchers reported the Quil!aja 
saponins to perform well as adjuvants, though not the best in either of these 
studies. Reconstituted viral envelopes (virosomes), specifically fusion-active 
influenza virosomes, were found to perform as a better antigen delivery system than 
ISCOMs for the protein antigen ovalbumin (Bungener eta!., 2002). The activities 
were reported as 25, 5, and 0.7 (proportions) for liposomes, ISCOMs and 
virosomes respectively. Chen eta/. (2002) on the other hand have reported that 
Semliki Forest virus particles (self-abortive viral particle that express respiratory 
syncytial virus (RSV) F and G proteins from an RNA replicon) produce a slightly 
better immune protection when administered alone than when these viral proteins 
were administered in ISCOM formulation (Hu eta!., 1998 and Chen eta!., 2002). 
The works of Robson eta!. (2003) and Beacock-Sharp eta!. (2003) suggest that 
dendritic cells may be the principal APCs responsible for the priming of CDS+ 
T-cells by ISCOMs in vivo. They further suggest that targeting the ISCOMs to the 
activated dendritic cells may further enhance their activity. Also among more recent 
studies involving iSCOMs are different methods of ISCOM construction and 
incorporation of various antigens (Konnings et al., 2002; Guan eta!., 2002) and 
attempts at the development of synthetic and semi-synthetic compounds resembling 
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Quillaja saponins but without their toxicicity and stability problems (Marciani eta!., 
2000; Kim and Gin, 2001 ). The semi-synthetic Quiflaja saponin analog, GPI-1 00, 
has been reported to stimulate an antibody profile that corresponds to a Th-1 type 
immune response as well as to induce CTL production against exogenous antigens 
(Marciani eta/., 2000). 
Clinical and veterinary applications of Quillaja saponaria Molina 
Preclinical studies have undoubtedly proven that Quiflaja saponins are useful 
as adjuvants in higher species for stimulating humoral and cell mediated immune 
responses. 
Vaccine applications 
The application of Quillaja saponins as adjuvants has highly promising uses 
in a large number of vaccines, including viral vaccines, bacterial vaccines, parasitic 
vaccines (such as against P yoelii), and cancer immunotherapy (for example, in 
Thomsen Friedenreich (TF) antigen found in epithelial cancer cells). Some 
anticancer vaccines with Quillaja saponin adjuvants have proceeded to clinical 
trials. QS-21 in a Phase I clinical study of a melanoma immunotherapeutic vaccine 
was found to enhance antigen-specific lgM and lgG responses (livingston eta!., 
1994; Kensil eta!., 1996). In veterinary vaccines, the Quillaja saponins have 
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already found widespread use. ISCOMs have been used extensively in viral 
vaccines. ISCOMs consisting offeline leukemia virus gp 70, HIV-1 virus, influenza 
virus, bovine leukemia virus, HSV-1 virus, to mention a few, have been tested with 
promising results in animal models. The purified QS-21 has also been tested in 
viral vaccines in its conventional form and the results were highly promising. 
In addition, bacteria vaccines such asS. pneumoniae, E. coli, N. meningitidis 
have been tested with Qui I-A The induction of CTL responses by Quillaja saponins 
has important consequences in the protection against intracellular bacteria such as 
Mycobacterium avium, Listeria monocytogenes and others. A number of routes of 
administration for the saponins in vaccine potentiation have been tried in preclinical 
research including nasal and rectal routes (Kensil eta!., 1996). 
Clinical developments and trials 
In 1994, Livingston eta/. reported a clinical trial being carried out on the 
adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate 
vaccine in patients with malignant melanoma. The results reported from this trial 
were favourable (Livingston eta!., 1994) and these authors were the first to report 
a Phase I clinical trial of a purified Quillaja saponin in humans (van Setten and van 
de Werken, 1996; Cleland et al., 1996). Another melanoma vaccine Phase I clinical 
trial has been carried out to evaluate the adjuvant activity of QS-21 in a vaccine 
containing the antigen MEUMMUNE-1 (a high molecular weight melanoma 
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proteoglycan chondriotin sulfate that mimics a murine anti-idiotype antibody). An 
influenza ISCOM vaccine prepared from a mixture of two of the fraction QH-A and 
QH-C, previously isolated and characterized by Ron berg eta!. (1995), is presently 
in human clinical trials (Barr and Mitchell, 1 996; Sjolander et a!., 1997a). The 
results of this trial are not yet available, however, reports of non-human primate 
studies conducted by an Australian company known as CSL Limited in collaboration 
with Chiron Corp of USA have shown promising results (Sjolander et af., 1997a; 
1997b; Coulter eta!., 1998; Deliyannis et af., 1998; Verschoor eta/., 1999). The 
product being tested is called ISCOPREP 7.0.3™. 
Qui I-A itself has not been tested in clinical trials of human vaccines. The first 
purified saponin to be tested in clinical trials was QS-21 after being first evaluated 
in preclinical vaccine testing in rabbits, dogs, monkeys and baboons and in a 
vaccine for cats. QS-21 has now been tested in Phase I and II clinical trials for 
melanoma vaccines and HIV-1 subunit vaccines (Kensil, 1996). The early Phase 
I studies suggest that saponin adjuvants may be effective adjuvants in cancer 
immunotherapy and other vaccines. Other clinical trials of QS-21 and of other 
purified saponins such as QS-7, QH-A/QH-C (ISCOPREP 7.0.3™) with other types 
of antigens such as HIV-1, influenza, herpes simplex virus, and so forth, are 
underway (Kensil, 1996; Sjolander eta!., 1997a; 1997b; Coulter eta! 1998; 
Deliyannis eta/., 1998; Verschoor eta!., 1999). 
Most of the recent literature only indicate that clinical trials with ISCOPREP 
7.0.3™ are in progress (e.g., Singh and O'Hagan, 2002 and Kersten and 
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Crommelin, 2003; !canova, 2003; Vogel et a/., 2003), however, no results are 
available so far. There could be many reasons for this absence of results. One 
reason could be that some clinical trials may take a long time to conduct and 
complete. Another possibilty is that unfavorable results are being encountered. This 
speculation is definitely not unfounded as evidenced by the report of Potter and 
Jennings (2003), whose study attempted to find an intelligible explanation for the 
fact that, although animal studies have shown ISCOMs to be among the most 
potent adjuvants (Ben-Ahmeida eta!., 1993; Ghazi eta!., 1995; Stieneker eta/., 
1995; Sjolander eta!., 1996; Coulter eta!., 1998; and Deliyannis eta!., 1998), the 
results obtained from human volunteers were disappointing (Martin, 1996). Potter 
and Jennings argued that animal and volunteer models are not comparable and 
postulate the underlying cause of the differences in the results obtained from animal 
and human studies to be due to the fact that ISCOMs possibly would only work 
better in un-primed subjects, at least with regard to antibody production while using 
influenza virus as the antigen (Potter and Jennings, 2003). Studies of superlative 
adjuvant activity of ISCOMs by previous researchers were carried out chiefly on 
un-primed mice, while volunteers are mostly primed by a previous infection and or 
previous immunization. Of course, the extrapolation ofthe findings of Martin (1996), 
and Potter and Jennings (2003) to ISCOPREP 7.0.3™ (and or other antigens) may 
not be correct, (Barret a!., 1998; Kersten and Cromelin, 2003;Vogel eta/., 2003) 
as this product has a different saponin composition to that of ISCOM™ (Cox eta!., 
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1997; lsconova,2003) used by Potter and Jennings. 
Still, the poor results obtained with Quillaja saponins in human studies could 
be attributed to the degradation of these products, in vivo or during vaccine storage 
to deacylated products which have been shown to possess less or no immunogenic 
properties (Kensil eta/.,1992; Marciani eta!., 2002a). 
Interestingly, this notion is being challenged by Liu eta/., (2002) who have 
found DS-1 (a deacylated Qui/!aja saponin) to induce a better Th-2-like response 
(induced higher lgG1 antibody production) than QS-21. However DS-1 was inactive 
in inducing lgG2a or CTL responses (Th-1 response). Marciani eta/. (2002b) are, 
however, questioning the authenticity and nature of the QS-21 used by Liu et al. as 
(according to them) it appeared to have been produced under sub-optimal 
conditions. 
In addition, other results from studies of the adjuvanticity of QS-21 and 
ISCOMs (in comparison to other saponins and other substances) have that these 
substances did not perform as well as previously reported (Ciarlet eta!., 1998; 
Estrada eta!., 2000; Liu eta!., 2002; !osef eta/., 2002; Bungener eta!., 2002a; 
2002b; Chen eta/., 2002). In the study of Ciarlet et at. (1998) the activity of QS-21 
was found to be inferior to that of Freud's adjuvant for virus-like particles (VLPs) 
administered parenteraly to rabbits in conjunction with these agents. VLPs are 
currently being investigated as a rotavirus vaccine (Ciarlet et a/1998). However, 
such results are few when compared to the number of studies that show Quillaja 
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saponins (including QS-21 and ISCOMs) to be adjuvants phenomenal activity. 
In spite of the few drawbacks mentioned earlier, Quillaja saponins are still 
being reported to perform superlatively as adjuvants in conjunction with various 
antigens. Reports of numerous studies: experimental animal studies, preclinical 
animal studies and clinical trials at different stages appear to be constantly being 
published, whereby, QS-21, Qui I-A, and various purified fractions of Qui I-A in their 
conventional (solution) and ISCOM formulations are being tested with different 
viral and bacterial vaccines. Many show favorable results, to mention a few: 
Marchand eta!., 2003; Qiao eta!., 2003; Furrie eta!., 2003; Heath eta! 2003; Chen 
eta!., 2002; Choi eta!., 2002; Paykari eta!., 2002; Huber eta/., 2002; Slingluff et 
a!., 2001; Boyaka eta/., 2001; Sjolander eta!., 2001; Evans eta!., 2001; Hu et al., 
2001; Hancock eta!., 2000 Shu eta!., 2000; da Fonseca eta/, 2000; Sabbatini et 
a/2000; Stittelaar eta/., 2000; Ragupathi eta!., 2000; Adluri eta!., 1999; Ennis et 
a! 1999; McNeal et a/., 1999; Rimmelzwaan et a!., 1999; Livingston et a!., 1998; 
Sjolander et a/1997b; Sasaki eta/., 1998; Clelland eta!., 1998; Dotsika eta!., 1997; 
Rimmelzwaan eta!., 1997; Burns eta/., 1997; Donnelly, 1997. There have been 
over 300 publications on the subject since 1997. 
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Chapter 2: Research Plan 
2.1 Scope 
The major challenges in the research of Quilfaja saponins as adjuvants have been: 
Firstly, the difficulty in the separation of the crude extract into individual 
components, due to the amphiphillic nature of the components and their tendencies 
to form mixed micelles. 
Secondly, the obtainable amount of each individual component during a 
separation is very small. This means that, the conventional rigorous, structural 
elucidation strategy involving NMR and MS is time consuming and difficult to 
implement. Our yields ranged from 0.05% to only 3% of the original crude extract 
when separated on a preparative column. 
Use of organic solvents in adsorption and reverse phase HPLC however, has 
permitted the purification of several adjuvant active saponins from the extract to 
near homogeneity. Compounds such as DS-1, DS-2 QS-111, QS-21, QS-7, QS-17, 
QS-18, QS-L 1, and fractions such as QH-A, QH-8, QH-C have been successfully 
separated and characterized (albeit some only partially). 
Several elution protocols have been documented in the literature. In our lab, 
a method was developed from the modification of one of the published protocols 
(Higuchi et a!., 1987; 1988) and the best results for analytical separation was 
obtained through gradient elution with a buffered acetonitrile and water mixture from 
a C5 reverse phase HPLC column. This method has been modified for large scale 
separation. 
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Depending on the method of separation and its efficiency, the number of 
components resolvable chromatographically has differed from one research group 
to another resulting in a very wide range of 23-60 as reported in the literature. Our 
separation has resolved the material into 80 components by adsorption reverse 
phase liquid chromatography/mass spectrometry (LC/MS) and an average of 70 
peaks by reverse phase preparative HPLC. 
To date only about eleven of these saponins out of a total of over fifty 
saponin peaks separable by HPLC, have been fully structurally characterized. 
Extensive immunological studies have been conducted on both Qui I-A and OS- 21 
(a purified Quillaja saponin having a molecular weight of 2012 (1989; without 
sodium) and a defined structure elucidated by Kensil eta!. in 1991 ). While the use 
of Quii-A as an adjuvant is well established in veterinary medicine, its use in 
humans has not been established due to its toxicological effects and the fact that 
its composition cannot be standardized from batch to batch. 
Some of the Qui!laja saponins with documented chemical structures and, for 
some, their biological activity are included in Table 4. 
Clearly, Quillaja saponins with fully characterized chemical structures and 
biological activities could be invaluable tools in vaccine research, especially so in 
the research and development of modern subunit vaccines which, despite their 
notable advantages over whole organism counterparts, possess the disadvantage 
of being weak immunogens and necessitates that adjuvant research be an integral 
part of vaccine research. 
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Table 4: Some Qui!laja saponins documented chemical structures 
Compound Molecular weight Reference Comments 
DS-1 1512 Higuchi eta!., 1987 desacylsaponin 
DS-2 1696 Higuchi eta!., 1987 desacylsaponin 
QS-111 2296 Higuchi eta!., 1988 same as QS-17 
QS-7 1886 Kensil eta!., 1991 
QS-17 2321 Kensil eta/., 1991 same as QS-111 
QS-18 2150 Kensil et al., 1991 
QS-21 2012 (+Na) Kensil eta!., 1991 most immunologically 
active 
1989 
QS-L 1 956 So eta!., 1997 
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2.2 Study Objectives 
The aim of this study has been to separate to purity (or near purity) some of 
the saponins of Quillaja saponaria Molina compounds, and to determine their 
structural identity and biological activity. Thus, this study has been comprised of 
two components: to isolate and determine the structure of the purified components, 
and to examine the toxicity, hemolytic activity and the adjuvant capability of the 
individual constituents. 
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Chapter 3: Materials and Methods 
3.1 Materials 
3.1.1 Chemical Analysis 
e Qui I-A was obtained from Superfos Biosector a/s (Denmark) as an off-white, 
crystalline solid. 
Ammonium acetate, AC.S grade or better was obtained from Fisher 
Scientific Company (U.S.A). 
e Acetonitrile, HPLC grade or better, from Anachemica Ltd. 
Water, was distilled, deionized, and filtered using Millipore type HA filters of 
0.22 iJm pore size. 
Methanol, dimethylsolfoxide (DMSO), chloroform, isopropanol, hexane, 
benzene, trifluoroacetic acid (TFA), acetic anhydride, acetic acid, pyridine, 
and methyl iodide were obtained as HPLC grade or better from Fisher 
Scientific Company (U.S.A). 
Sodium bicarbonate, sodium borohydride, and sodium metal were obtained 
in A.C.S. grade or better from Sigma-Aldrich, Inc. (ON, Canada). 
Dowex 50W-X8, a strongly acidic cation exchange resin with 8 % 
divinylbenzene cross-linking (X 8) was obtained from The Dow Chemical 
Company (MD, U.S.A). 
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Deuterated methanol (tetradeuteromethanol) of high purity (99.95 atom%) 
was obtained from MSD Isotope Laboratories (Montreal, QC. Canada). 
3.1.2 Biological Testing 
s Rat red blood cells (RBC) for the in vitro analysis of the hemolytic activity of 
the saponins were obtained from blood collected from Sprague-dawley rats 
from the laboratory of Dr. B. Van Vliet (Memorial University, St. John's, NL. 
Canada). 
Celis used in biological testing were of the J774 murine cell line, obtained 
from American Tissue Culture Collection (ATCC) (Rockville, MD. USA). They 
were grown to desired confluency at 37 °C in a 5 % C02 atmosphere and 
RPMI1640 medium supplemented with fetal bovine (calf) serum (FCS) (10 
% v/v), glutamine (2 mM), a penicillin/ streptomycin suspension( 100 ug/ml 
and 100 IJg/ml respectively) and sodium bicarbonate (0.15 % w/v). All cell 
culture materials mentioned above were purchased from Gibco Life 
Technologies (Gaitheisburg, MD, USA). Cells were grown in 75 cm2 flasks 
manufactured by Falcon (distributed by Becton, Dickinson, ON, Canada). 
" Enzyme linked immuno-sorbent assay (ELISA) kit for IL-1 a cytokine 
determination was purchased from PeproTech 
Laboratories Inc. (Rocky Hill, NJ, USA). 
Other reagents for cell culture and other biological experiments including the 
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ELISA assay; Tween-20, Bovine serum albumin (BSA), Avidin peroxidase 
conjugate, ABTS (2,2'- azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)) 
liquid substrate solution, phosphate buffered solution (PBS), 
lipopolysaccharide (LPS) from E. Coli,026:B6, Cat#L2654), and NonidetR 
P40 (NP40), were obtained from Sigma-Aldrich, lnc.(Ontario, Canada). 
3.2 Apparatus and equipment 
3.2.1 Chemical Analysis 
+ Millipore types HV and HA syringe filters of pore size 0.45 !Jm and 0.22 !Jm, 
respectively, were used for filtering solutions for HPLC, LC/MS and cell 
culture experiments. 
Solid Phase Extraction Kits were C8 silica packed columns of brand Strata TM 
and size 1 g packing material and 6ml volume obtained from Phenomenex. 
(CA, USA). 
HPLC analysis was carried out using analytical HPLC Phenomenex Jupiter 
C5 reverse phase HPLC column equipped with a guard column or cartridge 
(Specifications; 5 micrometre particle size, 300 A pore size, and 4.6 mm 
x 250 mm length). 
Semi-preparative HPLC Phenomenex Jupiter C5 reverse phase HPLC 
column equipped with a guard column (Specifications; i 5 micrometre particle 
size, 300 A pore size, and 22.1 mm x 250 mm length). 
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Hewlett Packard Series 1050 HPLC equipped with a Hewlett Packard 3396 
integrator was used for preliminary HPLC analytical analyses. 
Varian Aerograph HPLC , model 502000-00 was used for semi-preparative 
HPLC analyses. 
Beckman system gold HPLC equipped with a 126 solvent delivery system, 
a 167 UV detector and a 406 interface analogue was also used for analytical 
HPLC analyses. 
HP 1100 series LC with diode array detector was employed for LC/MS 
experiments. 
HP 1100 series mass spectrometer with an elestrospray ionization source 
was employed for MS and LC/MS experiments. 
Automatic time-base fraction collector, Frac 1 00 Pharmacia Fine Chemicals 
was used to collect fractions separated by means of the semi-preparative 
HPLC equipment. 
GLC packed column of 1.5 % silar 7CP on Gas Chrom Q (specifications: 
100-120 mesh; 183cm x 2mm id) obtained from Chrompack was used for 
GC-MS and gas liquid chromatography (GLC) analyses. 
Fused silica capillary GLC column of dimensions 0.32 mm id x25 m 
containing 3% OV-17 (Chompack) was used in GLC experiments. 
Sephadex LH-20 lipophilic gel permeation column, 40 em x 19 mm id 
(Pharmacia) was used to separate mixtures produced in the permethylation 
reaction. 
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Perkin- Elmer model gas chromatograph 
used for GLC experiments. 
a hydrogen flame detector was 
Hewlett Packard gas liquid chromatography-mass spectrometric detector 
(GLC-MSD) equipment of model 5985 B GC/MS/DS equipped with a dual 
electron impact-chemical ionization (EI-CI) source was used for GC-MS 
experiments, 
Macromass VG Quattro II MS/MS (Quadrupole-Hexapole-Quadrupole ) 
instrument fitted with electrospray ionization (ESI) source and coupled to 
HPLC (HP Series 1 050) was used forMS and tandem mass spectrometric 
(MSMS) analyses. 
Bruker DRX-500 MHz NMR spectrometer used for NMR spectroscopy. 
3.2.2 Biological Testing 
+ Bio-RAD Microplate reader Model3550 (Bio-Rad, CA, USA) was used for all 
the calorimetric determinations. 
Sorvall RT6000 Refrigerated Centrifuge, Dupont Canada Inc. Mississauga, 
(Ontario, Canada) was used for large volume centrifuging. 
Automatic C02 Incubator- Model GCA Precision LE-8744 was used for cell 
culture. 
Brinkmann Eppendorf Centrifuge 5415 C was used for micro volume 
centrifuging. 
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Beckman GS-6R centrifuge was used for centifuging of microtitre wei! 
plates. 
3.3 Methods 
3.3.1 Chemical Analysis 
3.3.1.1 HPLC Separation, Isolation and Purification of the Saponin Fractions 
i) Preliminary Analytical HPLC Separation 
Twenty microlitres of a 300 mg/ ml solution of Quii-A in 1 0 mM ammonium 
acetate was injected into the analytical column kept at a temperature of 
35°C. 
Peaks detected by UVabsorbance at214 nm were eluted from the analytical 
column by means of a linear gradient using the following water/ 
acetonitrile/1 0 mM ammonium acetate gradient with a flow rate of 1.5 
mllmin; t = 0-75%/15%/10%, t = 25-50%/40%/10%. 
The column was washed with a 1 OOmL of 100% acetonitrile after each run. 
1.5 ml fractions were either lyophilized directly after collection or stored 
frozen at -70 °C to be defrosted and freeze dried the following day. Dried 
samples were stored at -70 °C until needed for further separation or mass 
spectral analysis. 
67 
ii) liquid Chromatography/Eiectrospray lonization~Mass 
Spectrometry (LC/ESi=MS) 
Ten mi!!ilitres of a 300 mg/ml buffered solution of Quii-A in 10 mM 
ammonium acetate were eluted from the analytical column with a linear 
gradient of acetonitrile/water/1 0 mM ammonium acetate solution as follows; 
from 15: 75:10% to 40:60:10% over 40 min and from 40:60:10% to 90:0:10% 
in 20 min then kept at this concentration for 15 minutes. The flow rate was 
kept at 1 mllmin, ten percent of which was diverted into the ES source of the 
mass spectrometer. 
The LC/ESI-MS was carried out under the following conditions; the capillary 
voltage was set at -29 eV, the capillary temperature to 200°C, and the spray 
voltage was set to 25 kV. Nitrogen was used as sheath gas. 
The LC /UV traces were recorded online with a photodiode-array detector 
(HP 1100 serries). 
iii) Semi=preparative HPLC Separation 
Two hundred and fifty milligrams of a buffered aqueous solution of QuH-A in 
10 mM ammonium acetate solution was injected in to the column (kept at 
rom temperature) and eluted with the following water/acetonitrile/1 0 mM 
ammonium acetate linear gradient with a flow rate of 10 mllmin; t = 0 min-
75%/15%/10%, t = 25 min- 50%140%/10%, t = 75 min- 0%/90%/10%. 
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Better purity was achieved when the peaks were collected individually 
hand rather than by use of an automatic fraction collector as previously 
employed. By using manual collection, the peaks could be observed as they 
became eluted and could be collected in a timely manner from the beginning 
to the end of the peak. 
3.3.1.2 Solid Phase Extraction (SPE) of Crude Material 
~ SPE cartridges containing 1 g sorbent materia! were conditioned with one 
volume (volume of the cartridge = 6 ml) acetonitrile and rinsed with one 
volume of a buffer solution (1 0 mM ammonium acetate solution). The sample 
solution (50 mg in 500 !JL buffer solution) was applied and aspirated through 
the cartridge at a flow rate of 1-3 mllmin by means of an SPE vacuum 
manifold and pump apparatus. The cartridge was then washed with 1 mlof 
wash solution (15% acetonitrile in 10 mM ammonium acetate solution). 
The cartridge was dried under full vacuum for 2 - 5 minutes before being 
eluted with 90% acetonitrile in 1 OmM ammonium acetate solution. The elute 
was collected, dried, weighed and used in HPLC analysis. 
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3.3.1.3 Gas Chromatography= Mass Spectrometry (GC-MS) 
i) Sugar Analysis 
To determine the sugar composition of the saponin QF-23 the method 
outlined by Biermann and McGinnis, (1989), was adapted with some modifications. 
The method employed is as follows: 
> Acid hydrolysis; one mg of the dried sample was dissolved in 2 mL of 2 M 
trifluoroacetic acid (TFA) and kept at 100 oc for 12 hours. The mixture was 
evaporated to dryness on a rotary evaporator followed by addition of a 2mL 
of a saturated aqueous solution of sodium borohydride (NaBH4). One to two 
drops of glacial acetic acid was added, followed by addition of 2.0 mL of 
acetic anhydride in pyridine at a 1:1 ratio. 
The mixture was then kept at a 1 00 oc for a further eight hours, then 
evaporated on a rotary evaporator to dryness and dissolved in a sufficient 
amount of hexane (up to 1 mL) for GLC and GC-MS analyses. 
Gas Liquid Chromatography (GLC) and Gas Chromatography- Mass 
Spectrometry (GC-MS) of Alditol Acetates 
> GLC of the alditol acetates was performed on packed columns with 1.5% 
silar 7CP on Gas Chrom using helium as the carrier gas (Banoub et a!., 
1987). 
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GLC-MS was pertormed on the Hewlett Packard GC-MS instrument also by 
electron impact (EI) and by chemical ionization (CI) using methane as the 
reagent and carrier gas for Cl (Banoub et al., 1987) and the GLC columns 
specified in the apparatus and equipment section (3.2.1.). 
The obtained mass spectra were identified by the NIST (National Institute of 
Standards and Technology) MS data library. 
ii) Methylation Analysis 
The absolute configuration ofthe sugars present in the saponin fraction QF-
23 was determined essentially as described by Leontein eta!. (1978) and Gerwig 
eta!. ( 1978), which utilizes the trimethysilated (-)-2 butyl glycoside derivatives of the 
isolated mononsaccharides (Gerwig eta!., 1979; Banoub eta/., 1987) and by the 
method of circular dichroism measurement devised by Banoub and Shaw (1981 ). 
Methylation of the fraction was performed according to the method of Hakomori 
(1964), which is better understood as outlined by Bjorndal eta!., (1970), and by 
York eta/., (1985). In brief the method is as follows: 
~ one mg the dried saponin was dissolved in 1 ml of DMSO in a 6 ml hypo 
via and 1 ml of dimsyl sodium anion (methylsulfinyl carbanion; generated 
as outlined later) was added. 
The vial was flushed with nitrogen for one minute and stirred for an hour at 
room temperature with a magnetic stirrer, and with the vial capped with a 
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teflon lined stopper, vented with a G hypodermic syringe. 
After one hour, 1 ml of methyl iodide was added to the mixture, and the 
mixture was stirred for a further four hours without venting. 
The methylation mixture was then separated on a gel permeation column 
(LH-20 lipophilic Sephadex) and eluted with chloroform. One ml fractions 
were collected from the Sephadex column and spotted on a silica gel TLC 
plate before being charred with a 50:50 mixture of sulphuric acid in ethanoL 
The fractions that showed charring were pooled and evaporated to dryness 
and used for GLC and GC-MS analyses as outlined earlier for sugar analysis 
using chloroform instead of hexane and the results were compared to those 
found in the literature (Bjorndai eta!., 1967; Jansson eta!., 1976) 
The configuration of the sugars were verified by the method of Banoub and 
Shaw (1981 ), (see also Banoub eta/., 1983). 
Generation of the Dimsyl Sodium Anion. 
> Fifty milligrams of sodium hydride in oil was washed three times in benzene 
to remove the oil and the benzene was dried off by adding sodium metal to 
the mixture in a hypo vial. Excess benzene was blown off under a stream of 
dry nitrogen. 
The sodium hydride was then dissolved in 1 ml of DMSO and after the 
addition of a magnetic stirring bar, the vial was flushed with dry nitrogen for 
72 
one minute and capped with a teflon lined stopper. 
The mixture was then stirred at 60 oc for 90 minutes to 2 hours. A 21 G 
hypodermic syringe pushed through the stopper was used to vent off the 
generated hydrogen. A clear pale greenish solution was produced. 
The anion mixture was stored at -70 oc and used when needed. 
3.3.1.4 Mass Spectrometry (MS) 
~ Ten microlitres of the samples (buffered (with 10 mM ammonium acetate 
solution to basic pH) acetonitrile:water solutions) suspected to be pure, 
were injected into the Quatro II ESI MS/MS mass spectrometer and the 
solvent flow rate was kept at 0.4 IJL/min. 
Ionization temperature of 200 °C was used. Scans were done over a range 
of 300 m/z to 3000 mlz. Spectra were taken at fragmentation voltage of 25 
kV. 
The samples of interest were then dried under a gentle stream of nitrogen 
and stored at +4° for future analyses. 
Low-energy collision induced dissociation tandem mass spectrometry (CID-
MSMS) experiments were performed using argon as the collision gas in the 
collision cell. Cone voltage was set at 25kV and the collision energy at 180 
eV. 
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3.3.1.5 Alkaline Hydrolytic Cleavage of Fraction QF~23. 
~ Basic hydrolysis was carried out on 1.5 mg of the saponin fraction QF-23 by 
boiling in 3 mL of 6% NaHC03 in 50% methanol for one hour. 
The reaction mixture was then neutralized with a few drops of Dowex SOW-X 
8 and filtered through a sintered glass funnel. 
Finally the filtrate was evaporated to dryness and redissolved in 1 00 iJL of 
acetonitrile/water mixture (50:50) for mass spectrometric analyses. 
3.3.1.6 Nuclear Magnetic Resonance (NMR) Spectroscopy 
~ NMR spectra were recorded for 4. 72 mg and 1.85 mg of QF-22 and QF-23 
saponins, respectively, dissolved in deuterated methanol (CD300), to 
approximately 0.4 % w/v concentration, at room temperature. 
The samples were analysed with a 5mm triple resonance inverse probe in 
5 mm 00 capillaries. 
Chemical shifts were reported in ppm referenced against the solvent peaks. 
3.3.2 Biological Testing 
3.3.2.1 Evaluation of the Hemolytic Activity of the Fractions 
t Freshly collected and heparinized blood from Sprague-dawley rats was 
washed by centrifuging twice at 2000 rpm at 22 °C for 15 minutes with PBS 
(Oxoid, New Hampshire. UK), pH 7.4. Volume of PBS used for washing was 
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equal to volume of blood collected. The RBC pellet was then collected and 
further diluted with PBS in the following manner; 800 IJL of RBC were diluted 
to 4 ml to end up with a one in five dilution. 
A 100 1-JL of 1 mg/ml solutions of the saponins in PBS were added in 
triplicate to microtitre well plates and serially diluted two fold to make ten 
different dilutions. 
Twenty-five IJL of the diluted RBC was added to each plate well, and after 
15 minutes the plate was centrifuged at 2000 rpm for 5 minutes at 22 °C. 
Fifty 1-Jl of the resultant supernatant was then transferred to new microtitre 
plates before reading the absorbance at 540 nm using a Bio-RAD Microplate 
Manager. 
Three wells per sample were used, into which was added 50 1-JL of a 0.1% 
w/v solution of the detergent NP40 instead of sample solution for 100% lysis 
while three other wells were used containing only RBC and PBS to serve as 
blank and lysis was expressed as sample reading - blank reading/1 00 % 
lysis reading. 
The hemolytic activity of the compounds was quantitatively estimated 
graphically in terms of the hemolytic index at 50% haemolysis (HI50), which 
is the concentration of the saponin that gave 50 % haemolysis. 
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3.3.2.2 Toxicity Studies 
+ In the assay for intracellular dehydrogenase activity, cells of the J774 
monocytic cell line grown to 90 % confluence were seeded in 96-well 
microtitre plates and incubated for 24 hrs (1 00 iJL of a 104 viable cell/ml 
suspension per well). The medium was aspirated and serially diluted test 
samples were added to 100 iJL of fresh medium and incubated for 24 hours. 
The tests were carried out with eight control wells (having no samples added 
to them), while another eight cells had no cells in them representing 100 % 
killing. Four wells were used for each sample dilution. 
The samples were aspirated off the cells and a 1 00 iJL of fresh medium was 
added to the cells which were then allowed to recover for 24 hrs before 
aspirating the medium and adding to the wells a 100 !JL of medium 
containing a 1 in 10 dilution of a 5 mg/ml stock solution (in PBS) of 3-4,5-
dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT) and incubating for 
a further 4 hrs at 37°C. 
After incubation, the medium was aspirated, and 100 !JL 0.04 N HCI in 10 
% DMSO in isopropanol was added to the wells with vigorous agitation. The 
plates were then incubated for 20 minutes at room temperature before 
reading the absorbance at 595 nm with a Bio-RAD Microplate Manager plate 
reader, 
The concentration of the saponin sample causing 50 % cell death TC50 
(toxic concentration at 50%), was determined for each fraction. 
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3.3.2.3 In vitro Cytokine Production Determination as a Measure of Possible 
Adjuvant Aactivity 
i) Study of the Kinetics of Cytokine Production 
Cells of the J77 4 murine monocytic cell line grown to 90 °/o confluency were 
coated on to 84 wells of a 96 well microtitire plates at 105 cells per well and 
allowed to equilibrate over a 24 hours period before being inoculated (after 
aspiration) with a solution of LPS in fresh medium at 0.5 1-Jg/ml. A 100 1-JL of 
the LPS solution was added in 21 wells. Another 21 wells containing only 
cells and medium without LPS and 12 wells with no cells in them were 
subjected to the same conditions as for the ones containing the sample 
solution to act as controls. 
Plates were then incubated at 37 °C in a 5 % C02 atmosphere before the 
supernatant solutions were harvested from the cells at various intervals 
ranging from 12 to 84 hours in 12 hours increments, for IL-1 a 
determinations. 
Readings obtained from the wells in which no cells were added were 
subtracted from the readings as background readings while those from the 
wells containing the cells and medium alone were subtracted from the wells 
in which samples were added for constitutive IL-1 production by the cells. 
ii) Cytokine Induction by QF-23 
Cells of the J774 murine monocytic cell line grown to 90% confluence were 
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coated on to 96 well microtitire well plates and allowed to attach and grow 
over a 24 hours period before being inoculated with the different 
concentrations of saponin fraction dissolved fresh medium. 
The highest concentrations of saponin used was 1 0 % of the TC50 as 
determined in the toxicity studies. LPS was included as positive control. 
Untreated cells were incubated with medium alone to serve as constitutive 
control. While wells with medium alone were incubated concurrently with the 
test samples to serve as blank. 
The harvested supernatant medium solutions were assayed for the content 
of the cytokine interleukin-1 alpha ( I L -1 a) by sandwich enzyme I inked 
immuno-sorbent assay (ELISA). 
3.3.2.4. Enzyme Linked lmmuno-Sorbent Assay (ELISA) 
Initially the following ELISA protocol obtained from PetproTech laboratories Inc. 
(Rock Hill, NJ, USA) was followed for the determination of IL-1 a production by the 
cells; 
i) Plate Preparation 
The capture antibody provided with the murine IL-1 a ELISA Development kit 
obtained from PeproTech lnc.(Cat # 900-K82, Lot# 1 0082), which consisted 
of 50 ~g of affinity purified anti-mll-1 a, was reconstituted in 0.5 ml sterile 
water to obtain a concentration of 100 !JQ/ml. A sufficient amount of this 
78 
solution was further diluted to a concentration of 0.5 !Jg/ml and a 100 of 
this solution was immediately added to each ELISA plate well and the plate 
was sealed and incubated overnight at room temperature. The remaining 
capture antibody solution was aliquoted and stored frozen at -70°C, where 
it can be kept for more than 6 months. 
After the incubation period, the wells were aspirated to remove the liquid and 
the plate was washed four times with 400 !Jllwell of wash buffer (0.05 % 
Tween -20 in PBS prepared from 1 xPBS in sterile water from 1 Ox PBS). After 
the last wash, the plate was inverted to remove residual buffer and blotted on 
paper towel before adding 300 IJL of blocking buffer (1 % BSA in 1 x PBS) 
and incubating for at least an hour at room temperature. The wells were again 
aspirated and the plate was washed again with 400 !Jllwell of wash buffer. 
ii) Preparation of Standard Solutions and Samples 
The murine IL-1 a standard provided with the ELISA kit consisted of a 128 ng 
of recombinant mll-1 a which was reconstituted in 1 ml sterile water to make 
a 128 ng/ml solution which was a!iquoted and stored frozen at -70 °C. A 
sufficient quantity of this solution was further diluted to a 3 ng/ml 
concentration with diluent (0.05 % Tween-20 and 0.1 % BSA in 1 x PBS). 
This solution was then serially diluted as required and a blank of diluent was 
also used. 
A 100 iJL of standard or sample was added to each well in triplicate and 
incubated at room temperature for at least two hours. 
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iii) Detection of the ll=1a 
The provided 50 ~g of the detection antibody (biotinylated antigen-affinity 
purified goat anti-mll-1 a) was reconstituted in 0.5 ml sterile water to a final 
concentration of 100 ~g/ml. A sufficient volume of this solution was further 
diluted to a concentration of 0.5 ~g/ml in diluent (the rest was aiiquoted and 
stored at -70 °C). 
After the incubation period, the plate incubated with the standards and 
sample solutions was aspirated and washed four times with wash buffer and 
a 100 ~L per well of the 0.5 ~g/ml solution of the detection antibody was 
added immediately after preparation and the plate was incubated at room 
temperature for a further two hours. 
The plate was then aspirated and washed four times before a 100 ~L of a 
1:2000 dilute solution of avidin peroxidise (in diluent) was added and the 
plate incubated for 30 minutes at room temperature. 
The plate was again aspirated and washed ten times with wash buffer before 
adding a 100 ~~ of the substrate solution to each well. The plate was then 
incubated at room temperature for colour development which was monitored 
with an ELISA plate reader at 405 nm to obtain OD readings of not more than 
0.2 absorbance units for zero standard concentration and 1.2 absorbance 
units for the highest standard concentration. 
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Although the murine interleukin one alpha a) ELISA development 
used in this experiment was purported to be adequate for the detection and the 
quantitative measurement of natura! and/or recombinant miL-1 a in a sandwich 
ELISA format within the range of 32-2500 pg/mL problems were encountered with 
the above protocol which necessitated several trials that involved modification of the 
above procedure at various stages from adjustment of concentration of the kit 
components used (i.e. capture antibody, highest standard concentration, detection 
antibody), to trying out different incubation periods and the number of washings 
after each incubation, to determining the optimum avidin peroxidase dilution, and 
finally, the optimum wavelength for the determination of the optical density in 
monitoring colour development after the addition of the substrate was also 
investigated. 
Subsequently the above protocol was modified as follows: Concentrations of 
the capture antibody, highest standard concentration and detection antibody used 
in the protocol were, 0.25 IJg/mL, 1.5 ng/mL and 0.25 !Jg/mL, respectively, instead 
of 0.5 IJg/mL, 3 ng/mL and 0.5 !Jg/mL; 150 !JL (intead of 300 !JL) of the block buffer 
was used; plates were washed five times instead of four times after each incubation 
period and fifteen times instead often times after incubation with a 1:4000 (optimum) 
dilution of avidin peroxidase. Best results were obtained when colour development 
was monitored every five minutes at 405nm and readings that gave the best 
standard curve were usually obtained between 15 and 40 minutes (see results 
section, pages 162-165). 
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3.3.2.5 Statistical Analysis 
Data was analysed statistically using Prism GraphPad lnStat Analysis 
software using non-parametric, unpaired, two tailed t-test. Tests having probability 
(P) values of less than 0.05 were considered significant. 
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Chapter 4: Results and Discussions 
The following topics will be covered in results and discussions 
1) Preliminary analysis 
2) LC/MS elution profile of Quii-A 
3) Large scale separation of components by means of semi-preparative 
HPLC 
4) Solid phase extraction 
5) Mass spectrometry 
6) One pure compound having molecular weight 1560 (QF-23) structurally 
characterized 
7) Analysis of the sugar content and linkages of QF-23 
8) NMR spectroscopy performed for two compounds, QS- 21 molecular 
weight 1989 and for the compound QF-23 having molecular weight of 
1560 
9) Five more compounds of near homogeneity separated by semi-
preparative RP-HPLC including two of the ones documented in the 
literature. The compounds having molecular weights 1217, 1257, 1353, 
1389, 1856, 1989, and 955, the latter two have been identified before by 
other researchers. 
i 0) Hemolytic activity studies 
11) Toxicity evaluation of fractions QF-15,QF-21, QF-22 (QS-21 ), and 
QF-23 
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12) Studies of the kinetics of !L-1 a production a murine monocytic cell 
line 
13) Evaluation of the immune stimulating activity of fraction OF -23 
4, 1. Chemical analyses 
4.1.1. Separation, isolation and purification of saponin components 
The purification of the Quillaja saponins has been carried out mainly using 
reverse phase high performance liquid chromatography (RP-HPLC). This required 
some initial investigations to determine the optimum conditions for separation. 
Initially the separation of these components in our laboratory was carried out by 
means of a preparative thin layer chromatography (TLC). Attempts using RP- HPLC 
in various gradients of acetonitrile: water on C18 and C8 stationary phases proved 
impractical and afforded poor separation of the components (Sharpe, 1997). 
Excellent separation was later achieved using C5 reverse phase HPLC column 
which was found to provide a superior resolution than when a C8 column was used 
(Thompson, 1998). 
i) Preliminary Analysis 
Preliminary investigations involved the separation ofthe crude extract Qui I-A 
by means of an analytical column to investigate the elution characteristics of the 
material and to carry out method development and optimization. The results of this 
analysis set the foundation for large scale separation according to the guidelines 
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on HPLC method development found in the literature (Snyder eta!., 1988; 1997; 
Meyer, V. R., 1999). 
Preliminary analytical separation of Qui I-A using a C5 column gave rise to 
an elution profile (Figure 4) which resembled that found in the literature (van Setten 
eta!., 1995; So eta!., 1997). This profile shows clearly defined and well resolved 
peaks. On average, 50 peaks were apparent A compound having a molecular 
weight of 1560 was resolved at this stage. This compound was easily obtainable in 
a highly pure form. The compound has since been isolated in the semi-preparative 
HPLC separation and called QF-23. Structure elucidation by means of mass 
spectrometric techniques, that included electrospray ionization- mass spectrometry 
(ESI-MS) in the negative mode (Figure 29), CID-MS/MS (Figure 28), CVID-MS 
(Figure 27) and some cleavage reactions, resulted in the proposal of the following 
structure for QF-23 as shown in Figure 5. 
ii) liquid Chromatography-Mass Spectrometry (LC-MS) 
This procedure gave a tremendous amount of information about elution 
characteristics of the material separated and the individual components. The 
technique employed was the liquid chromatography/electrospray ionization-mass 
spectrometry (LC/ESI-MS). 
The photodiode-array and the mass detector signals obtained during the 
LC/ESI-MS experiment, as shown in Figure 6 and Table 5, give a summary of the 
report obtained. 
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Figure 4. 
I I QF-23 I )~J; 
·" 
::: 
~time (min) #, Time (m ~ 
Elution profile of Qui I-A as separated by means of RP-HPLC using a 
C5 analytical column. Absorbance was measured at214nm. The time 
intervals on the x-axis are 0, 10, 20, 30, 40, and 50 minutes. 
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Figure 5: 
C-3 
Glc UA 
H08 
Gal 2m 
Api 
Proposed Structure of Compound QF-23 
Glc UA =glucuronic acid, Xyl =xylose, Gal = galactose, 
Fuc = fucose, Rha = rhamnose, and Api = apiose 
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Figure 6: 
5 10 15 20 Time (min) 25 3 
Diode array detector (DAD) signal (top) and mass spectral detector 
(MSD) signal (bottom) as obtained from the LC/ESI-MS analysis of 
Quii-A. The MSD signal is lagging behind the DAD signal by about 
one minute. Absorbance was measured at 214 nm in milli absorbance 
units (mAU). Absorbance in the MSD signal is given in counts. 
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Table 5 (Legend) S~.Jmmary of the full report obtained from the LC/MS 
experiment carried out on Quii-A. 
10 mL of a 300 mg/ml buffered solution of Qui I-A in 10 mM ammonium 
acetate were eluted with a gradient of acetonitrile/water/1 0 mM ammonium 
acetate solution of; from 15: 75: 10% to 40:60:10% over 40 min and from 
40:60:10% to 90:0:10% in 20 minutes then kept at this concentration for 15 
minutes. The flow rate was kept at 1.5 mUmin, ten percent of which was 
diverted into the ES source of the MS instrument.The LC/ES!-MS was 
carried out on the analytical column and under the following conditions: the 
capillary voltage was set at -29 eV, the capillary temperature to 200°C, and 
the spray voltage was set to 25 kV. Nitrogen was used as sheath gas. 
The LC UV traces were recorded online with a photodiode-array detector. 
The results given in this table are for one of three experiments that were carried out and found to 
give similar results. 
*1 Entry #; Serial number of the entry into the table. In most cases the MSD signal has been 
matched up with a corresponding DAD signal, with the MSD signal lagging behind by 
anywhere from 0.02 to 0.238 of a minute (1.2-12 seconds) with most peaks differing in 0.15 
minutes (9 seconds). Some MSD signals were found to not have corresponding DAD 
signals. This was attributed to the fact that the compounds whose ions were detected by 
the MSD at these times do not absorb very we!l in the specified UV range. Similarly some 
DAD signals could not be matched up with any MSD peaks, this could be due to the fact that 
the compounds that were detected by the DAD at those times do not ionize in the negative 
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mode. Still both cases could happen simply because the integration was not carried out at 
those times. 
*2 Peak#; Corresponds to the peaks integrated in this report. The numbers in brackets correspond 
to the peak numbers included in the appendix. 
*3 Elution time; MSD retention time 
*4 Most Abundant ions; Ions having 100% abundance or closer in the TIC at this given retention 
time. 
*5 Total Abundance for the peaks; Obtained manually from the MSD signaL The compound 
having molecular ion mass of 2297 m/z known as QS-111 (Higuchi et al., 1988) and QS-17 
(Kensil et al., 1991) was found in the highest MSD peak at retention times 22.823 minutes. 
*6 Components; reported after integration 
*1 Total number of ions; Do not correspond with the number of components detected as some 
ions are seen as coming from a single component 
*8 Other ions detected; Ions that are seen as coming from one component are entered in an 
identical fashion, differentiated by italics, bold, bold italics, and thereafter by('),(")("'), etc. 
Peaks for which this data is not entered are included in the appendix and the corresponding 
peaks in the appendix are given in brackets. 
*9 Purity Assessment; as obtained after integration of the MSD signal. Ali the peaks were seen 
as being impure, having more than one components. Some peaks did have as few as two 
components only. 
*1 0 DAD Purity assessment; gives clearer quantitative peak purity calculations 
*11 # of spectra; Components # as reported by the DAD were seen to be different from those 
reported by the MSD for corresponding peaks. Threshold limit of 999.000 is a default purity 
threshold limit. 
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"12 UV absorption; Provides a quantitative estimate of the components. Compound with 
molecular ion mass of 1353m/z (QF-15) was found in the highest DAD peak at retention 
time 18.197 minutes. 
*13 Peak elution time; In the DAD signal is ahead of the MSD signal 
*14 Peak# DAD signal; Some are included in the appendix. The numbers in brackets are definitely 
in the appendix. 
*Hi Compounds' UV absorption characteristics; Between 190 and 400 nm as recorded by the 
DAD. Has been classified as saponin like and non-saponin like for the purposes of this 
report (see Figure 7). 
"16 Time difference between the peaks; Gives a good indication of whether the MSD and the 
DAD signals being matched could be considered as corresponding. 
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Table 5 Summary of the full report obtained fmm the LC/MS experiment carried out on Quii-A 
MSD signal DAD signal 
Entry Peak Elution Most Total Total Total Other ions Purity Purity #of uv Peak Compds Time 
# # time Abundant Abunda·· #of #of detected Asse- assess- spectra abso- elutio Pk# uv difference (min) ion nee for com- ions ssme men! within rption ntime abspln between (MSD this peak pone·· detec- nt factor purity out of (DAD Charact- the peaks 
signal) out of nts ted out of threshol 1000 (min) signal) eristics (MSD-
800 000 delec- 1000 d limit of mAU (saponin DAD 
ted 999.000 or non- signal 
saponin) times) 
(*4) (min) (*1) (*2) (*3) (*5) (*6) (*7) (*8) (*9) (*10) (*11) (*12) (*14) (*13) (*15) (*1Ei) 
1 3 1.675 1110 450000 530, 734, 755, im- 999.495 3/3 180 1.575 3 saponin 0.100 
- - 881 ,929,986' pure 
1110,1131,1157, 
1168,1506,1597, 
1796,2121,2184, 
2698, 
2 4 1.919 1061 340 000 - - 1061,2039,2950 im- - - - - - - -
pure 
3 - - - - - - - 999.142 5/5 400 2.020 6 saponin 
4 - .. - - - - - - 999.984 3/3 400 2.092 7 Saponin -
5 - - - - - - - 999.979 3/3 400 2.195 8 saponin -
6 .. - - - - - - .. 999.982 3/3 100 2.341 9 saonin -
7 5 2.791 1543 100 000 
- -
662,1560,2017, im- 963.915 2/5 250 2.636 10 saponin .0155 
pure +non-
saponin? 
8 6 3.213 1270 100100 10 18 543,1261,1270, im- - .. - - - - -
1316,1362,1369, pure 
1426,1845,1855, 
2015,2034,2487, 
2571,2660,2773 
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9 7 3.391 603,1450, 250 000 5 8 537,603,797,850, im- 995.211 7/7 400 3.147 12 saponin 0.244 
2203 1450' 1 020,2045 pure 
2204 
10 8 3.547 2727 200 000 4 12 537,547,785,850 im- 99.698 3/3 100 3.501 15 saponin 0.048 
1020,1197,1450, pure 
1602,2106,2677, 
2727,2805 
11 9 3.682 2006,2613 220 000 5 7 1018,1448,2007, im-
-
.. 
-
-
.. 
- -
2360,2614,2727, pure 
2805 
-
12 10 3.828 1951 260 000 5 10 925,972.1476, im- 999.914 3/3 50 3.741 18 saponin 0.087 
1633,1795,1951, pure 
2006,2606, 
2727,2944 
--" 
-
13 11 3.994 926,2771 240 000 - 7 926,979,985, im- 989.363. 1/5 50 3.846 20 saponin 0.148 
1130,1723,2771' pure 
2819 
14 12 4.223 2558 280000 6 9 939,1076,1227, im- - - - - - - -
1344,2450,2497 pure 
2553, 2820,2950 
15 - - - - - - - - 999.414 3/3 50 4.302 23 saponin -
16 13 4.493 2382 180 000 5 7 879,1024,1946, im- 999.902 3/3 50 4.462 24 saponin 0.031 
2793 2106,2107,2382, pure 
17 14 4.844 510 220 000 3 5 510,1139,1696, im- 999.950 3/3 50 4.698 26 saponin 0.146 
1809,2954 pure 
18 15 5.160 2447 220000 6 817,2182,2387, im- 99.980 3/3 50 5.047 28 saponin 0.113 
2545,2760,2935 pure 
19 16 5.449 700,1318, 700,776,1307, im-
- - - - - - -
1747,2203 230000 7 9 1318,1600,1748, pure 
1767,2036,2203, 
2638 
!---------· -~·--·~~-m-~~ ·~=~~"~•mm m~'-"'" 
-·--1-----·--
20 - - - .. .. - - - 999.024 5/5 50 5.462 31 saponin -
21 17 5.722 1996 180000 2 4 840,1487,1996, im- 99.834 3/3 50 5.695 32 saponin 0.027 
2501 pure 
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22 18 5.884 655,1476 180 000 3 5 655,1477,1614, im- - - .. - - - -
1951,2445 pure 
23 19 6.089 1387,2471 180 000 7 16 624, 871' 920, im-
,2713 1083' ,1388,1436, pure 999.834 3/3 50 5.945 35 saponin 0.144 
1594,1725,1887', 
1932, 1969,2217", 
2471 ,2705' ,2713" 
,2746",2948 
24 20 6.383 1057 25000 6 12 528,798,933, im- 999.264 3/3 50 6.216 37 saponin 
1057,1059,1151' pure 0.167 
1330,1407,1433, 
1555, 1854' ,2801' 
2886 
25 - - - -
- - - - 3/3 6.364 38 non- -
997.575 100 saponin , __ , 
··-·---
1----- f..--
·-
26 21 6.624 925,2317 25000 5 8 776,925,926,927, im- 999.302 3/3 150 6.604 40 non-
1262,2317,2679' pure saponin 0.020 
2862 
27 22 6."731 1541,1798 260 000 - 6 551,769,915,927, im- - - -
-
.. 
- -
1039, 112"1, 1262, pure 
1541,1747,1799, 
28 23 6.933 871,1027 240 000 5 6 871,1028,1214, im- 999.539 3/3 6.901 ~~-- saponin 0.032 
1688,1694,2138, pure 50 
29 24 7.231 2453,2568 260 000 6 8 525,574,620, im- 999.570 3/3 7.083 45 saponin 0.148 
2351,2452,2453, pure 50 
2568, 
30 25 7.480 955 260 000 
- 5 797,955,969, im·· 999.140 2/7 7.332 47 saponin 0.152 
1065,2912 pure 50 
--
31 26 7.817 955 260 000 8 19 543,773,911,955 im- 999.592 3/3 50 7.587 49 saponin 0.230 
962,1123,1259,1 pure 
330,1398,2785 
-
32 27 7.968 955 280 000 3 9 511,797,798,962, im- 999.689 5/5 50 7.923 51 saponin 0.045 
969,1738,2109, pure 
2162,2912 
···--~ O~OD 
33 28 8.090 955 300 000 2 2 721,955 im- 999.927 3/3 50 8.039 53 saponin 0.051 
pure 
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34 29 8.223 955 320 000 7 14 675,721,954,955, 
- - - - - - -(8.219) 963,969,1257, im-
(20) 1558,1653' ,2089, pure 
2228,2267 ,2462'. 
2700' 
35 30 8.364 955 340000 3(2) 9(6) 955,956,970, im-
1572,2157,2298, pure 99.989 3/3 100 8.258 56 saponin 0.106 (21) 2455,2873 (41) 
36 31 8.504 624 360 000 - 8 624,797,955,970, im- 986.975 2/5 100 8.449 58 saponin 0.055 
1689,2624,2711, pure (43) (22) 2862 
37 32 8.918 675,2120 280 000 - 7 629,675,1856, im- 912.651 4/5 50 8.837 60 non- 0.081 
2120 .. 2330,2430 pure saponin? (23) (45) 
38 33 9.220 1349 280 000 9 13 645,674, im- 551.069 3/5 150 9.178 62 saponin 0.042 
741,763,925,944, pure + 
1123,1311,1349, non-(24) 1350,1608,1816, (47) saponin 
2580 
39 34 9.486 2143 220 000 4 5 2064,2143,2211, im- -
- - - - -
.. 
(25) 
2289,2515 pure 
40 35 9.786 1217 260000 - 8 608,1217,1218, im- 999.504 3/3 250 9.749 65 non- 0.037 
1219,1220,1331, pure saponin (26) 1768,2207 (50) 
41 36 9.996 761, 1812 300 000 8 8 im- 983.882 1/3 100 9.976 67 s 0.020 (27) pure (52) 
42 41 11.059 1371,1866 260 000 
- 8 1371,1867,2520 im- 994.498 3/3 50 10.918 
- saponin 0.141 
2520 pure 
43 44 12.244 600 000 - 9 525,746,836,154 im- 973.384 2/5 150 12.099 82 saponin 0.145 
1673 1,1689,1674,167 pure 
3,2149,2816 
44 45 12520 1866 660 000 5 10 741,837, 843, im- 999.921 3/3 200 12.264 84 saponin 0.256 
- 1661,1675,1688, pure (65) 
1751,2062,2290, 
2842 
95 
45 46 12.610 2842 680000 9 16 741,782,636, im~ 99.265 3/3 50 12.589 86 saponin 0.021 
1312,1565,1674 pure (67) 
1675,1687,1689, 
2061 ,2753,2843, 
2845. 
46 47 13.012 1565, 580 000 7 14 633,782,789, im~ 
- - - - - - -(36) 1566 1189,1379,1511, pure 
1565,1566,1567, 
1568', 1579" ,1580 
1692, 1895,2398" 
47 
- -
.. 
-
- - - im- 999.602 5/5 75 - saponin 
-
pure (13.025 (68) 
48 48 13.221 1511 560 000 5 12 510,755,789, im- 999.920 3/3 150 13.184 90 saponin 0.037 (37) 1431,1511,1512, pure (69) 
1519' ,1525,1526', 
1581,2604, 
49 - 14.051 1505 260 000 2 3 731 '1505 ,2254 im- - - - - - - -(39) pure 
50 - - - - - .. - - 999.881 5/5 50 14.052 - saponin -
(73) 
51 59 1"1.024 1383 660 000 
- 13 691,865,1353, im- 999.162 5/5 200 16.961 112 saponin .063 
1354,1383,1384, pure (85) 
1497,1583,1715, 
1730,1870,1882, 
2733 
52 - - - - - - - .. 999.742 717 600 17.226 114 saponin 
53 60 1"7.230 1383 660 000 4 8 676,1349,1353, im- - - - .. - - -
1354,1355,1567, pure 
- 1581,2199 
54 61 17.459 1862,1876 660 000 7 18 525,649,831 ,937'. im·· - - - - - .. -
1 045,1207"'' 1339 pure 
,1340,1861", 
1485"',1862", 
1863'' 1869" ,1875 
- ',1876, 1927,2017, 
2187 
·~~~~~ ~~ ~~·~·~· 
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~ 
55 62 17.825 1515,1699 660 000 .. 11 757,849,1515, im- 999.953 5/5 150 17.804 117 saponin 0.021 
2547 1516,1517,1699, pure 
1701,1713,1875, 
2434,2547 
56 63 18.184 1353 740 000 6 7 676,713,1353, im-
- - - - - - -
1354,1355,1467, pure 
1468 
57 - 18.272 1353 740 000 6 7 676,713,1353, im- 999.990 3/3 1150 18.197 120 saponin 0.075 (47) 1354, 1355,1467', pure (89) 
1468" 
58 64 18.49'7 1485 680 000 8 18 im- 999.995 3/3 200 18.480 121 saponin 0.017 (48) pure (91) 
59 65 18.770 1221 680 000 
- 9 1221 '1222,1223 im- 999.994 3/3 780 18.718 123 saponin 0.052 (49) pure 
·~-· 1--
60 67 19.588 1353 540 000 7 12 im- 999.820 3/3 50 19.577 127 saponin 0.011 (51) pure (95) 
61 68 20.197 1191 52000 3 5 1191,1192,1193, im- 999.945 6/6 50 20.062 130 saponin 0.135 (52) 1305 pure 
·-
62 70 20.618 1433 700 000 3 6 716,1177,1433, im- 999.875 3/3 100 20.532 134 saponin 0.086 
1434 pure 
63 71 20.743 1433 640 000 7 14 im-
- - -
.. .• 
- -(54) pure 
64 72 20.968 1475 680 000 4 8 737,767,768, im- 999.865 5/5 150 20.763 137 saponin 0.205 (55) 1405',1475,1476" pure (101) 
,1477,1478", 
2214" 
65 . 21.794 1059 640 000 8 15 im .. 999.998 3/3 350 21.884 144 saponin 0.031 
(58) pure (106) 
66 76 21.915 1059 560 000 2 5 1059,1060,1061, im-
- -
. 
- - - -
. 1592,568 pure 
-
67 - 22.489 1475 '120 000 5 7 767,831,1475, im- - - . .. . - -
(60) 1476,1477,1632, pure 
1799' 
-
68 79 22.661 1758 760 000 4 16 im- 999.867 717 350 22.602 149 saponin 0.059 
(61) pure (110) 
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69 80 22.823 2297 840000 9 20 im- -
- - - - -(62) pure 
70 81 23.079 2310 780 000 4 9 1148,1166,2298', im- 999.915 8/8 500 22.907 152 saponin 0.190 
- 2303,2304,2309, pure 
2310,2311' ,2577 
71 ~3.179 2310 780 000 2 5 1147,1148,2295, im- - .. 
- - - - -
2304,2310, pure 
72 83 23.359 2018,2150 720 000 
- 9 1155,2012,2018 im-
- - -
.. 
- - -(63) 2310 2032,2134,2150, pure 
2163,2296,2310 
73 84 23.693 2150 720 000 9 20 im- 999.520 5/5 600 23.448 156 saponin 0.245 (64) pure (115) 
74 
- - - - - - 976.979 2/5 1050 23.717 - saponin 
75 85 23.908 2149, 850 000 -
-
1475,2018,2134, im- 999.977 5/5 1050 23.717 158 saponin 0.190 
2166 2150,2163,2166 pure 
76 86 24.744 1856, 700 000 - - 1768,1856,1857, im- - - - - - - -(66) 1989 1858,1987,2002, pure 
2003,2004,2586 
77 - - - - - - .. - 999.876 3/3 200 24.791 - saponin .. 
(119) 
'18 <>I L:>.L20 1989 640 000 - - 1856,1989,1990, im- 998.797 717 200 25.097 162 saponin 0.123 
(67) 2003 pure 
79 88 25.485 1989 620 000 .. - 675,1855,1858,1 im- - - - - - - -
(68) 989,2002,2003,2 pure 
004 
~~~~~ 
80 89 26.299 2030, 580 000 - - 1014,1517,1856, im- - .. - - - - . 
(69) 2044 2031,2043 pure 
81 90 26.575 2030, 340 000 8 21 853,845,875,882, im- 999.471 m 150 26.337 166 saponin 0.238 
2043 1014,1016, 1022', pure 
1033", 1691"',170 
5,1706,1825'", 
1869, 1875", 1897, 
1898', 1899' ,2038, 
.......__ 
2045,2046,2118, 
98 
82 91 26.956 1560 480000 4 8 809,1560, im- - - - - - - 0.020 
pure 
83 92 27.051 1560 540 000 5 8 im- 983.421 1/7 50 26.936 168 saponin 0.115 
(72) pure (126) 
84 93 27.196 1560 460000 5 6 810,1560,1561, im- - - - - - - -
2024,2334,2683 pure 
85 94 27.392 1560 380000 4 6 810,1560,1561' im- - - - - - - .. 
(74) 2024,2334,2683 pure 
86 95 28.018 1856 220 000 
- -
756,985,1723, im- 980.865 2/3 25 27.981 173 saponin 0.037 
1856,18581870, pure 
1973,1974,1988 
87 99 30.008 1856, 300000 - - 779,809,852, im- 997.569 3/3 25 29.936 182 saponin 0.072 
(77) 1972 2340 pure (138) 
-
88 122 39.418 2135 50000 2 2 1518,2135, im·· - - - - - -
pure 
99 
A group of compounds were noticed to have similar UV absorption characteristics 
(Figure 7) typical for saponin compounds (Ahmad and Basha, 2000). These were 
concentrated more in the portion of the chromatogram from ten to thirty minutes 
retention time. In this area the highest UV absorption was on average obtained at 
about 214 nm. Very few peaks along the spectra or chromatogram showed high 
purity (Figure 8), emphasizing the tendency of the components of this materia! to 
co-elute. 
Some high molecular weight ions were detected at the beginning of the run, 
as evidenced from the inspection of the total ion chromatogram (TIC) of the 
experiment shown in Figure 9. Some of these peaks did not, however, show the 
"typical" saponin UV absorption characteristics shown before, but were 
nevertheless intriguing. Figures 7 and 9 show the UV absorption shown by some 
of these compounds. These compounds were found to be eluted from the column 
as early as the first five minutes. Inspection of the mass spectra revealed the 
presence of ions with very high molecular weights, many of which do not appear to 
have been identified anywhere in the literature (Table 6). The actual stability of 
these ions is however not known. They could also be due to the formation of dimers 
between the molecules of the stable components. Preliminary inspection however 
did not point towards this speculation. The ions belonging to sixteen molecules of 
the compounds previously detected by other researchers were identified in the 
mass spectra of this experiment (Table 7). 
{Cont. on p. 109) 
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Characteristic saponin UV absorption as obtained from the diode 
array signal of the LC/MS experiment carried out on Quii-A. a), b), c) 
and d) represent the absorption characteristics of the compounds 
eluting at retention times 23.717, 26. 337, 1.997 and 2.637 minutes 
respectively. 
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Figure 8: An example of purity assessment of the peak at retention time 
23.909 minutes in the MSD signal (Figure 88). That same peak is 
detected at 23.717 minutes in the DAD signal (Figure 8A). Figure 
8C shows the ions that are detectable in that peak. 
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Figure 9: a) Total ion chromatogram (TIC) showing high molecular weight 
compounds with saponin like UV absorption characteristics being 
eluted early in the LC/MS separation of Quii-A. Ions having 
molecular weights of m/z 1426, 2660 and 2773 are clearly 
detectable. 
b) Shows the absorption characteristics observed for these 
compounds. 
c) Shows the absorption characteristics of compounds eluted as 
early as 1.577 minutes as being saponin !ike. 
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Table 6: Some of the high molecular weight compounds detected the mass spectra 
of the LC/MS experiments that were not previously identified by other 
researchers 
Molecular Elution Times (min) uv 
ion mass absorption 
MSD DAD Caharacteri-(m/z) sties 
2438 17.825 17.804 saponin like 
2447 5.160 5.047 saponin like 
2450 4.223 
-
-
2453 7.231 7.083 saponin like 
2487 3.213 - -
2509 5.722 5.695 saponin like 
2515 9.485 - -
2520 11.059 10.918 saponin like 
2547 17.825 17.804 saponin like 
2558 4.223 
-
-
2567 7.231 7.083 saponin like 
2571 3.213 - -
2580 9.220 9.178 ? 
2613 3.682 I saponin like 15.419 15.395 
2624 8.504 8.449 saponin like 
2638 5.449 - -
2660 3.213 - -
2677 3.549 3.501 saponin like 
2679 6.624 6.604 non-saponin like 
2698 1.675 1.575 saponin like 
2705 6.089 5.945 saponin like 
106 
2713 6.089 5.945 saponin like 
2727 3.549 3.501 saponin like 
2746 6.089 5.945 saponin like 
14.684 14.560 
2771 3.994 3.846 saponin like 
2773 3.213 - -
2785 7.817 7.587 saponin like 
2793 4.493 4.462 saponin like 
2794 9.996 9.976 saponin like 
2801 6.383 6.216 saponin like 
2820 4.223 - -
2848 12.610 12.589 saponin like 
2862 6.624 6.604 
2872 8.364 8.258 saponin like 
2912 7.968 7.923 saponin like 
16.378 
2935 5.160 5.047 saponin like 
2950 4.223 - -
2954 4.844 4.698 saponin like 
9.220 9.178 
9.498 
107 
Table 7: Ions belonging to molecules of the compounds previously detected 
by other researchers that were identified in the mass spectra of 
the LC/ESl-MS experiment. 
Motecujar Detected by Researchers Compound I Elution Times (min) I ion Name 
mass (where known) MSD DAD (m/z) 
956 So eta!., 1997 QS-L 1 7.847-8.504 7.587-8.20 
1512 13.012 
Higuchi et al., 1987 DS-1 13.221 13.184 
19. i 10 19.110 
1626 van Setten et al., 1995 10.485 14.684 
14.684 14.560 
i640 van Setten et a/., 1995 19.1:0 19.110 
1696 Higuchi eta/., 1987 DS-2 4.844 4.698 
17.825 17.804 
20.743 
30.199 
1788 van Setten et al., 1995 18497 18.480 
19.110 19.110 
21.233 21.229 
22.124 22.073 
1862 van Setten et a!., 1995 17.459 17.226 
17.825 17.804 
1869 van Setten eta/., 1995 17.459 17.226 
26.575 26.337 
1876 van Setten et ai., 1995 17.459 17.226 
17.825 17.804 
1886 Kensil eta!., 1991 QS-7 18.770 18.718 
19.585 19.577 
1989 Kensil et al., 1991 QS-21 24.744 -5.485 23.971-25.097 
2018 Kensil eta/., 1991 10.818 10.520 
17.459 17.226 
22.661 22.602 
2150 Kensil et a/., 1991 QS-18 23.693 23.448 
van Setten eta!., 1995 23.908 23.717 
2296 Higuchi eta!., 1988 QS-Iil 8.364 8.258 
22.124 22.073 
22.823 
23.179 
2321 Kensil eta!., 1991 QS-17 6.624 1 6.604 
Table 7: Ions of molecules previously detected by other researchers 
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Other very useful information that was obtainable from the LC-MS of Quii-A 
was the extracted ion chromatogram (EIC) (Figure 1 0). With this information it was 
possible to pinpoint the exact peak of a given molecular ion. 
iii) Semi~preparative HPLC 
The aim of this undertaking was to obtain large amounts of individual 
components or fractions in pure or near pure form. Sufficient quantities of the 
purified saponin fractions were necessary to facilitate further chemical analyses and 
biological investigations. The separation by means of a semi-preparative HPLC 
column resulted in an elution profile that surprisingly showed better separation than 
the one obtained by analytical separation (Figure 11 ). Batch to batch differences 
in the elution profiles were noticed. The UV detector used was limited to a maximum 
column loading of 250 mg of crude material. This amount resulted in very low 
yields, necessitating multiple runs before an amount of material sufficient for further 
analyses could be obtained. This exercise was found to be inconsistent, 
cumbersome and resulted in material loss, as the fractions collected were 
distributed in several containers. The ideal situation would have been to separate 
as much as 2.5 g of Qui I-A all in one run. This would have required the purchase 
of a flow cell suitable for semi-preparative separations to be used with the analytical 
HPLC systems available in our laboratory or alternatively to obtain access to an 
HPLC system designed specifically for semi-preparative HPLC separations. (top. 113) 
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Figure 10 A) Extracted ion Chromatogram (EIC) for QF-22 (QS-21) Mwt 1989 
(iii) and QF-23 Mwt 1560 (iv). The spectrum shows the ion detected at 1989 
mlz to be concentrated more on the peak eluted at 25.485 minutes (MSD 
signal,(ii )) which corresponds to the peak eluted at 25 .097 minutes in the 
DAD signal (i). While the ion detected at 1560 m/z is concentrated at 26.387 
minutes (MSD signal) which corresponds to the peak seen at 26.337 
minutes in the DAD signal. 
Also see legend to Figure 10 B (page 1 05) for more explanation. 
(Y-axis of the rest of the figures except for the DAD signal give 
abundance of the ions in counts. Y -axis in the DAD signals gives UV 
absorbances in milli absorbance units (mAU). X- axis give retention 
times in minutes.) 
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Figure 10: B) EIC of ions, detected at m/z, 1257, QF-11 (ii 1389, QF-15 
(iv), 1560 QF-23 (V), 1856, QF-21 (vi), 955, QF-9 (QS-l1) (vii) 
and QF-22 (QS-21) (viii) m/z 1989. (i) and are the MSD and 
DAD signals. 
(Y-axis of the rest of the figures except for the DAD signal give 
abundance of the ions in counts. Y -axis in the DAD signals 
gives UV absorbances in milli absorbance units (mAU). X- axis 
give retention times in minutes.) 
The ions of the same molecular mass can be seen eluting at different points 
on the profile. Several probable explanations for this occurrence could be brought 
forward: 1. These could be ions of the same compound that are for some reason 
showing different affinity properties to column material (e.g different isomers of the 
same molecule of the compound). Isomerization of the compounds of Quillaja 
sapaonaria Molina have been reported by other researchers before (van Setten et 
a!., 1995, Cleland eta!., 1996). In fact both the identified isomers of QS-21 were 
found to be immunologically active (Cleland eta/., 1996). 2. These could be ions 
of compounds with different molecular structures but same molecular weight. The 
compounds could exist as such in the Quillaja extract, they could also have been 
formed as a result of the breakdown of other compounds while the column, 3. 
These ions could also be multiply charged ions of compounds of higher molecular 
weight. 4. The ions could be daughter ions formed during fragmentation of ions of 
higher molecular weight compounds. 
Figure 10: B) EIC of ions 111 
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Figure 11: Elution profile of Qui I-A from a semi-preparative column; C5 RP-
HPLC with a guard column; 15 1Jm, 300 A, 22.1 mm x 250 mm. 
Numbers on peaks refer to retention time minutes. 
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Neither of these were possible. As a result of repetitive runs fraction QF-23 was 
obtained in pure form (Figure 12). An average of 1.0 mg was obtained from 250 
mg of Qui I-A About fifty HPLC runs, with an average of 250 mg crude Qui I-A were 
carried out. A total of 35 fractions were collected and recovery of each fraction 
varied from 0.2 mg to 13.4 mg dry weight. Fractions QF-30 to QF-35 were obtained 
in the lowest amounts while fractions QF-17, QF-20, QF-21 and QF-22 were 
obtained in larger amounts. 
Name change 
The name of the compound P5 ( Quillaja saponin with molecular weight 
1560), separated during preliminary analytical HPLC was changed to QF-23 
(Quillaja Fraction number 23) after semi-preparative separation. The basis for the 
name change was due to the fact that this fraction was collected in the twenty-third 
fraction while using the automatic fraction collector set to collect fractions at two 
minutes intervals. In addition, the name QF-23 is in conformity with the naming 
system that has been commonly used by other researchers on this subject of 
Quillaja saponins; such as QS-21, QH-A, QS-L 1, and OS -1. 
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Figure 12: Mass spectrum of compound QF-23, molecular mass 1560 m/z, as 
obtained after purification by means of semi-preparative RP-HPLC. 
The singly charged ion of this molecule is detected at m/z 1559.9, 
while the ion detected at m/z 779.3 represents the doubly charged 
ion, [M-2Hf, of the molecule of QF-23 
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4.1.2 Drying of the fractions 
Removal of the solvents employed in the purification of the Quii-A 
constituents was fundamental to the process and imperative for the successful 
analysis of the saponins. This proved to be a challenge. The fractions had to be 
obtained free of solvents, which were mainly organic (acetonitrile) and a buffered 
aqueous solution (water containing ammonium acetate mostly in 1 mM 
concentration), because they interfered with subsequent analyses (both chemical 
and biological). For example, in biological testing fractions are diluted either in PBS 
or in cell culture media both of which are aqueous solutions and the presence of 
organic solvents in these instances would have detrimental consequences. 
Likewise, the presence of water in nuclear magnetic resonance experiments was 
undesirable as it would cause interference. The preservation and drying method 
employed should preserve the integrity of the constituents of the fractions and not 
lead to the hydrolysis or deterioration of the components. The feasibility and 
suitability of several drying methods were investigated, including freeze-drying, 
cryo-crystallization, air drying and drying under a gentle stream of the inert gas 
nitrogen. It was found that drying by blowing away the solvent under a gentle 
stream of nitrogen was a suitable method of drying as shown by the before and 
after spectra of the tested fractions in Figures13 and14, respectively, as being 
identical, showing no deterioration of the sample. 
(cont. on p. 11 B) 
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Figure 13: ESI-MS mass spectrum of pure novel compound, QF-15, 
detectable at m/z 1389.3. The ions detectable at m/z 712.3 and 
713.4 represent the potassium salt of the doubly charged ion of the 
original compound having molecular weight 1354 Dalton. 
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Figure 14: ESI-MS spectrum of pure novel compound QF-15 after drying and 
storage. The ion of this compound is detectable at 1353.5 m/z and 
as a potassium salt at 1389 m/z. The potassium salt of the doubly 
charged ion is observable at 712.4 and 713.4. AI! the ions detected 
in this spectrum represent one compound, having molecular weight 
1354 Dalton. The other ions are probably due to isotope differences. 
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The peak observed at m/z 712 is the doubly charged ion of the compound detected 
at m/z 1389. Preservation at -70 °C is recommended for the solvated samples while 
storage at +4 ° C was found to be adequate for dried samples. 
4.1.3 Purity assessment 
The purity of the separated fractions could be determined by a number of 
techniques, including, TLC, re-injection into an analytical HPLC column alone or 
equipped with a mass spectrometer or mass spectrometry alone. The latter method 
of purity assessment was used because it was the quickest and most accurate of 
these methods. For example the MS spectrum shown in Figure 15 shows that the 
fraction analyzed is clearly impure while the samples analyzed in Figures 13 and 
14 are shown to be of relatively much higher purity. 
4.1 .4 Determination of the chemical nature of the components. 
The chief constituents of the bark of Quillaja saponaria Molina tree are 
saponins, which together with other extractable material (in water, ethanol or water 
ethanol mixtures) constitute 20-25% of the weight of the bark. The saponins 
themselves are estimated to constitute 5% of the bark weight and 20% of the 
extractable material from the freshly prepared extract of the bark. The rest of the 
(cont. on p. 120) 
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Figure 15: Impure analyzed fractions: a) fraction QF-35 
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extractables are tannins and phenolic compounds which are separable from the 
saponin extract of Quii-A via dialysis, gel filtration and dial filtration (Kensil eta/., 
1996). In our research we have employed SPE to eliminate these non-saponin 
materials from Quii-A. However, we have abandoned this procedure because it is 
not known if these are active or inactive immunologically, as it has been purported 
that the immunological activity of Qui I-A may very well be due to its non-saponin 
constituents as well as its saponin ones (Campbell and Peerbaye, 1992). We 
accordingly decided to collect fractions from all of the elution profile in case we 
become interested in including these components in our research (these are 
labeled QF-1 to QF-1 0). 
Quii-A extract also has been shown to contain proteins - 0.5%, fat- 4%, 
fibre- 0.3%, ash- 2.5%, moisture- 5.5%, and other carbohydrates, including starch 
and sugars - 70%. Calcium oxalate and uronic acid may also be found in the bark 
extract. Upon hydrolysis of the saponins the principal sapogenins yielded are 
quillaic acid and gypsogenin (Wallis, 1967; Plato eta!., 1986; Trease and Evans, 
1972; 1996; Anagaude, 1999) . 
Interest has been focused on analyzing fractions found to contain high 
molecular weight compounds (showing singly charged ions at 800-3000 m/z) as 
demonstrated by mass spectrometry because these are highly likely to be saponins. 
Consistently, fractions that will exhibit a considerable amount of frothing upon a 
slight agitation will contain saponins. For example, the fraction R6 T9 obtained 
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during the sixth run showed frothing upon agitation and was shown to contain the 
compound designated QF-9, showing a molecular ion at m/z 955, in pure form 
(Figure 16). This compound is of high molecular weight and shows frothing, 
therefore it is considered a saponin and indeed a compound with this molecular ion 
has been identified as a Quillaja saponin and structurally characterized by So eta!., 
(1997) and named QS-l1. Inspection of the diode array detector signal of the 
LC/ESI-MS spectrum at the region of retention time nine minutes, (which also 
corresponded to the retention time of nine minutes at which a molecular ion of 955 
m/z was identified in the MS detector signal), showed this compound possessed a 
UVabsorption characteristic found to be typical of saponins as shown in Figure 17, 
which is comparable to Figure 7 (p. 1 01 ). On the other hand, fractions collected in 
vials R6T5, R6T19, and R6T40 did not show any frothing upon agitation; mass 
spectral analyses of the fractions showed them to contain compounds of lower 
molecular mass and inspection of the LC-MS spectrum in their area of collection 
showed them to have non-saponin UV absorption characteristics as shown in 
Figures 18 and 19. The conventional tests for carbohydrates may prove not very 
useful in this case as some non-saponin materials are carbohydrate in nature and 
these tests may not be able to discriminate between the saponin and non-saponin 
carbohydrates. 
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Figure 1 S: Pure compound Mwt 955 Daltons. ESI-MS of pure fraction QF-9 
isolated by means of semi-preparative RP-HPLC. The ion of the 
molecule of this compound is detected at m/z 955.4, 956.3 and 
957.5. Signals observed at m/z 477.8 and 478.2 correspond to the 
doubly charged ions of this molecule. This compound has been 
previously isolated, characterized and named QS-L 1 by So eta!., 
(1997). 
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Figure 17: UV absorption characteristic of fraction QF-9, detected at molecular 
ion 955 m/z, found to be typical of saponins as shown previously in 
Figure 7. 
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Figure 18: 
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Figure 19: UV absorption characteristics of some non-saponin compounds 
(compare with Figure 7, p. 101-1 02). The compounds eluted at 6.37 
minutes a) have their UV absorption maximum at 310 nm. While 
those eluting at 1.297 minutes b) absorb maximally at about 214 nm. 
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4.1.5 Solid Phase Extraction (SPE) 
The chromatogram obtained after solid phase extraction appeared as 
shown in Figure 20. This chromatogram shows that the material eluted in the 
first 43 minutes of a 95 minute run was removed by SPE (compare with 
Figures 4, 6, and 11 ). Other differences in the chromatograms are due to the 
batch to batch differences in the Quii-A material. This procedure (SPE) was 
introduced with the hope of eliminating non-saponin material from Qui I-A as 
it appeared to have detrimental effects on the column that led to the 
shortening of column life. In addition, simplification of the HPLC separation 
process was anticipated. However, this idea was abandoned after the results 
of the LC/MS of whole Qui I-A showed the presence of high molecular weight 
compounds being eluted at a very early stage. Some of these high molecular 
weight compounds are likely to be saponins, as the vials in which they were 
collected showed frothing upon agitation. The inspection of the diode array 
signal of the LC/MS spectrum in the corresponding area of collection of these 
compounds showed them to possess a characteristic UV absorption for 
saponins (Figure 21 ). And indeed, fractions QF-9 (QS-L 1 ), containing a 
compound having molecular mass m/z 955 (Figure 16, p. 122), and QF-11, 
having molecular mass of m/z1257 (Figure 22, p.132), were collected from 
this area. These compounds may also be biologically active. 
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Figure 20: Elution Profile of Qui I-A after solid phase extraction. Most of the 
material eluted in the first 40 minutes is eliminated. Compare with 
Figures 4 and 16. 
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Figure 21: UV absorption characteristics for a) QF-9 (QS-L i }, having molecular 
mass m/z 955 and b) QF-11, having molecular mass of m/z 1257 
collected from the early area of the elution profile. 
129 
Consequently, a decision was made to collect samples from all sections of the 
chromatogram. More so because there is the possibility that the non-saponin 
components of Qui I-A may also be responsible for some of its immunological 
activity. Of the 50 mg crude Qui I-A used in the SPE experiment only i 6.1 mg were 
retained. 
4.1 .6 Mass Spectral analysis 
This technique was employed to assess the purity of the fractions separated 
and for the purpose of structural elucidation of the isolated components. The 
techniques that were used included electrospray ionization-mass spectrometry 
(ESI-MS), cone voltage induced dissociation- mass spectrometry (CVID-MS) and 
collision induced dissociation-tandem mass spectrometry (CID- MS MS). Mass 
spectrometric analysis was carried out on some samples suspected to be of higher 
purity than the others (based on the observations made on the beginning and the 
ending of the peaks from which they were obtained during manual collection). Six 
compounds were obtainable in pure or near pure form. Figures 12, 13, 14, 16, 22, 
23, 24, 25, and 26 show mass spectral analysis of some of these compounds 
collected from semi-preparative HPLC runs. Four of the compounds collected in 
pure form are novel. Table 8 gives the molecular weights of the compounds 
obtained in pure form. 
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Table 8: Molecular weights of the compounds obtained in pure form. 
Fraction mlz Comments 
I 
QF-9 955 QS-L 1 
QF-11 1217(1257) Novel 
QF-15 1353(1389) Novel 
QF-21 1856 Novel 
QF-22 1989(2012) QS-21 
QF-23 1560 Novel 
The numbers in parenthesis represent the same compound with its 
potassium or sodium salt (differences of 39 or 23 in the molecular 
weights). Indeed one or the other molecular ion was found in 
corresponding vials of the HPLC runs. 
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Figure 22: ESI- MS of pure novel compound QF-11 with the ion of the molecule 
of its potassium salt detected at m/z 1257. The molecular weight of 
this compound is 1218 Daltons and the ion of this molecule is 
detected at 1221 m/z. The peak observed at 1284 mlz represents the 
sodium salt of the potassium salt. All three major peaks represent the 
same compound. 
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Figure .23: ESI-MS scan of QF-1. Molecular ion of compound QF-1 is 
detectable at m/z 1109.9 
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Figure 24: ESI scan of fraction QF-21, ion of this compound QF-21 is 
detectable at 1856 mlz 
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Figure 25: Pure compound QF-22 (QS-21 ), molecular ion m/z 1989. lon 
detectable at 2029.7 is of the potassium salt of this compound. 
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QF-23 was the purest fraction collected as it produced a spectrum only 
one major peak at m/z 1560, Figure 26, and because of that was chosen for further 
structural evaluation 
i) Cone voltage dissociation of QFm23 
Cone voltage dissociation was carried out on the ion of the molecule of QF-
23. This involved the fragmentation of the ion at different cone voltages ranging 
from 50 to 200kV. A series of daughter ions were observed as probable daughter 
ions at m/z 629, 715, 773 and 895 of compound QF-23 (Figure 27). 
ii) Collision induced dissociation tandem mass spectrometry (CID-
MS/MS) 
Collision induced dissociation tandem mass spectrometry was also carried 
out on QF-23. This experiment involves the fragmentation of a selected ion. The ion 
is selected from the first mass analyser, fragmented by means of collision with an 
inert gas, usually argon or xenon (in our case argon was used), in a collision cell. 
The fragmented daughter ions are then analyzed in another mass analyser, hence 
MS/MS. Probable daughter ions of QF-23 were observed in the CID-MS/MS carried 
out on QF-23 at 25 cone voltage and collision energy of 180 e Ions of 
importance were detected at m/z 671, 715, 833 and 894 (Figure 28). 
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Figure 26: ESI spectra of compound QF-23 acquired in the negative ion mode. Spectrum obtained with 
cone voltage 50 kV. a) is very clean and is without any noise. The ion detected at m/z 779 in 
spectrum. b) is the doubly charged ion [M-2Ht of the compound. 
1560.34 
a) 
1558.1 
%-
1580 28 
/ 
0 I '"I 'I"" I " 1'"' f'l-·rl-+-r-rrrrr..-rr-r'r-r~c-rl ~· ,,--, ~,-1-', ,-,-, ,,--, n-1 ,,--, ,.,., .,.., ,.,., ..,...~,,.,..,..,, •~•-r-• •~I,-' ,~,-,-, n-1 .,_, ,.,., .,..,,.,., .,..,n-,...,.,~,1~·-r'o"i"h',..,.-,-r;-r-n--r-rr,.,_,..,..,.·...-rt-rn--rn--n--rrrr·~n--r-~ m'z 
500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2Q90 
b) 
],,, ;~~·'cccc~~1}1j~-,..18f"ri"J"flr'1'"FIII'Tf'MI orli'"h1f_,.l.,.,li""Fij'f41~1 •rflrt"n. I'Tf"t"'!ll-r'o,.,, f"T"IM> iTI l"'"fl-rl r"fiiT"ilr-t"I"MI ~rrn"'T'"Y~'r 
500 600 700 800 900 1000 1100 1200 1300 1400 1500 
1570.18 
.,..,.,.,'Mi "l'"T 1'Af'\"'''...,..,H'?I "F> Ff'f 'Fi jr-1"1 "1""1 1M"I"!""j TFI'I 'r11 IFI'I.,-1 '""'' "M"fj f'"l'"' M! ..,_[ mfz 
1600 1700 1800 1900 2000 
Figure 26: ESI spectra of compound QF-23 
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Figure 27: Cone voltage induced dissociation of fraction QF-23. Possible fragmented 
daughter ions of the parent molecule are observable at m/z 629, 715, 773 
and 895 in spectra c), d) and e) and the presence of the daughter ions at 
m/z 715 is visible in b) at minute abundance. As the cone voltage is 
increased and the fragmentation of the molecular ion at 1560 is increased 
the magnitude of this peak become diminished as compared to a) and b) 
where there has been no or very little fragmentation. This provides 
additional evidence that the fragments are indeed from the compound with 
the molecular ion at 1560 m/z. 
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101.15 
Figure 28: Collision induced dissociation tandem mass spectrometry analysis of the molecular ion of the compound 
QF-23 detected at m/z 1560. The fragmentation of this ion was achieved at a collision energy of 180 eV 
and cone voltage of 25 kV. A series of daughter ions are observed at m/z 628, 715 and 833 
corresponding to plausible fragmentation products of QF-23 
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This information gave much insight into the fragmentation pattern of this 
molecule, and formed the basis of the proposed molecular structure shown in 
Figures 5, 31, and 43. Figure 31 on page 143 describes how the daughter ions 
identified in these experiments correspond to the different parts of the 
molecule of the compound QF-23. 
4.1. 1 Cleavage reactions 
In addition to the experiments mentioned above, QF-23 was subjected to 
alkaline hydrolytic cleavage reactions. This reaction was carried out on the pure 
saponin compound to selectively cleave the molecule at positions that will leave the 
naked aglycone or the prosapogenin (that is the saponin molecule minus any 28-0 
bound acyl moiety). Figure 29 shows the ESI-MS of the chemical derivatives of the 
alkaline hydrolysis of fraction QF-23 which resulted in the appearance of a peak at 
411 m/z representative of the ion formed by the aglycone quillaic acid. Thus, 
confirming the identity of QF-23 as a Quiflaja saponin. The chemical structure of the 
ion formed from qui !laic acid aglycone, detected by negative ion ESI-MS scan of the 
alkaline hydrolysis products of QF-23 is as shown in Figure 30. 
Evaluation of the scans observed after the CID-MS/MS and the voltage 
induced dissociation of the molecule of QF-23 led to the proposal of the following 
structure and fragmentation patten of QF-23 (Figure 31 ). 
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Figure 29: ESI-MS scans of the alkaline hydrolysis products of QF-23. The scan was acquired using cone voltage 
25 kV. The ion detected at m/z 411 is suspected to have been liberated from the quillaic acid aglycone 
during alkaline hydrolysis (see Figure 30). The presence of this ion supports the identity of QF-23 as 
a Quillaja saponin. 
141 
Figure 30: Structure of the ion liberated from the aglycone of the Qui!laja 
saponin QF-23 during alkaline hydrolysis. This ion is detected at m/z 
411.48 in the ESI-MS scan of alkaline hydrolysis products of this 
compound shown Figure 29. The molecule of the compound was 
cleaved at the highly reactive positions of C-3 and C-28 to liberate 
quillaic acid which then was oxidized to yield the qui!laic acid ion 
detected at m/z 411.48. The rearrangement of the aglycone qui I laic 
acid during isolation has been reported before (Kubota eta!., 1969 in 
van Setten and van de Werken 1996). The presence of this ion in the 
ESI-MS scan confirms the identity of this compound as a Quillaja 
saponin. 
.... ~Q 
OHC'',_... 
Hydrolysis 
Decarboxylation 
Followed by 
Isomerization 
[412-H+]- m/z 411 
Figure 30: Structure of aglycone liberated from the pro-sapogenin during 
alkaline hydrolysis. 
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Figure 31: Proposed fragmentation pattern and structure for the deprotonated 
precursor ion of the molecule of QF-23 at m/z 1560. The detection of 
the daughter ions at m/z 629, 671, 715, 790, 833 and 894 in the 
scans obtained after cone voltage dissociation of the ion of the 
molecule of QF-23 (Figure 27), CID-MS/MS of this ion (Figure 28) 
and the ESI-MS scan of the alkaline hydrolytic products of this 
compound (Figure 29) led to the proposal of this fragmentation 
pattern which is based upon the "X-type sugar fragmentation" 
principles outlined by Doman and Costello (1988). 
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4.1.8 Gas Chromatography/Mass Spectrometry (GC/MS) 
This experiment was aimed towards determining the exact configuration and 
binding sites (linkages) of the sugar moieties that make up the molecule of the 
saponin QF-23. The GC/MS experiment required a permethylation reaction to be 
carried out on the saponin molecule to be analyzed in order to break it up into 
smaller molecules (including the sugars) which were then volatilized and 
investigated by this technique. When fraction QF-23 was subjected to GLC and 
GC/MS, the results showed the compound to contain the following sugars as listed 
in Table 9 and the linkages to be as indicated in Table 10. 
This compound did not show the presence of either glucose, or arabinose 
molecules unlike QS-7 (Kensil eta/., 1998) and QS-21 (Kensil eta/., 1991 ).Taking 
into consideration the structural elements that are common to all Quillaja saponins 
that have been characterized to date (Figure 2, Figure 3 and Table 1 ), the presence 
of rhamnose in a 1:1 ratio and the presence of xylose in a 2:1 ratio, with one of the 
xylose molecules as a terminal sugar was confirmed. This evidence, in conjunction 
with one of the recent publications on structural analysis of some Quillaja saponins 
(Nord and Kenne, 1999) suggests the sugar arrangement for QF-23 shown in 
Diagram 2. 
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1 1 -0-C-3 4 0~ Ac 1 
D-Gal ~ D-GicUA -quillaic acid -- D - Fuc ~ D - Rha 
~ 3 aglycone -0-C-28 1 21 4 
t 
1 D-Xyl 
D - Xyl ~-D-Api 
1 3 1 
Diagram 2: Sugar arrangement in QF-23 Numbers represent the glycosidic 
linkages in the structure. GlcUA = glucuronic acid, Xyl= xylose, 
Gal = galactose, Fuc = fucose, Rha = rhamnose, Api = Apiose and 
D= dextrorotatory 
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Table 9 Sugar Analysis 
D- Apiose, L- Fucose ,0- Xylose, L- Rhamnose, D-Galactose and D-Giucuronic acid; 
1: 1: 2: 1: 1: 1 
Table 10 Methylation Analysis 
A. Three terminal non- reducing sugars were detected; 
1. 1,5- di - 0- Acetyl - 2,3,4,6- tetra- 0- Methyl- D- galactitol 
2. 1,5- di - 0- Acetyl- 2,3,4, - tri- 0- Methyl- D- xylositol 
3. 1,4- di - 0- Acetyl - 2,3,5- tri- 0- Methyl- D- apiositol 
B. Other sugars were found to be glycosylated 
Sugar giycosylation 
positions 
4. 1 ,2,3,5,6- penta- 0- Acetyl- 4- 0- Methyl- D- glucuronitol; GlcUA:- C-2, C-3 
5. 1 ,3,5- tri - 0 -Acetyl - 2,4- di 0- Methyl - D- xylositol; 2nd Xyl:- C-3. 
6. 1 ,4,5- tri - 0 -Acetyl - 2,3- di- 0- Methyl - L- rhamnosito!; Rha:- C-4 
7. 1, 2,4,5- tetra- 0- Acetyl- 3- 0- Methyl- L- fucositol; Fuc:- C-2, C-4 
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4.1.9 Nuclear Magnetic Resonance (NMR) spectroscopy. 
Three NMR experiments were carried out on two of the separated 
components QF-23 and QF-22. The experiments carried out were: 1) a one 
dimensional proton acquisition experiment CH NMR), 2) an inverse chemical shift 
correlation experiment, Heteronuclear Multiple Quantum Correlation (HMQC) that 
gives the signal of 'H coupled directly to 13C, and 3) a long range chemical shift 
correlation experiment ; Heteronuclear Multiple Bond Correlation (HMBC) that is 
suitable for long range 1H - 13C connectivities. This experiment detects all the 13C 
even those that are not directly bonded to 1 H. This experiment has a higher 
sensitivity than the more familiar COLOC (COrrelation LOng -range Coupling ) 
since it is an inverse experiment. The advantage of inverse chemical shift 
techniques (Akitt and Mann, 2000; Rouessac and Rouessac, 2000) is that they 
detect insensitive nuclei such as 15N, or 13C through the detection of a very high-
sensitivity nucleus, typically the proton. These techniques are most suitable for 
large biomolecules in which the sensitivity of 13C is greatly diminished by the very 
often low % by weight of the carbon element C3C) in the molecule, making it 
necessary to have very large amounts of pure compound in order to perform a 
direct 13C acquisition experiment. Moreover because of the large size of these 
molecules they have very long relaxation time and as such 13C acquisition 
experiments may require a very long time to run. Nevertheless, an inferred 13C NMR 
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was obtainable form the two dimensional experiments. NMR spectra were recorded 
for saponins dissolved in deuterated methanol (CD3-0D) at room temperature. 
The 1H NMR spectrum of QF-22 which was obtained using deuterated 
methanol appeared to match the spectrum of QS-21 that was acquired under similar 
conditions and found in the literature (Nord and Kenne, 1999) (Figure 32). 
Thereby, confirming the data obtained from the molecular weights that QF-22 was 
in fact QS-21, a well known Quillaja saponin (Kensil eta!., 1991 ). 
The results of the three experiments revealed the presence of an aldehyde 
(9.5 ppm) and an olefinic proton (5.6 ppm) in the molecules of both the compounds 
tested as well as two carbonyl groups in the molecule of QF-23, while the number 
of the carbonyl groups detectable in the molecule of QF-22 was three. A signal 
corresponding to a carboxyl group was also identified in each of these molecules. 
Figure 33 a) shows the aldehyde and the olefinic proton while Figure 33 b) shows 
the carbonyls and the carboxyl groups as detected in the NMR spectra of the 
molecule of QF-23. These findings are indeed in agreement with our proposed 
structure of QF-23 and the known structure of QS-21 (Kensil eta/., 1991 ). 
Further analysis of the data obtained from the NMR experiments is 
summarised in Figure 34 and Table 11 that show the configuration at the anomeric 
carbon atom of the sugars (hemiacetals) that make up the molecule of QF-23 and 
the assignment ofthe 1H NMR chemical shifts in ppm for the residues in the quillaic 
acid portion and the oligosaccharides of the this molecule. 
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Figure 32: A)1H NMR spectrum of QF-22, B) 1H NMR spectrum of compound S6 
and C) 1 H NMR spectrum of compound S2a. The 1 H NMR spectrum 
of QF-22, A), matches that of compound S6 (Nord and Kenne, 1999), 
spectrum B), which is QS-21, a Quillaja saponin of known molecular 
structure (Kensil et al., 1991 ): Confirming that QF-22 is equivalent to 
QS-21. The spectrum shown in C) is quite different from that obtained 
from QF-22, showing that the compound S2a (Nord and Kenne, 1999) 
is clearly different from QF-22. All three spectra were acquired under 
similar conditions. 
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Figure 33: a) 1H NMR spectrum of QF-23; b) HMBC spectrum of QF-23. 
In a) the signal due to he aldehyde proton is visible as a singlet at 905 
ppm while that of the olefinic proton is seen at 506 ppm also as a 
singlet b) shows the carbonyl and the carboxylic acid signals at the 
proton chemical shifts of 1 016 and 1.19 ppm respectively. 
a) 
! 
I I 
I 
~f'-------0 ___l<.A._H_H-_______ c~c~-lA}JJ~J)~~ L 
b) 
Figure 33: a) 1H NMR spectrum of QF-23; b) HMBC spectrum of QF-23 
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Figure 34: a) 1H-NMR spectrum of QF-23 from 1-6 ppm b) 1H-NMR spectrum of 
QF-23 from 1-6 ppm showing the anomeric carbon atoms of the sugar 
molecules and the coupling constant calculations used in determining 
the sugar configurations (Table 11 ). Qa-1 and Qa-3 represent the 
carbon atom residues in the quillaic acid portion of the molecule. 
GlcUA =glucuronic acid, Xyl= xylose, Gal= galactose, Fuc =fucose, 
Rha = rhamnose, and Ara = arabinose 
a) 
b) 
Gal 
GlcUA 
I 
I :X l(l) 
Api \ 
Xyl('t Qa-1 
' . . . . ' ' y ~ ---;;1 
Figure 34 1H-NMR spectra of QF-23 
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Table 11: Assignment of the 1 H NMR chemical shifts in ppm and configuration 
for residues in QF-23. The data in this table is obtained from Figure 
34. 1. Qa-1 represents the carbon number in the quilliac acid 
(aglycone) portion of the molecule; Qa-3 represents the third carbon 
atom in the aglycone. G!cUA-1 to Api-1 represents the first carbon 
atom in the respective sugar molecules in the compound. 2. Figures 
represents the chemical shifts observed for the hydrogen atoms 
attached to the respective carbon atom residues as documented in 
the literature ( Higuchi eta!., 1987; Guo eta!., 1997; Nord and Kenne, 
1999). 3. Represents chemical shifts for the protons attached to the 
respective carbon atoms as observed from the 1H NMR of QF-23 
(Figure 34). 4. All the J couplings are calculated in Hz; d and s 
represent doublet and singlet, respectively. 5. Configurations of the 
anomeric carbon atoms were assigned conventionally in accordance 
with the J coupling figures. 0 = Dextrorotatory; L = levorotatory; p = 
pyranoside; f = furanoside. Sugar abbreviations are as explained in 
Figure 34. 
Table 11: 
Residw.u~1 
Qa-1 
Qa- 3 
GlcUA-1 
Xyl(l)-1 
Gal-l 
Fue-l 
Rha-1 
Xyl(2)-1 
Api -1 
Assignment of the 1H NMR Chemical Shifts in ppm 
and configuration for residues in QF-23 
Lit. Ref 2 QF-233 1JH-H couplings4 Sugar Configurat:ion5 
1.11/1,72 1.11/1.72 - -
3.86 3.86 - -
4.46 4.48 d J= 6.24 ~-Dp 
4.58 4.59 d J= 1.59 o:-Dp 
4.46 4.48 d J= 6.10 ~-Dp 
5.34 5.34 d J= 6.24 a-Lp 
5.02 4.99 d J= 6.29 a-Lp 
4.69 4.72 d J= 1.59 a-Dp 
5.27 5.02 s J= 0 ~-Df 
152 
i 
4.2 Biological Testing 
The second leg of this research project involved the determination of the in 
vitro biological activity of the isolated fractions. The biological investigations that 
were carried out on the purified saponins included hemolytic studies, toxicity 
studies and cytokine (IL-1 a) induction. Figure 35 shows the fractions that were 
investigated for biological activity. Not all biological testing were performed on all 
of the fractions shown due to lack of availability of sufficient quantities. 
4.2.1. Evaluation of the hemolytic activity of the fractions 
The hemolytic activity of two saponin fractions was determined by an in vitro 
spectrophotometric analysis on rat's (Sprague-dawley) red blood cells (RBC) 
utilizing the detergent NP40 as a positive control and the dilution solution PBS as 
the constitutive control. The results of this experiment obtained for fractions QF-23 
and QF-11 are as shown in Figure 36 (page 155). Fraction QF-11 appeared to 
have lower hemolytic activity than QF-23 at lower concentrations with an estimated 
Hl50 of 400 ~g/ml as compared to that of 333 ~g/ml (estimated) for QF-23. 
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Figure 35: A trace of semi-preparative RP HPLC showing fractions which 
were used to estimate biological activity of saponins. 
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Figure 36 : Hemolytic activity of some Qui!!aja saponins. Hemolysis is 
estimated graphically as Hl50 (Hemolytic Index Fifty) which 
is the concentration of the drug that gives 50 % hemolysis. 
QF-11 (HI50 = 400 IJg/mL) appear to be less hemolytic 
than QF-23 (HI50 = 333 IJQ/mL). Mean values ± SO of 
the values obtained in triplicate (n=3) were plotted. 
a) 
b) 
Hemolytic Activity of QF-23 
M.Wt 1560 
Estimated Hl50 > 333llg/ml 
[QF-23] J.!glml 
Hemolytic Activity of QF-11 
M.Wt 1257 
120~--------------------------~ 
Estimated Hl50= 400 llQ/ml 
[ QF-11] J.!g/ml 
Figure 36 : Hemolytic activity of some Quillaja saponins 
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4.2.2. Toxicity of sapcmins to murine monocytic cell line J774A 
The toxicity of the saponins was determined in vitro using the MTT method 
as developed by Ford eta!. (1989). Toxicity of four chromatographically pure 
samples, QF-23, QF-22 (QS-21 ), QF-21 and QF-15 was assessed. QF-23 was 
found to have similar in vitro toxicity on murine monocytes as that of QF-22 (QS-21) 
(TC50 = 2. 96 !Jg/ml for QF-23 and 3.981 !Jg/ml for QF-22 (QS-21 ). Compound QF-
15 (Mw 1389) exhibited much lower toxicity (TC50 = 25.12 !Jg/ml) than the other 
fractions tested (Figure 37 and Table 12). Toxicity of QF-21 was found to be 1.51 
!Jg/ml. The fractions chosen for toxicity studies were samples from various parts 
of the elution profile as shown in Figure 35. 
4.2.3. In vitro cytokine production determination as a measure of 
adjuvant activity 
Assessment of the adjuvant capability of any compound can be performed 
by measurement of a number of immunological parameters. These parameters are, 
induction of antibodies, T-cell proliferation, production of cytotoxic T-lymphocytes, 
and induction of cytokine by cells of the immune system including antigen 
presenting cells (APC). These parameters can be determined in vivo and in some 
circumstances in vitro. 
(cont on p. 159) 
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Figure 37: Results of the toxicity studies of Quillaja saponin fractions. 
Toxicity measurements in terms of TC50 are given in Table 12. The toxicity of 
QF-21, QF-22 and QF-23 is somewhat comparable, with QF-22 (QS-21) being the 
less toxic of the three. Values are means± SD and each point is an average of four 
readings. Survival curves were drawn using Graph Pad Prism, fitting the values to 
a sigmoidal curve. 
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Table 12: TC50 for tested Quillaja saponin fractions 
Fraction Molecular Weight TC50 (J.Jg/ml) 
(Daltons) 
QF-15 1389 (1353)1 25.117 
QF-21 1856 1.514 
QF-22 (QS-21 )2 ' 1989 (2012)3 3.981 
QF-234 1560 2.955 
1. Corresponding vials contained compound of either molecular weight. 
Compound having a Mwt of 1389 is the potassium salt of the compound with 
Mwt 1353 (the difference in masses is approximately 39 ). 
2. Fraction QF-22 is equivalent to the well known QS-21. 
3. One compound (ion mass 2012) is the sodium salt of the other 
(difference in masses is 23). 
4. Compound QF-23 is the compound with a characterized structure. 
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We assessed the adjuvant capabil of one of the saponins vitro through 
measurement of cytokine induction by cells for the following reasons: a) the results 
of these experiments give a general indication of the adjuvant capability of the 
saponin, and b) the induced cytokine measured, ll-1 a (a Th-1 associated cytokine) 
is known to have direct effects on B-cell and T -celi proliferation and APC activation. 
ll-1 a measurement is therefore indicative of the adjuvant potential of compounds 
tested. Qui!!aja saponins have been found to have a potent stimulation of both 
these immune responses. The first step in immune recognition by cells is initiated 
following uptake of antigen by APC, which then produce ll-1, a cytokine which 
activates the immune processes such as T cell and B cell proliferation and 
macrophage phagocytosis. The ll-1 a produced in our assay following cell 
treatment with Quillaja fractions was measured by ELISA See Diagram 3 (p. 160). 
The cell line used in this investigation was the Murine J77 4, a monocytic cell 
line which we are using as an APC. This cell line can be stimulated with mitogens 
such as LPS to produce ll-1 a and other cytokines as shown in Diagram 3. The 
ELISA protocol for quantifying the ll-1 a production required considerable pre-test 
optimization to establish assay conditions; a substrate dilution of 1 :4000 and an 
incubation time of between 20- 50 minutes after addition of substrate to plates, and 
the plates were best read at 405 nm. 
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Diagram 3: Schematic representation of immune recognition of antigen. 
160 
The results obtained under these conditions were found to produce a better 
standard curve than other conditions investigated. (FigureS 38,39 and 40). The 
maximum measurable standard concentration of murine IL-1 a was determined to 
be 1.5 ng/mU. Optimum production of IL-1 a (1 .031 ng/ml/1 05/48h) following LPS 
stimulation was found to occur by 48 hrs, when 105 cells/well were stimulated with 
0.5 IJg/ml of LPS (Figure 41 ). This time point was chosen to analyse the IL-1 a 
produced following exposure to various saponins. The cells were found to have a 
constitutive IL-1a production of about 10-50 pg/ml!105/48h. QF-23 was found to 
stimulate J774 cells to produce the cytokine IL-1 a as shown in Figure 42 between 
0.25 IJg/ml and 11Jg/ml QF-23. The level of IL-1 a produced was concentration 
dependant, and ranged from 80-230 pg/ml IL-1a/105/48h. Although much lower 
than the levels produced by LPS stimulation, they were significant (P= 0.0004 -
0.0336). We concluded that QF-23 was therefore, a relatively good adjuvant 
capable of activating the monocytic cells and perhaps other APCs, if combined with 
a vaccine antigen. It was also noted that the effective concentration of this 
compound was well below its toxic concentration of 31Jg/ml established for QF-23 
in this cell line see (Figure 37 and Table 12 on pages 157 and 158) . 
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Figure 38: ELISA protocol optimization showing variations in the color of 
developer avidin peroxidase. Plates for the experiments to construct 
standard curves for IL-1 a determination were prepared as outlined in 
Chapter 3 (3.3.2.4), pages 69 to 72. Different avidin peroxidase 
concentrations ranging from 1 in 2000 (in diluent) to 1 in 10 000 were 
used in the detection stage of these experiments. In other experiments 
the highest concentrations of the standard IL-1 a used was also varied 
(either 1.5 ng/ml or 3.0 ng/ml were used). These experiments were 
conducted because it was found out that the color development after 
the addition of the substrate took place too quickly to permit the 
acquisition of OD readings necessary to construct a standard curve. 
Av2T= Avidin peroxidase diluted to 1 :2000; Smx = S= 1.5 ng/ml (or 3.0 ng/ml) 
=maximum concentration of the standard solution used was 1.5 ng/ml, 7 min, 2 min 
= the time that the measurements were carried out after addition of substrate; 405 
nm is the wavelength at which the optical density (00) measurements were 
obtained. None of the above conditions appeared to produce a reliable standard 
curve. Readings per point were taken in triplicates and plotted values are mean 
values plus or minus standard deviations. 
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Figure 38: ELISA protocol optimization 
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Figure 39: Standard curves at different time variations. Optimization of the 
experimental conditions for ELISA in the determination of the cytokine 
IL-1 a production by QF-23. these experiments optical density 
readings were obtained at different time intervals after the addition of 
the substrate for color development. The avidin peroxidase enzyme 
concentration was maintained at 1 in 4000. 
Sm=Smx = maximum concentration of the standard IL-1 a . The rest of the 
notations are as explained in Figure 38. Although the standard curve obtained 
using the avidin peroxidase dilution of 1 :4000 and measuring the 00 after 50 
minutes with the highest standard concentration at 1.5 ng/mL and the curve 
obtained by measuring the 00 after 8 minutes with the maximum concentration of 
the standard curve at 3 ng/mL appear to be as equally good as the one obtained 
at 36 minutes with 1.5 ng/ml highest concentration of standard, the latter was 
chosen because it was more convenient and in agreement with the recommended 
time of the ELISA kit manufacturer. Readings per point were taken in triplicates and 
plotted values are mean values pius or minus standard deviations. 
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Figure 39: Standard curves at different time variations 
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Figure 40: Standard curves obtained for the ELISA experiments using 00 
readings obtained at different wavelengths. Graph labeling is as 
explained in Figure 38. The following conditions of; avidin peroxidase 
dilution factor, 1:4000, maximum standard concentration of 1.5 ng/mL 
and 00 measurements obtained 36 minutes after addition of 
substrate at 405 nm, were chosen as optimum experimental 
conditions for subsequent IL-1 a determinations. These specifications 
produced a desirable standard curve under as close to recommended 
conditions as possible. Readings per point were taken in triplicates 
and plotted values are mean values plus or minus standard 
deviations. 
In conclusion, 36-50 minutes were best times for obtaining 00 reading, the 
best wavelength for measurement of 00 readings was 405 using 1.5 ng/mL 
of miL-1 a as the maximum standard concentration. 
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Figure 40: Standard curves obtained for the ELISA experiments (cont. on p.165) 
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Figure 40: Standard curves obtained for the ELISA experiments (from p.164) 
(end of Figure 40) 
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LPS: IL-1 a Cone. vs time 
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Figure 41: Kinetics of cytokine Production Studied using LPS 0.5 IJg/mL, 
and 1 05 cells/well. Amounts of I L -1 a produced by J77 4 murine 
monocytic cells incubated with an LPS solution for different 
time periods were measured and plotted against time. 
Maximum IL-1a production was found to occur after 48 hrs of 
incubation. Afterwards the cytokine production appear to 
become greatly diminished, probably due to cell death. 
Readings were taken in triplicates per time. Plotted values are 
mean values plus or minus standard deviation. 
166 
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Figure 42: Cytokine Induction by QF-23. Concentrations of IL-1 a produced by 
J77 4 murine monocytes treated with different concentrations of the 
saponin QF-23 were measured. The determination was carried out at 
the optimum ELISA conditions for the ideal standard curve 
determined earlier; avidin concentration used 1 :4000, measurements 
carried out 30 minutes after addition of substrate color developer and 
the highest concentration of standard solution being 1.5 ng/ml. Mean 
values± SD of four readings (n=4) per point were plotted. Values 
obtained at saponin concentrations of 250, 500, and 1 000 ng/ml 
were found to be significantly different from the control (P = 0.0336, 
0.0181 and 0.0004, respectively). This is the results of one out of 
three independent experiments. The results of two of the experiments 
were found to be similar. While one gave an insignificant value at the 
saponin concentration value of 500 ng/ml, probably due to 
experimental error. 
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4.3 Summary of Findings 
1. The complex mixture of Qui!laja saponins have a tendency to co-elute due to 
similar separation properties. However, a few pure saponin fractions were 
isolated and screened for biological activity. 
2. Ions of molecules much higher than those reported in the literature have been 
detected in the LC/ MS experiment some of them eluting early in the HPLC 
separation process. 
3. Eight compounds have been separated in pure or near pure form having 
molecular weights 955 (QF-9), 1217 and1257 (QF-11 ), 1353 and 1389 (QF-
15), 1560 (QF-23), 1856 (QF-21 ), and 1989 (QF-22). At least four of them 
are novel and were not published structures ( QF-11, QF-15, QF-21 and QF-
23). The compounds with the molecular weights of 1217 and 1257 could be 
the same as well as the compounds with the molecular weights of 1353 and 
1389. The difference between the two being a potassium ion molecular 
weights might arise from one being the potassium salt of the other. 
4. The structure of compound QF-23, molecular weight 1560 Figures 5 and 43) 
was proposed from data obtained from mass spectrometry and CID-MS/MS. 
This structure has since been supported by NMR and GC/MS data. 
168 
5. Fraction QF-22 having molecular weight 1989 has been positively identified as 
QS-21 (a well established fraction of Quillaja saponaria Molina). 
6. Toxicity studies carried out on four of the separated fractions revealed that a 
novel compound QF-15 with molecular weight 1389 the lowest toxicity and 
that the toxicity of QF-23 and QS-21 is more or less equivalent. 
7. QF- 23 appears to have immune stimulating activity (IL-1 a) and possible 
adjuvant activity in our model system. 
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Figure 43: 
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Structure of compound QF-23, Molecular weight 1560 Daltons 
We propose the above structure for QF-23. This structure has been 
elucidated from a combination of molecular weight, fragmentation pattern, sugar 
analysis, and NMR data. It differs from previously reported structures in that the 
fucose is substituted at the fourth hydroxyl group with an acetyl group rather than 
being un-substituted as in the compounds DS-1 and DS-2 (Higuchi eta!., 1987). 
The fucose is sometimes substituted with a long chained hydrocarbon as in the 
compoundsQS-17, 18and21 (Kensiletaf., 1991). QF-23retainssimilaritywiththe 
reported structures of other compounds (e.g. QS-17, 18 and 21) in having an apiose 
attached to the xylose in the C-28- 0 bound glycosidic moiety. It also has a 
similarity with QS-21 and DS-1 in not having a glucose molecule attached to the 
rhamnose. 
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Structure QF-23 
Chapter 5: Conclusions 
Quii-A has been found to be a complex mixture of triterpenoidal saponins 
and other substances from the bark of Quil!aja saponaria Molina as previously 
reported by other researchers ( Daaslgard, 1970; 197 4; Higuchi eta!., 1887; 1988; 
Kensi! et a!., 1991; van Setten and van de Werken, 1995). Over a hundred 
molecular ions, which may or may not be related, were detected in the first five 
minutes of the LC/MS investigation of this material. A great deal of evidence lead 
to the conclusion that contrary to earlier reports (Kensil eta/., 1991; van Setten and 
van de Werken, 1995) some of the material which was eluted in the first ten minutes 
of the analytical separation was saponin in nature (high molecular weight 
compounds that showed saponin like UV absorption characteristics, and whose 
solutions exhibited a substantial amount offrothing with slight agitation). However, 
most of the material that was considered non-saponin in nature was found to be 
more concentrated in the first ten minutes of the separation than anywhere else. 
The LC/MS experiment has enabled us to collect information which can be used to 
pinpoint (more or less) the exact position (retention time) of any given ion (or 
compound) of interest from the components of the bark extract of Quillaja saponaria 
Molina, Quii-A Some of the data obtained from this investigation also provides 
valuable preliminary information regarding the fragmentation pattern of these 
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compounds. Several compounds of very high purity were also separated and 
isolated in sufficient quantities to enable the use of further specialized techniques 
to determine with adequate precision the structure of at least one of the separated 
fractions QF-23 and to evaluate some of its biological activities, together with that 
of some of the other components. 
A number of challenges were encountered and most have been overcome 
in this research project. The most difficult and time consuming task was found to be 
the separation of the highly complex bark extract. The components were found to 
be poorly separable and had a tendency to co-elute. In addition, the Quillaja 
saponins appeared to irreversibly adsorb to the column and this caused loss of 
resolution after several separations. This necessitated the acquisition of several 
columns during the course of the research project. In an attempt to combat this 
problem the Quii-A materia! was absorbed with a solid phase extraction technique 
(which was later abandoned). The literature described a method of droplet counter 
current chromatography (DCCC) as an excellent method for preparative separation 
of saponins when combined with silica column separation (Nakamura eta!., 1994; 
Higuchi et al., 1988). However, we lacked the necessary equipment for this 
particular technique and thus we could not achieve such a separation. 
A suitable drying method was identified only after elaborate and labour 
intensive attempts with other methods that included the design and construction of 
a specialized piece of drying equipment (for cryo-crystallization). The drying of the 
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separated fractions after semi-preparative HPLC posed a very difficult problem due 
to the organic/aqueous solvent and the very low percentage of the solid material in 
a large amount of liquid that was more organic than aqueous at certain instances 
along the gradient of elution: resulting in the formation of a mixture with an eutectic 
point which made freeze-drying impossible with the equipment that we had. 
The LC/ESI-MS experiment has thrown much light in the elution 
characteristics of Qui I-A, a Quillaja saponin. No other research group known to us 
has as yet reported having undertaken this venture. Maillard and Hostettmann 
(1993) developed a method of online mass analysis of crude plant extracts, which 
has been applied by Wolfender et at. (1993) and Perret eta!. (1999) on phenolic 
and terpene glycosides including those of Rogeria adenophylla J, Gentiana 
dasyantha Gilg. and Phytolacca dodecandra L'Herit but not as yet on Quillaja 
saponaria Molina. Moreover the method we applied is different from the one they 
developed. They used thermos pray mass spectrometric analysis while we engaged 
the sli.ghtly more advanced API technique of ESI-MS. The analysis and publication 
of this LC/MS data could be a very interesting undertaking that may also require a 
tremendous amount oftime. The adjuvant activity of the compound QF-23 revealed 
in the in vitro examinations means that this compound is worth investigating further. 
Equally important is the further investigation of the chemical nature and the 
immunological adjuvant capability of the novei compound QF-15 that was found to 
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have a considerably lower toxicity to the murine monocytic cell line used in this 
investigation than other saponins tested. 
Thus far, a very efficient and precise procedure for semi-preparative 
separation has been developed (albeit, not without problems, which contributed to 
the length of time it took to complete this project). This method can even be further 
refined by the use of specialized equipment as directed earlier in the results and 
discussion section (page 1 09). By means of this separation, adequate amounts of 
the following fractions, QF-1, QF-9, QF-11, QF-15, QF-21, QF-22 and QF-25 were 
successfully obtained in pure form. Some of these fractions are still available while 
others have been consumed during the course of this study but can still be easily 
obtained. 
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Chapter 6: Prospects and Future Directions 
Although the primary objectives of this project were achieved (viz, separation 
of components in pure or near pure form and in sufficient quantities to enab!e 
further investigations, structural elucidation of one of the components and 
investigation of the biological characteristics of several fractions), much work is still 
required to further characterize the Quil!aja saponins and their adjuvant activity. 
Several areas of concern became apparent Separation, purification and 
characterization of the saponin constituents of this plant extract still remain an area 
of great importance. The large number, over 80 saponin components detectable 
by means of LC/ESI-MS from the commercial extract, Quii-A, still require 
considerable identification and analysis. Knowledge of the molecular structures, 
adjuvant activity, toxicological effects, and other biological activity of the individual 
saponins, may result in the discovery of less toxic, non-hemolytic saponins 
possessing immune-stimulating properties that may be suitable for use in humans. 
Structure-function activity studies and research on the mechanism of action of the 
saponins may help us identify regions of the molecule responsible for adjuvant 
activity, hemolytic activity or toxicity. If no naturally occurring saponin compound 
with all the properties of an ideal adjuvant exist, then, potentially, one could 
synthesise or modify naturally occurring saponins and test their properties. The 
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information necessary to determine these structures is still elusive, and further work 
is still necessary. 
In future expansions of this project further biological and chemical 
characterization of these already separated components can be undertaken, and 
the spectrum of investigations already effected to other fractions may even be 
broadened to include X-ray crystallography in the structural evaluations of the 
compounds (preliminary investigation of which has shown the saponins to crystall-
ize in a manner that is suitable to enable the conduction of this experiment) and 
effects of the fractions on cell division, in vivo toxicological and adjuvant activity 
examinations, and studies of the fractions in ISCOM formulations, to be included 
in the spectrum of the biological evaluations carried out on these saponins. Further 
investigation of a number of different columns and or different stationary phases for 
the purpose of obtaining better HPLC separation of the components of the extract 
of Quillaja saponaria Molina (Quii-A) may also be a useful future endeavour. 
The immune stimulating characteristics of the Quillaja saponins needs to be 
investigated further to gain insight into the possibility of manipulating adjuvant 
concentrations and/or composition to obtain a particular required immune response, 
for example. In actuality a great deal of benefit can be acquired from the studies of 
the type and amount of immune responses obtainable with the different kinds of 
antigens and the Quillaja saponins as adjuvants. A comparative study of the activity 
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of the saponins as adjuvants to that of the existing adjuvants can assist in 
establishing the exact position of these saponins as adjuvants. 
In vitro screening for adjuvant activity may not be the ideal way to determine 
the activity of saponins. In vivo screening of the isolated components is also 
necessary to compare known adjuvant fractions such as QF-22 (QS -21) with the 
newly characterized QF-23. Animal models, also, are only indicative of possible 
adjuvant activity in humans but are a necessity in the development of therapeutic 
and prophylactic agents used in humans, including vaccines, for a variety of 
reasons, such as to determine the safety and efficacy of the agents before their use 
in humans. Such studies employing isolated Quillaja saponins in ISCOM 
technology, shown to be the most efficient formulation of saponin adjuvants, will 
also be necessary. 
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Appendix 
Parts of the report of the LC/ESI=MS experiment carried out on the 
material Quii=A (Referred to in Table 5, pages 89-99) 
Note: 
1. The pages in the appendix are representative of the computer generated data 
from which Table 5 was constructed. 
1. Mostly those peaks for which data relating to other ions detected in that peak 
have not been entered in Table 5 are included in the appendix. 
2. Peak numbers corresponding to peaks included in the appendix are given in 
brackets in Table 5. 
3. Entry# 'son the top of the pages in the appendix refer to the entry numbers in 
Table 5. 
4. Peaks are arranged in the appendix in the order in which they are entered in 
Table 5 and mass detector (MSD) signal peaks are placed together (MSD 
signa! sheets on top) with their corresponding peaks from the diode array 
detector( DAD) signal. The MSD signal sheets that do not have matching 
DAD data sheets could not be matched to any data produced in the DAD 
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because of the reasons given in the legend to Table 5 (pages 89-91 ). 
5. DAD signal pages in the appendix have matching peak elution times to their 
corresponding entries in Table 5. 
Annotation to Appendix 
The following information refer to all of the pages to be found in the 
appendix. There are two categories of data sheets presented in this appendix 
1) data generated from the MSD signal and 2) data generated from the DAD signal. 
To aid with the comprehension of the data, two sample pages have been provided, 
one for each category, and are labeled sample explanation page numbers 1 (page 
180) and 2 (page 183) for MSD and DAD signals respectively. 
Sample Explanation Page # 1 (page 180) for MSD signal pages 
Figure A ~ TIC for Quii-A separated on analytical RP-HPLC C5 column. 
Shows the total ion chromatogram (TIC); gives a complete trace of the spectrum. 
i) x-axis - retention time in minutes 
ii) y-axis- Total abundance of ions a particular peak given in counts. 
iii) a trace of all the peaks detected 
iv) a peak at a given retention time, being integrated. 
179 
Sample Name: Quilla:ja 
________ Entry Nu!llber in Table 5 -"' 41 
,
1
--------Tn -r-Msm TJC;-MS File-{F:\DATA\OLENKIE\QUICA3:D+BSB) --APf-Es;-~eg;-Scan-;-Frag: 2~----~--------- - -----
A (ii) --
800000 • j: (iv) e f g (iii) 
Sample Explanation Page 1 (MSD Signal Pages) 
r1 /h 
r
1 1d \ lr ' i 
lr 
I 40oooo - a b c 11 
3ooooo ~~~~ 11 :~~~~~ . \ ~~~M~i~,,wu '-tlll~U Jti..li.~,.L..U 
. ;) 
600000 
700000-
500000-
-,,,'.I 
0 
-,-- 1· ··· r-' 
··--·-~---- _(i) ____ 1_()_ ______ --~ ___ 2Q _____ _ 
310 ,-~-4b .,. ----,-----~----····r·-5'0~-T _______ 1 ____ , -----,-ero··-. ---r- ---,--~--T--·?0----.,- --, -----r-.. --.- -ab··---r---- , -----r~r--90------r------.--.-
----~---~------~---~----------~----~-~---------~~---~--------~--------------
B [- -- -.-~--l\71501 SPC; lli'ne=!J.8g2:1 U:l68ofF:\o-ATA\DCENKTE\QUJCA3:[J'FBSB-APr-Es;-Ne- , 
I (ll) N <') 
I 120001 zs·. (iii) ~ Max: 12173 
1oooo _ (iv) 
8000 ·-
6000-
4000-
2000-
0-
QO 
<P 
'<t 
cci ~ 
(() '<t 
~ Ol 
N 1'-
.. J '""·~·J .. , .. ~-.c.-..1 ..... 
D Peak #27 at 9.997 min ( 9.892 to 10.175 min) 
c - l MSD1 2794, EIC=2793.7:2794.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) ~~ MSD11812, EIC=1811.7:1812.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) (ii : ' MSD1 761, EIC=760. 7:761.'7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
40000 
35000-
30000 
25000-
20000-
15000 . 
10000 
5000- / 
0 -
-r ---, -g----r----r~ .---,..- -~~~ ~~ _:--=_-=;-...:.:=-.----~------T---r------r--··-r-~--,--,---..--
~~- ~1.)2: __ 5~---- 10 10.05 10.1 
- > The analysis found 8 component,,s, indicating an impure peak. <-
Component 1: 
Component 2: 
Component 3: 
Component 4: 
Component 5: 
Component 6: 
Component 7: 
Component 8: 
Peak at Scan 465.0. Top ions are 
Peak at Scan 466.0. Top ions are 
Peak at Scan 467.3. Top ions are 
Peak at Scan 468.0. Top ions are 
Peak at Scan 469.0. Top ions are 
Peak at Scan 471.0. Top ions are 
Peak at Scan 472.0. Top ions are 
Peak at Scan 473.1. Top ions are 
Instrument 1 3/11/2003 6:33:17 PM linda 
2794 
1812 
761 
1524 
1523 
1770 
2168 
768 
Page 158 of 214 
MSD = mass detector signal 
TIC= total ion chromatogram 
API-ES = ionization mode; atmospheric pressure ionization- electron spray 
Neg.= ionization polarity; negative 
frag:25 = fragmentation voltage; 25 kV 
Regions: a , b, c, d, e, f, g, h, i, j are apparent and have been investigated 
and shown to contain the following major ions given in m/z: a-111 0; b-1996; c-956 
(QS-L1; So eta/., 1997); d-1673; e-1512 (DS-1; Higuchi eta!., 1987) and 1696 
(DS-2; Higuchi eta/., 1987 and van Setten eta/., 1995); f-1193; g-1759 and 2012 
(QS-21; Kensil et al., 1991 ); h-1856 (van Setten eta!., 1995), 1987 (QS-21; Kensil 
et al., 1991) and 2190; i-1560 (QF-23); j-1856. 
Figure B 
Shows the Apex of mass spectra of peaks detected at a specific retention time 
(shows the ions detected in that peak). 
i) x-axis- ion masses in mass per charge (m/z) 
y- axis abundance of each ion detected (in counts) 
iii) spectrum of all ions detected that peak 
iv) actual abundance of the most abundant ion detected in that peak (in counts) 
SPC = spectrum of peak chromatogram 
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time= retention time of peak being examined (minutes) 
Figure C 
Is the extracted ion chromatogram (EIC) and shows the spectrum of the ions 
detected in that peak, provides a close up of the elution characteristics of each ion. 
i) x-axis - retention time in minutes 
ii) y-axis -abundance, in counts. 
Section D 
Specifies the Peak number for the peak being integrated (the peak is numbered 
upon integration), shows the time range of integration, the number of components 
detected in that peak and gives an assessment of the purity of that peak. 
Section E 
Gives the ions detected in each component 
Sample Explanation Page # 2 (page 183) for DAD signal pages 
Figure F 
Shows the chromatogram obtained from the diode array detector (DAD) signal 
i) x-axis - retention time in minutes 
y-axis- absorbance milli absorbance units (mAU) 
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Sample Explanation Page 2 (DAD Signal Pages) 
Peak :52 at 9.976 min Name ? 
G~ 
(ijj) 
I 
\ 
-----co---~----- --.:..-__ ---_--,..__ __ 
200 360 
--, ! f 
375 
Sample Name: Quillaja 
Entry Number in Table 5 = 41 
··~-~ ··----- -~- -----· 
I I 
i i -~---· '• ~. - --'-,'..L, _'-,~=-~~-_1:.._·~:·~_-_.,_J_:_.~_--_~ ~ __ ·-·_· __ ~m~_-_-:_njl ·--~--~-,---~-~-~- - 5'o-· ····-·r--~--~~ ~---~-~ - ··--a'o
- - -------------- --- -- -- ----- ----- -
H 
re·(tfyi.lser.r_:L / L / / / 7: .LZ J. L / .L L L .L..L. L L../ /./ ./_/_/_L../_/_L../...:.L..../_L~.L./...J_g-g1l 
~7'").::_~-- +, ~ T f . - ,-~~ _j 
\l 9.9 . .. ------- - 10 1Q.1___~-----~---.mid 
I 
-> The purity factor is within the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
997.948 (3 of 3 spectra are within the threshold limit.) 
990.000 (Set by user) 
No Reference 
3 (Selection automatic, All) 
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i absorbances of all the peaks 
iv) peak to be examined, eluted at a given time 
DAD = diode array detector (signal) 
Sig: 214.16 = gives wavelength at which peaks are being detected in nanometers 
(nm) 
Figure G 
Shows absorption characteristics of the components being detected in a specific 
peak designated by a peak number (given at time of intergration) 
Figure H 
Graphical representation of the the peak purity assessment 
Section I 
Interpretation of the peak purity: threshold 990.000 is the instrument default 
Method employed in the analysis 
LC Instrument Parameters 
DAD Lamp used: UV lamp 
Injection Volume: 20 ~L 
184 
LC Instrument Conditions 
Column Temp. (Left) 
Column Temp. (right) 
Pressure 
Flow 
MSD Instrument Parameters 
ionization polarity: negative 
ionization mode: API-ES 
MSD Instrument Conditions 
Quad Temp. 
Gas Temp. 
Rough Vacuum 
High Vacuum 
Capillary Current 
Cham Current 
Drying Gas (Flow rate) 
Neb Pressure 
At Start 
35.0 
35.0 
187.4 
1.5 
At Start 
99 
350 
2 
4.6 X 10-6 
47 
2 
12 
50 
185 
At Stop 
35.0 °C 
35.0 °C 
53.3 bar 
0.0465 mL!min 
At Stop 
99 oc 
350 oc 
2 Torr 
4.6 x 1 o-s Torr 
2000 nA 
8 ~A 
12 Lim in 
50 psig 
Data File F:\DATA\OLENKIE\QUILA3.D 
-----------c:_T-MSD1 IIC, MS File (1-:\DAIA\OCEf\IKIE\UOTLA-::r.D+BSB) API-ES, Neg, Scan, Frag: 25 
Samnle Name: Ouillaja 
Entry Number in Tab_le 5 = 6 Q 
800000 
700000 
600000 
500000 
400000 
300000 
200000 
100000 
0-
10 
-l\7!SD1 SPC, time-
18000 
16000-
14000 
12000 
10000 
8000 
6000 
4000 
2000 
0-
(") 
N 
N N 
tD N .,.... 
,JL.J 
5 0 1000 
20 
N 
r--.: 
00 
00 
30 40 
Max; 18143 
~.A,, .. " .... 1 ....... . 
1500 2000 2500 
------
Peak #51 at 19.587 min (19.414 to 19.907 min) 
50 
-l 
f-: 1----. 
;----, 
'----
50000 
40000 
ml 
60 70 80 90 
MSD1 2476, EIC=2475.7:2476.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 1887, EIC=1886.7:1887.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 1353, EIC=1352.7:1353.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 1354, EIC=135~.z:~354.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
/ 
I '--
I '--
----
-----
--= _-_-----: --~-::. -----~---,-~-~ :J ----,---------------.;o-~r-""~---
19.7 19.8 19.5 19.6 
-> The analysis found 7 components, indicating an impure peak. <-
Component 1: 
Component 2: 
Component 3: 
Component 4: 
Component 5: 
Component 6: 
Component 7: 
Peak at Scan 913.0. Top ions are 
Peak at Scan 917.0. Top ions are 
Peak at Scan 920.1. Top ions are 
Peak at Scan 921.0. Top ions are 
Peak at Scan 921.8. Top ions are 
Peak at Scan 929.0. Top ions are 
Peak at Scan 929.9. Top ions are 
2476 
1887 
1353 1354 706 
1467 1468 1389 
676 1391 
1222 
1221 
--------- -----------------------------------------------------------------------------------------
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Uata J:<'lle 1<': \DATA \OLENKIE \QUILA3. D 
Peak :95 at 19.577 min Name : ? 
---~--____ j __ ~-------~--
Sample Name: Quillaja 
Entry Number in Table 5 = 6 0 
·--~--LTLf--T--Ll __ L_l _l_r· 
"----~--r---------~--~-- -
80 
!''"''u;e,'·~~.~~ ~:~~~~~-"·===•j 
,- -~~-ji!_-:=-===:=:_ ___ 1~:5 · --~-=-~~--::_ __ 1~:§_==-~:--:~y-~-~~1-9X=~~ 
-> The purity factor is within the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
999.923 (3 of 3 spectra are within the threshold limit.) 
990.000 (Set by user) 
No Reference 
3 (Selection automatic, All) 
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Data File F:\DATA\OLENKIE\QUILA3.D 
---[] MSD1 IIC, MS File (F:\OATA\OLENKIE\QOILA3.D+B~PI-ES, Neg, Scan, Frag: 25 
Sample Name: Quillaja 
Entry Number in Table 5 = 6 3 
-----. ---·--- ----- --
800000 
700000. 
600000 
500000 
400000 
300000 
200000 
100000 
0 
"----'--,----.------.---~-,--------.---~~~----,------,--~~----r----,-~~-~~--,-~----.----~-,------.------,-----,--- ---,------,-----,--------,------,----,-----,---~~~---+~----r----r----r--r~-~~.---l 
10 20 __ _______c3__:_0 _________ 40 _________ ______::_:50=---------- 60 70 
16000 
14000 
12000 
10000 
8000 
6000 
4000 
2000 
0 
Peak #54 at 20.743 min 
-> The analysis found 
Component 1 : Peak at 
Component 2: Peak at 
Component 3: Peak at 
Component 4: Peak at 
Component 5: Peak at 
Component 6: Peak at 
Component 7 : Peak at 
Max: 16443 
<0 
N 
<:; 
N 
...-
0 
co 
co 
N 
~ 
2000 2500 ml 
(20. 667 to 20.902 min) 
7 components, indicating 
Scan 973.0. Top ions are 
Scan 973.9. Top ions are 
Scan 975.2. Top ions are 
Scan 976.4. Top ions are 
Scan 977.7. Top ions are 
Scan 979.0. Top ions are 
Scan 980.3. Top ions are 
Instrument 1 3/11/2003 6:33:17 PM linda 
80 90 
50000 
~ l MSD1 834, EIC=833.7:834.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 1-~ MSD1 1607, EIC=1606.7:1607.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
~----, MSD11155, EIC=1154.7:1155.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
:·: MSD1 1684, EIC=1683.7:1684.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 0 MSD1 ;_98~ EIC=1682.7:1683.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
40000 
30000 
20000 
/ "-
/ "-
1 \ 
I \ 
I \ 
\ 
~ 
10000 k c"O'~"o~"~"'"'""~~" ~··· : •.. C ·.· •••.• ~:-:. ·~· ~~ •c ..• 
20.7 ' 20:75 ' ' ' 2d.8 
an impure peak. <-
834 
1607 1155 1608 
1684 1683 
2880 2312 1156 
2311 1968 
1163 2325 
2327 
20.85 
min 
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co 
co 
T-
Data File F:\DATA\OLENKIE\QUILA3.D Sample Name: Quillaja 
,~~----~---------------~---____ EJ1try .1\!um~~r in Table 5 = 6 5 
MSD1 IIC.~S File (F:\DAI A\OLENKIE\QOILA3.0+BSB) API-ES, Neg,- Scan,-Frag: 25 I 
800000- ~I 
700000 II II 
600000 
500000 
400000 
300000 
200000 
100000 
0 
10 20 30 
~ 
Max: 33327 
30000 
25000 
20000 
15000 
10000 
5000 
0 LJ 
5 0 1000 1500 2000 2500 
Peak #58 at 21.794 min (21.699 to 22.022 min) 
ml 
50 
25000 
20000 
;---, 
R 
'------
60 70 80 __ ~~----90~~--~m~in 
MSD1 2166, EIC=2165.7:2166.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2165, EIC=2164.7:2165.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2846, EIC=2845.7:2846.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2071, EIC=2070.7:2071.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2180, EIC=2179.7:2180.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSO;t 2181, EIC=2180.7:2181.7 {F:\DATA\OLENKIE\QUILA3.D+BSB) 
/ ' 
' " 
\ 
\ 
15000 --- ----=-:-:-_<s~:::: .. :.> .. \ 
10000 ' -......:.:~,, 
~~----,~- ----
5000 ~ ~ ,-~~ -:-.. :·-::;::::::: =-= 
o~~--~~~-.~~~~-'~--~~'--~r-~-~r--~~~-~----~-f==--y~:=~~=:=~~r=:-~=~r===~-:~-~~~~~ 
21.75 2 .8 21.85 21.9 21.95 
-> The analysis found 8 components/ indicating an impure peak. <-
Component 1 : Peak at Scan 1020.1. Top ions are 2166 2165 
Component 2 : Peak at Scan 1022.0. Top ions are 2846 2071 1961 
Component 3 : Peak at Scan 1023.4. Top ions are 2180 2181 
Component 4: Peak at Scan 1024 .1. Top ions are 1962 2034 
Component 5 : Peak at Scan 1026.9. Top ions are 2579 
Component 6 : Peak at Scan 1029.2. Top ions are 1059 1060 1061 
Component 7 : Peak at Scan 1030.0. Top ions are 1592 
Component 8: Peak at Scan 1031.2. Top ions are 1173 
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Data File F:\DATA\OLENKIE\QUILA3.D 
Peak :106 at 21.884 min Name : ? 
-> The purity factor is within the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
999.848 (3 of 3 spectra are within the threshold limit.) 
990.000 (Set by user) 
No Reference 
3 (Selection automatic, All) 
' 
Instrument 1 3/11/2003 6:33:17 PM linda 
Sample Name: Quillaja 
Entry Number in Table 5 =:: 6i5 
. -·---~- 1 L-+t--1-,--L-,-----L.T ______ J 1 __ 
__ , ----- ---- ---~-------...-~----------.--· ~--·---r-----
80 min 
Page 80 of 214 
Data File F:\DATA\OLENKIE\QUILA3.D 
--o- MSD1 IIC, MS File (F:\DAIA\OLENKIE\QUILA3.D+BSB) API-ES, Neg, Scan, Frag: 25 
Sample Name: Quilla1a 
Entry Number in T~le 5 = tiS 
800000 
700000 
600000 
500000 
400000 
300000 
200000 
100000 
0 
17500 
15000 
12500 
10000 
7500 
5000 
2500 
0 
10 20 
('") 
10 
N 1'-
oi '<I" 
0 
(}) 
l' '·"' "~ .... ~ • .J.~. ;,.,.,., JJJ 
5 0 1000 1500 
30 40 
"': 
Max: 19396 
<0 
~ 
1--: 
2000 2500 
---
Peak #61 at 22.659 min (22.600 to 22.703 min) 
ml 
50 60 0 80 90 
~ l MSD1 1757, EIC=1756.7:1757.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) L~ MSD11758, EIC=1757.7:1758.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
~--~ MSD11765, EIC=1764.7:1765.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
;··: MSD11772, EIC=1771.7:1772.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
n MSD11148, EIC=1147.7:1148.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
~-:.:__-MSD.!:_:I.88_6,_1;:_1_9_=~-~~~:7:1886.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
-------------
22500 
20000 
17500 
15000 
12500-: 
10000-
----
- ---- _______ ::::-o- --"'-.: . .-:::_::.::::..::,~ •• ~,,:.-::::~-
----------
7500 
22.62 22.64 22.66 22.68 
-> The analysis found 4 components/ indicating an impure peak. <-
Component 1: 
Component 2: 
Component 3: 
Component 4: 
Peak at Scan 1062.1. Top ions are 
Peak at Scan 1063.4. Top ions are 
Peak at Scan 1064.4. Top ions are 
Peak at Scan 1065.2. Top ions are 
Instrument 1 3/11/2003 6:33:17 PM linda 
1757 1758 878 
1765 1772 2017 
1148 1886 1871 
1885 2035 1147 
Page 192 of 214 
...... 
0> 
...... 
LJata Flle F:\DA'l'A\OLENK1E\QUILA3.D Sample Name: Quilla8a 
Entry Number in Table 5 = 68 
Peak :110 at 22.602 min Name : ? 
r. ·--·------- - --··-- -·----~--···-···----~---------- -----~--------------------~--- -------- ------~---- ·----~-~------ ·---
~~, 
,, \ 
r . 
. \ 
\ 
200 ··· ':'-. 25~_:-:~ 2~0· ·· · • 2!5 • • ~ 3bo • · · •· · 325- • ·~350' ~;75 -···,;-I ~ -·-··· ·~·· -· ---·. .. . .. ~· ~- .. ·- .. -·-----. ·~ .. ~ ·- -· ... ~· .. ~~ .. ---·· ·~ ~--· ---·-~~- ··~·-- --··~~· -·~~~m 
r -~ --~------~~~--·--· 
/ 
~-·--~-~---, 
/~~---------~~··~-// 
SefeyUS&-2:J...J__.__ZJ ' z z~~~_::r~ ::LLJ. ~~__z:::r~ 
L--------~---t-t-~----* ____ • ____ .___----t---* . . I 
--------.-------,--------~-~--,--r---r---- _T ____ -r~ 
~--- -~ 22.2 :22;4_____ 22.6 min 
-> The purity factor is within the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
999.437 (7 of 7 spectra are within the threshold limit.) 
990.000 (Set by user) 
No Reference 
7 (Selection automatic, All) 
' 
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C\1 
0> 
..--
Data File F:\DATA\OLENKIE\QUILA3.D 
800000 
700000 
600000 
500000 
400000 
300000 
200000 
100000 
0 
~-.--.-~~~---,---.--~~~- --,--.-
10 -=2-=-0 _______ 30 ___ _ 
--M-SD1 SPC, tlme=22. 700:23.019 of F :\DA I A\OLENKIE\QU~LA3-.D+BSB 
Max: 
00 
20000 
15000 
10000 
API-E , 
28270 
<D 
.0 
0 
CXl 
N 
5000 
0 ·- ..... ·~l'-.Ll " j"'"'"-I...IJIIJ.UIWI~~ .......... ___ _L 
2000 2500 m/ 
Peak #62 at 22.823 min (22. 703 to 23.020 min) 
9 
-> The analysis found 9 components, indicating an 
Component 1 : Peak at Scan 1068.8. Top ions are 
Component 2 : Peak at Scan 1069.9. Top ions are 
Component 3: Peak at Scan 1071.6. Top ions are 
Component 4 : Peak at Scan 1073.0. Top ions are 
Component 5 : Peak at Scan 1075.5. Top ions are 
Component 6 : Peak at Scan 1077.1. Top ions are 
Component 7: Peak at Scan 1078.2. Top ions are 
Component 8: Peak at Scan 1078.8. Top ions are 
Component 9 : Peak at Scan 1079.8. Top ions are 
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Samole Name: Quillaja 
Entry Number in Table 5 = 6 g 
,------------------------------- --- ----
45000 
40000 
35000 
-1 ~: 
I---_; 
:--; 
[j 
MSD1 1081, EIC=1080.7:1081.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2151, EIC=2150.7:2151.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2149, EIC=2148.7:2149.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 694, EIC=693.7:694.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 2164, EIC=2163;7:2164.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
' 
30000 -------- \ ~\ 
25000 ~-
20000 \ ~ 
15000 -~~ 
10000- ---~ 
5000 ---- - -"--c:.__:_~_c_.-~-=-
0 -"--,2~2-..7-5~~~-22.8~'--22.8Sr~ ·~:9"r=-~Cc-, -~~-c 
---------
impure peak. <-
1081 
2151 2149 2150 
694 2164 2163 
2178 2177 2179 
2224 
2805 2298 1166 
1148 
2296 2304 
2303 2295 2297 
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Data File F:\DATA\OLENKIE\QUILA3.D 
1 e (F:\DA I A\OLENKIE\QUILA3.D+BSB) API-ES, Neg, Scan, Frag: 25 
Sample Name: Quillaja 
Entry Number in Table 5 = 7 3 
800000 
700000 
600000 
500000 
400000 
300000 
200000 
100000 
0 
40000 
30000 
20000 
10000 
0 .. __ ,_t_._JL. .L. l' 
5 0 1000 
20 30 40 
I A\OLENKIE\QUILA3.D+BS 
Max: 48694 
<0 
cxi 
~ 
0 
"<t 
"<1: N N 0> <0 C') 
..0 co 0> 
1'- co N 
"<t ~ 
~k.~j 
···'•"'"'. ~ . ---~--~-~---·-
-
1500 2000 2500 
Peak #64 at 23.697 min (23.497 to 23.784 min) 
ml 
50 60 70 80 90 
L, ~ MSD1 2031, EIC=:2030.7:2031.7 (F:\DATAIOLENKIE\QUILA3.D+BSB) 
MSD1 2025, EIC=2024.7:2025.7 (F:\DATAIOLENKIE\QUILA3.D+BSB) 
~---~-~ MSD1 2032, EJC:::2031.7:2032.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
:--; MSD1 2033, EIC=2032.7:2033.7 (F:\DATAIOLENKIE\QUILA3.D+BSB) 
MSD1 1980, EIC=1979.7:1980.7 (F:\DATAIOLENKIE\QUILA3.D+BSB) 
35000 ~~ 
~ 
30000 -----~-~ ~ 
- ~- "'-._ 
25000 ~ 
20000 ------._/ ~ 
---·,::-- -~ 
15000 -' -~ 
~~ 10000 ----..:: ~ 
5000 :~·::-:::~:??,~:~::;.;;.-,;::,·.=~ .- -.- -~ 
o~~~~~~~~~~~~~~~~~~~~~F=~f=~ 
23.55 23.6 23.65 23.7 
-> The analysis found 9 components, indicating an impure peak. <-
Component 1: Peak at Scan 1105.0. Top ions are 2031 2025 1850 
Component 2: Peak at Scan 1106.0. Top ions are 2032 2033 2021 
Component 3 : Peak at Scan 1107.0. Top ions are 1980 
Component 4: Peak at Scan 1108.6. Top ions are 1885 1886 1887 
Component 5: Peak at Scan 1110.0. Top ions are 1074 
Component 6: Peak at Scan 1112.0. Top ions are 2932 
Component 7: Peak at Scan 1113.1. Top ions are 2149 2152 2158 
Component 8: Peak at Scan 1114.0. Top ions are 2150 1022 
Component 9: Peak at Scan 1115.0. Top ions are 1476 1351 2151 
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Data File F:\DATA\OLENKIE\QUILA3.D 
Peak :115 at 23.448 min Name 
I~ ~- ---- - ----------~-------------------
11' '" ,,, \ l' ,, 
I '). 
\ 
\ 
-~-----
? 
- ~--~---··---------~--- -------- ·- -~--
-~-~-~------- ---- ----- ---------------------------1 
200 
1·---- --- -- -r· ··-.---,------,- ·-- r ,_ -
225 250 275 
,--, r-·------~-. ---~--------,---------- r·-1 
325 350 375 nm 300 
-> The purity factor is within the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
Warning 
998.657 (5 of 5 spectra are within the threshold limit.) 
990.000 (Set by user) 
No Reference 
5 (Selection automatic, All) 
Spectral absorbances > 1000 mAU (see help for more information) 
' 
Instrument 1 3/11/2003 6:33:17 PM linda 
Sample Name: Quillaja 
Entry Number in Table 5 = 7 3 
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Data File F:\DATA\OLENKIE\QUILA3.D 
Signal DAD1 A, Sig=214,16 Ref=off (F:\DATA\OLENKIE\QUILA3.D) 
Sample Name: Quillaja 
Entry Number in Table 5 = 7 7 
-- mAU --- - .. - -----11' ·a:r---~-----~--- ---------· 
0 II~ 1ooo t'O' l 1 ,., 
at ~I ID 
aoo - ': 'I (\J 
IV j:J 1 V 600 _ I ~·· ., . .,II. 
: . 1) I ~ /: ~. i! 
400 , ! I 1: iii' fi ! /::: ,. : 
200 j !. I j r Jyl\l\, }l\_\'1l Iii ·ij \, 
J / ! j I . ! ,, /1! }! 1 If): r~fl1:)11, )' •·· 
i . I''"'''II~Uf.'H'lt~··-q~·fllHU-Hj''l' ~~·.•!:'1'' I It 0 ., . :, ·: .. !:c:::::'·"~:, .. ':.·l!_.cilri!aJ..: •t_U! -~'' tl ':L!!. 11 ..• .::! H-!!l+!li+t,--4-,-4-fH-,-.!-f.--,-- _____ -'-/, ____ . .-L._,..L-+J--,'--,_L/,'-,'-,--------c,----'-t- ----'-,-'+,-·'·r·.Lr _,_ 1 _____ .1 -----· ____ _ o _l- -- -----~---- --20 - ----------y·- -----.------4o --- ----~.------T----------60-- ---- ,-------------------r~---------.--- -- ---af)-------, --
________ min, 
Peak :119 at 24.791 min Name : ? 
--
1 
' 
\ 
\ 
\ 
\ 
"-.... 
----------------------------
left>ytiser==L.FL7C7-==z.=_--z-..cz---==c7'= CCLTC?~LI I z=mJ..--z== 990 
- --- - * • ·- -- -- --- -- - I 
\ 
225 250 275 
-> The purity factor lS within the threshold limit. <-
Purity factor 999.876 (3 of 3 spectra are within the threshold limit.) 
Threshold 990.000 (Set by user) 
Reference No Reference 
Spectra 3 (Selection automatic, All) 
' 
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CD (J) 
...... 
Data File F:\DATA\OLENKIE\QUILA3.D 
' 800000 
700000 
600000 
500000 
400000 
300000 
200000 
100000 
0 
~ MSD1 SPC, tlme-27.005:27.11~AIA\OLENKIE\QUILA3:0+BSB 
\ 80000 J r;li Max: 85068 l,~,l· 
1 60000 
1 50000 i 
140000 i 
30000 ~1 
20000 ~ 
~ 
()) 
0 
<X) 
<D 
. 10000j II L' L~, ~1d~~ ~· ~50~ "'~ ~' iooo . .. '2,;;0 - _ - ml 
Peak #72 at 27.051 min (27.012 to 27.119 min) 
80000 
70000 -
60000 
50000 
40000 
30000 
20000. 
Samnle Name: Quillaja 
Entty_ N~mber in Table 5 :::;: B 3 
------------------- -----, 
L. _; MSD1 2343, EIC=2342.7:2343.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
MSD1 1730, EIC=1729.7:1730.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
~--~ MSD1 2340, EIC=2339.7:2340.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
;- ; MSD1 1559, EIC=1558.7:1559.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) g MSD11562, EIC=1561.7:1562.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) L _- MSQ.1 go9;-EIB=8El8:-7:809-o-7 (F:\9AF-A\QI.JoNKIB.QUII.A3.[)+El_SB_) 
----.. __ 
-> The analysis found 3 components, indicating an impure peak. <-
Component 1: 
Component 2: 
Component 3: 
Peak at Scan 1270.0. Top ions are 
Peak at Scan 1271.0. Top ions are 
Peak at Scan 1272.1. Top ions are 
Instrument 1 3/11/2003 6:33:17 PM linda 
2343 1730 1231 
2340 1559 
1562 809 1897 
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)ata File F:\DATA\OLENKIE\QUILA3.D 
Signal DAD1 A, Sig=214,16 Ref=off (F:\DATA\OLENKIE\QUILA3.D) 
mAU 3 ~I 1000 
" ~I ai 800 
-v VI I 
600 II 
400 Nl 200 ~ "" J .. ,,dJ ,,~, '~~·~)~ ~ ~ w""'" 0 
) 20 40 60 
Peak :126 at 26.936 min Name ? 
80 
Sample Name: Quillaja 
Entry Number in Table 5 = 83 
min 
~~/~--:_--~->~ .----···· 
/ --- / / ~ I 
--- ---/ I 
------------------------~~~~~ 
26.75 27 
-> The purity factor exceeds the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
643.362 (4 of 7 spectra exceed the threshold limit.) 
990.000 (Set by user) 
No Reference 
7 (Selection automatic, All) 
Instrument 1 3/11/2003 6:33:17 PM linda 
27.25 zl.5 27.75 mio 
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Data File F:\DATA\OLENKIE\QUILA3.D Sample Name: Quillaja 
D MSD1 IIC, MS file (F:\DAfA\OLENKIE\QUILA3.D+BSB)PJ'I-ES, Neg, Scan, Frag: 25 
__ __ ____ ___ Entry Number in Table 5 :=== 8 7 
800000 
700000 
600000 
500000 
400000 
300000 
) 
200000 
100000 
0 
Max: 13129 
12000 
10000 
8000 
6000 
4000 
2000 
0 L~~-L. ..... ..................... 
1500 ___ _;__20:__:0_:_0 __ -=2-=--50_;__0 _ __ __.rn!'-'--"--"' 
Peak #77 at 30.007 min (29.774 to 30.313 min) 
50000 
40000 
30000 
20000 
10000 
----------
~ l MSD11560, EIC=1559.7:1560.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) ~~ MSD11559, EIC=1558.7:1559.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
' MSD1 779, EIC=778.7:779.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
~ -= MSD1 809, E?-IC=808.7:809.7 (F:\DATA\OLENKIE\QUILA3.D+BSB) 
;\ 
I \ ~-----/ \ / _/ ------~--
/ / 
I 
I 
I 
/' 
I \ 
/ 
' \ 
0 ---"-C:~-.---~-~~-----.~--~--,-----.-- -----,---~3t1-~ ~ 
L__ _______ 29.c__'_:;__9 ______ _:3c_:_0 _____ 3 _.1 -··- 30.2 
-> The analysis found 7 components, indicating an impure peak. <-
Component 1 : Peak at Scan 1407.0. Top ions are 1560 
Component 2 : Peak at Scan 1410.3. Top ions are 1559 779 2341 
Component 3: Peak at Scan 1414.9. Top ions are 809 
Component 4 : Peak at Scan 1416.1. Top ions are 1561 
Component 5: Peak at Scan 1420.0. Top ions are 971 
Component 6: Peak at Scan 1421.0. Top ions are 2077 
Component 7: Peak at Scan 1422.0. Top ions are 1287 
Instrument 1 3/11/2003 6:33:17 PM linda Page 208 of 214 
m 
m 
...... 
Data .b'lle F:\DATA\OLENKIE\QUILA3.D Sample Name: Quillaja 
Entry Number in Table 5 = B 7 
-4-~ll'flt!illi:lillllll:itlttl:l''tllilit'I!JllJ.'llit!tt!'fllJJJUJllJIUWJUlLJl_jJ":nn~f+h--li'-,-Lj---Hf-~,--~----"+r-------------'--r'-'tf-+-r~-+'=--+:r~=:;::==:':::c:=::;::="2:==:;::=::C:±;=c~~:::':2:===;=']===::;::====:j 
40 -~----~-~6_0~-------------------a~o _________________ m~i~r 
Peak :138 at 29.936 min Name ? 
- - ---- -~-=-==--~-=-=---=---- -------
T I 
' ' 
' ' ~~-~ 
'------
29.8 
-> The purity factor exceeds the threshold limit. <-
Purity factor 
Threshold 
Reference 
Spectra 
849.505 (2 of 3 spectra exceed the threshold limit.) 
990.000 (Set by user) 
No Reference 
3 (Selection automatic, All) 
Instrument 1 3/11/2003 6:33:17 PM linda 
30 30.2 min 
Page 96 of 214 
0 
0 
N 
References 
Ahmad, V. U. and Basha, A Spectroscopic data of saponins: The triterpenoid 
glycosides set. CRC Press. Boca Raton, FL. USA (2000). 
Ahmeida, E. T. S. B., Jennings, R., Erturk, M., and Potter, C. W. The lgA and 
subclass lgG responses and protection in mice immunised with influenza 
antigens administered as iscoms, with FCA, ALH or as infectious virus. Arch. 
Viral. 125: 71-86 (1992). 
Akitt, J. Wand Mann, B. E. NMR and chemistry : an introduction to modern NMR 
spectroscopy. 4th ed. Cheltenham, U.K. : S. Thornes; 273-334 (2000) .. 
Allison, A. C. and Byars, N. E. Immunological adjuvants and their mode of 
action. In: Vaccines: New approaches to Immunological Problems. Ellis. R. W. 
(ed.). Butterworths-Heinermann, London. U. K. 431-49 (1992). 
Anaguade, S. A. Quillaja Extracts. [On-line] Available: 
http://www. readysoft. es/anagal ide/eng I ish/products/qui//aja%20extract. htm 
(1999). 
201 
Anisimov, M. and Chirva, V. J. Die biologische Bewertung von 
Triterpenglykoside. Pharmazie, 35: 731-738 (1980). 
Audibert, F. M. and Lice, L. D. Adjuvants: Current status clinical perspectives 
and future prospects. lmmunol Today 14:(6): 281-4 (1993). 
Banoub, J. H. and Shaw, D. H. Isolation and characterization of 3-acetamido 
-3,6-dideoxy-L-glucose from the core oligosaccharides obtained from the 
aquatic gram-negative bacteria Aeromonas hydrophila and Vibrio anguillarum. 
Can. J. Biochem. Nov-Dec;59(11-12):877 -9 (1981 ). 
Banoub, J. H., Choy Y. M., Michon, F., and Shaw, D H. Structural investigations 
on the core oligosaccharide of Aeromonas hydrophila (Chemotype II) 
lipopolysaccharide. Carbohydr Res. Apr 1;114(2):267-76 (1983). 
Banoub J. H., Michon, F., and Hodder, H. J. Structural elucidation of the 
a-specific polysaccharide of the phenol-phase soluble lipopolysaccharide of 
vibrio-anguillarum. Biochemistry-and-Cell-Biology.; 65 (1 ): 19-26 (1987). 
Beacock-Sharp, H., Donachie, A M., Robson, N.C., and Mowat A M. A role for 
dendritic cells in the priming of antigen-specific CD4(+) and CDS(+) T 
202 
lymphocytes by immune-stimulating complexes in vivo. lnt lmmunol. 
Jun; 15(6):711-20 (2003). 
Behboudi, S., Morein, B., and Ronnberg, B.; Isolation and Quantification of 
Quillaja saponaria Molina Saponins and Lipids in iscom-matrix and iscoms. 
Vaccine, 13 (17): 1690-6 (1995). 
Behboudi, S., More in, B., and Villacre-Eriksson, M. C. In vitro activation of 
antigen presenting cells (APC) by defined composition of Quillaja saponaria 
Molina triterpenoids. Clin. Exp. lmmunol. 105 : 26-30 (1996). 
Behboudi, S., Morein, B., and Villacre-Eriksson, M. In vivo and In vitro Induction 
of IL-6 by Quillaja saponaria Molina Triterpenoid Formulations. Cytokine, 9 (9): 
682-87 (1997). 
Behboudi, S., Morein, B., and Villacre-Eriksson, M. C. Quillaja saponin 
Formulation that Stimulate Proinflamatory Cytokines Elicit a Potent Acquired 
Cell-Mediated Immunity. Scand.J.Immunol. 50: 371-377 (1999). 
Ben-Ahmeida E. T., Gregoriadis G, Potter C. W., and Jennings R. 
lmmunopotentiation of local and systemic humoral immune responses by 
203 
ISCOMs, liposomes and FCA: role in protection against influenza A in mice. 
Vaccine. Oct; 11 (13): 1302-9 (1993). 
Bengstrom-Mollaouglu, M., Lovgren, K., Akeblom, M. L., Fossum, C., and 
Morein, B. Antigen-specific increases in the number of splenocytes expressing 
MHC class II molecules following restimulation with antigen in various physical 
forms, Scand. J. lmmunol. 36: 565-74 (1992). 
Bernhardt, M, Sturm, C, Shaker, K. H., Paper D. H., Franz G., and Seifert K. 
Structurally related immunological effects of triterpenoid saponins. Pharmazie. 
Sep;56(9):7 41-3 (2001 ). 
Biermann, C. J. Hydrolysis and other cleavage of glycoside linkages. In: 
Analysis of carbohydrates by GLC and MS. Biermann, C. J. and McGinnis, G. D. 
(eds.) CRC Press. Boca Raton, FL. USA ( 1988). 
Biermann, C. J. and McGinnis, G. D. Analysis of carbohydrates by GLC and MS. 
CRC Press. Boca Raton, FL. USA ( 1989). 
Birk, Y.; Saponins, in Toxic constituents of Plant Foodstuffs. Leiner, I. E., Ed., 
Academic Press, New York, U.S. A. pp 169-210 (1969). 
204 
Birk, Y and Peri, I . Saponins . In toxic constituents of plant food stuffs, 2nd 
edition, volume.1, edited by Lienier, I. E., Academic Press, New York. pages 161-
182 (1980). 
Bjorndal, H., Lindberg, B., and Svensson, S. Mass Spectrometry of partially 
methylated alditol acetates. Carbohyd. Res. 5; 433-440 (1967). 
Bjorndal, H., Hellerqvist, C. G. Lindberg, B., and Svensson, S. Gas-Liquid 
chromatography and mass spectrometry in methylation analysis of 
polysaccharides. Angew. Chem. lmternat Edit. 9: 610-619 (1970). 
Bamford, R. The comparative selectivity of adjuvants for humoral and cell 
mediated immunity. II. Effect on delayed type hypersensitivity in the mouse and 
guinea pig and cell mediated immunity to tumour antigens in the mouse of 
Freund's incomplete and complete adjuvants, Alhydrogel, Corynebacterium 
parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. 
lmmunol. 39: 435-41 (1980). 
Bamford, R. lmmunomodulators From Plants and Fungi. Phytotherapy Res. 2: 
159-63 (1988). 
205 
Bamford, R., Stapleton, M., Winsor, S.,Beesley,J. E., Jessup, E. A., Price, K. R., 
and Fenwick, G. R. Adjuvanticity and ISCOM formation by structurally diverse 
saponins. Vaccine, 10 (9): 572-7 (1992). 
Boyaka, P. N., Marinaro, M., Jackson, R. J., van Ginkel, F. W., Cormet-Boyaka, 
E., Kirk, K. L., Kensil, C. R., and McGhee, J. R. Oral QS-21 requires early IL-4 
help for induction of mucosal and systemic immunity. J lmmunol. Feb 
15; 166( 4 ):2283-90 (2001 ). 
Bradley, L. M., Duncan, D. D., Tonkonogy, S., and Swain, S. L. Characterization 
of antigen-specific CD4+ effector T cells in vivo: Immunization results in a 
transient population of MEL 14, CD45RB helper cells that secretes interleukin-2 , 
3, and 4 and interferon gamma. J. Exp. Med. 17 4: 547-59 (1991 ). 
Brewer, J. M. and Alexander, J. The adjuvant activity of nonionic surfactant 
vesicles (niosomes) on the Balb/c humoral response to bovine serum albumin. 
Immunology, 75: 570-75 (1992). 
Brewer, J. M. and Alexander, J. Studies on the adjuvant activity of nonionic 
surfactant vesicles: adjuvant driven lgG2a production independent of MHC 
control. Vaccine, 12: 613-9 (1994). 
206 
Brewster, M. E., Hora, M. S., Simpkins, J. W., and Bodor, N. Use of 
2-hydroxypropyl-betacyclodextrin as a solubilizing excipient for protein drugs. 
Pharm. Res.8: 792-95 (1991 ). 
Bussiere, J. L., McComrmick, G. C., and Green, J. D. Preclinical Safety 
Assessment considerations in Vaccine Development. In: Vaccines Design: The 
Subunit and Adjuvant Approach, Powell and Newman (eds.). Plenum Press, New 
York, 61-79 (1995). 
Bungener, L., Huckriede, A., Wilschut, J., and Daemen, T. Delivery of protein 
antigens to the immune system by fusion-active virosomes: a comparison with 
liposomes and ISCOMs. Biosci Rep. Apr;22(2):323-38 (2002). 
Campbell, J. B. and Peebaye Y.A. Saponin. Res. lmmunol, 143: 526-30 (1992). 
Campbell, J. B. Saponins In: The Theory and Practical Applications of 
Adjuvants. Stewart-Tull, D. E. S. (ed.). West Sussex: John Wiley and Sons Ltd. 
95-128 (1995). 
Chao, A. C., Nguyen, J. V., Broughall, M., Recchia, J., Kensil, C. R., Daddona, 
P. E., and Fix, J. A.; Enhancement of Intestinal Model Compound Transport by 
207 
DS-1, a Modified Quillaja Saponin. J. Pharm. Sci., 87 (11) 1395-9 (1998). 
Chavali, S. R. and Campbell, J. B.; Adjuvants Effects of Orally-Administered 
Saponins on Humoral and Cellular Immune Responses in Mice. lmmunobiol. 
174: 347-59 (1987a). 
Chavali, S. R. and Campbell, J. B.; lmmunomodulatory effects of orally-
administered saponins and nonspecific resistance against rabies infection. Int. 
Arch. Allergy Appl. lmmunol., 84(22): 129-34 (1987b). 
Chavali, S. R., Francis, T. and Campbell, J. B. An in vitro study of 
immunomodulatory effects of some saponins. Int. J. lmmunopharmac., 9 (6): 
675-83 (1987). 
Chavali, S. R., Barton L. D. and Campbell, J. B. lmmunopotentiation by 
orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally 
against rabies. Clin. exp. lmmunol. 7 4: 339-43 (1988). 
Chen, M., Hu, K. F., Rozell, B., Orvell, C., Morein, B., and Liljestrom, P. 
Vaccination with recombinant alphavirus or immune-stimulating complex antigen 
against respiratory syncytial virus. J lmmunol. Sep 15; 169(6):3208-16 (2002). 
208 
Ciarlet, M., Crawford, S. E., Barone, C., Bertolotti-Ciarlet, A, Ramig, R. F., 
Estes, M. K., and Conner, M. E. Subunit rotavirus vaccine administered 
parenterally to rabbits induces active protective immunity. J Viral. 
Nov;72(11 ):9233-46 (1998). 
Ciucanu, I. and Kerek, F. A simple and rapid method for the permethylation of 
carbohydrates. Carbohydr. Res. 131: 209-17 (1984). 
Claassen, I. and Osterhaus, A The iscom structure as an immune enhancing 
moiety: experience with viral systems. Res. lmmunol. 143: 531-41 (1992). 
Clark, N., Kushner, N. N. Barrett, C. B. Kensil, C. R., Salsbury, D. and Cotter, S. 
Efficacy and safety field trials of recombinant DNA vaccine against leukemia 
virus infection. J. Am. Vet. Med. Assoc. 199 (1 0): 1433-43 (1991 ). 
Cleland, J. L., Kensil, C. R., Lim, A, Jacobsen, N. E., Basa, L., Spellman, M., 
Wheeler, D. A, Wu, J-Y and Powell, M. F. The isomerization and formulation 
stability of the vaccine adjuvant QS-21. J. Pharm. Sci., 85 (1 ): 22-23 (1996). 
Cleland, J. L., Lim, A, Daugherty, A, Barron, L., Desjardin, N., Duenas, E. T., 
Eastman, D. J., Vennari, J. C., Wrin, T., Berman, P., Murthy, K. K., and Powell, 
209 
M. F. Development of a single-shot subunit vaccine for HIV-1. 5. programmable 
in vivo autoboost and long lasting neutralizing response. J. Pharm. Sci. 
Dec;87(12): 1489-95 (1998). 
Connolly, J. D. and Hill, R. A. Triterpenoids. Nat Prod Rep. Aug; 19(4):494-513 
(2002). 
Coughlin, R. T., Fattom, A., Chu, C., White, A. C., and Winston, S. Adjuvant 
activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine, 
13 (1): 17-21 (1995). 
Coulter, A., Wong, T. Y., Drane, D., Bates, J., Macfarlan, R., and Cox, J. Studies 
on experimental adjuvanted influenza vaccines: comparison of immune 
stimulating complexes (lscoms) and oil-in-water vaccines. Vaccine. 
Jul;16(11-12):1243-53 (1998). 
Cox, J. C., Coulter A, Macfarlan, R., Beezum, Z., Bates, J., Wong, T. Y., and 
Drane, D., Development of an influenza-ISCOM™ vaccine. In Gregoriadis G, 
editor. Vaccine design: the role of cytokine networks. New York (USA): Plenum 
Press; p.33-37 (1997). 
210 
Cox, J. C. and Coulter, A R. Advances in adjuvant technology and application. 
In: Animal Parasite Control Utilizing Biotechnology. Yang, W. K. (ed). CRC 
Press, Boca Raton, FL., 49-111 (1992). 
Cox, J. C., Sjolander, A, and Barr, I. G. ISCOMs and other saponin based 
adjuvants. Adv Drug Deliv Rev. Jul 6;32(3):247 -271 (1998). 
Crober, D. Effect of De-oderase on ammonia levels in a deep pit cage layer 
house. In: Biotechnology in the Feed Industry. Loyns, T. P. (ed.). Altech. 
Nicholasville, KY. 367-8 (1991 ). 
Dalsgard, K.; Thinlayer chroatographic Fingerprinting of Commercially available 
saponins. Dansk Tidsskrift for Farmci. 44 (8): 327-31 (1970). 
Dalsgaard, K. Saponin adjuvants Ill. Isolation of a substance from Quillaja 
saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. 
Arch. Gesante Virusforsch. 44: 243-54 (1974). 
da Fonseca, D. P., Frerichs, J., Singh, M., Snippe, H., and Verheul, A F. 
Induction of antibody and T-cell responses by immunization with ISCOMS 
containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine. Aug 
15; 19(1 ): 122-31 (2000). 
211 
Defago, G., Role des saponines dans Ia resistance des pi antes aux maladies 
fongiques. Ber. Scweis. Bot. Ges., 87: 79-132 (1977) 
Deliyannis, G., Jackson, D. C., Dyer, W., Bates, J., Coulter A., Harling-McNabb, 
L., and Brown, L. E., lmmunopotentiation of humoral and cellular responses to 
inactivated influenza vaccines by two different adjuvants with potential for human 
use. Vaccine. Dec; 16(20):2058-68 (1998) 
Diwan, F. H., Abdei-Hassan, I. A., and Mohammed, S. T. Effect of saponin on 
mortality and histopathological changes in mice. East Mediterr Health J. 
Mar-May;6(2-3):345-51 (2000). 
Doman, B. and Costello, C. E. A Systematic Nomenclature for Carbohydrate 
Fragmentation in FARMS/MS of Glycoconjugates. Glycoconjugate J. 5: 397-409 
(1988). 
Donnelly, J. J. New developments in adjuvants. Mech Ageing Dev. Feb; 93(1-3): 
171-7 (1997). 
Dotsika, E. K., Sandquist, B., Morein, B., Morgan, A., and Villacres-Eriksson, M. 
C. Influence of Quillaja saponaria Triterpenoid Content on the 
212 
lmmunomodulatory Capacity of Epstein-Barr Virus lscoms. Scand .J. lmmunol. 
45: 261-68 (1997). 
Ennis, F. A, Cruz, J., Jameson, J., Klein, M., Burt, D., and Thipphawong, J. 
Augmentation of human influenza A virus-specific cytotoxic T lymphocyte 
memory by influenza vaccine and adjuvanted carriers (ISCOMS).Virology. Jul 
5;259(2):256-61 (1999). 
Espinet, R. G.; Nuevo Tipo de Vacuna Anti aftosa a Complejo Glucovirico. Gaeta 
Veterinaria, 13: 265-77 (1951 ). 
Estrada, A, Katselis, G. S., Laarveld, B., and Sari, B. Isolation and evaluation of 
immunological adjuvant activities of saponins from Polygala senega L. Camp 
lmmunol Microbial Infect Dis Jan;23(1 ):27-43 (2000). 
Erturk, M., Jennings, R., Phillpott, R. J. and Ptter, C. W.; Biochemical 
characterization of herpes simplex virus type-1-immunostimulating complexes 
(ISCOMs). Vaccine, 9: (1991 ). 
Evans, T. G., McElrath, M. J., Matthews, T., Montefiori, D., Weinhold, K., Wolff, 
M., Keefer, M. C., Kallas, E. G, Corey, L., Gorse, G. J., Belshe, R., Graham, B. 
213 
S., Spearman, P. W., Schwartz, D., Mulligan, M. J., Goepfert, P., Fast, P., 
Berman, P., Powell, M., and Francis, D. NIAID AIDS Vaccine Evaluation Group. 
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during 
HIV-1 envelope subunit immunization in humans. Vaccine. Feb 28;19 (15-16): 
2080-91 (2001 ). 
Evans, W. C. Trease and Evans' Pharmacognosy, 14th edn. WB Saunders 
Company Ltd. London, U.K. 304-5 (1996). 
Ford, C. H. J., Richardson, V. J., and Tsaltas., G. Comparison of tetrazolium 
colorimetric and [3H ]- uridine assays for in vitro chemosensitivity testing. Cancer 
Chemotherapeutic Pharmacology.24: 295-301. (1989) 
Fossum, C. Bengstrom-Mollaouglu, M., Lovgren, K., Watson, D. L. and Morein, 
B. Effects of iscoms and their adjuvant moiety (matrix) on the initial proliferation 
and 11-2 responses in vitro. Comparison of spleen cells from mice inoculated with 
iscoms and/or matrix. Cell. lmmunol. 129: 414-25 ( 1990). 
Francis, G., Kerem, Z., Makkar, H. P., and Becker, K. The biological action of 
saponins in animal systems: a review. Br J Nutr. Dec;88(6):587-605 (2002). 
Frebbe, L. M. and Bralley-Mullen, H. Immune potentiating effects of the 
adjuvants SGP and Quii-A. I. Antibody responses to T-dependent and 
T -independent antigens. Cell lmmunol. 99; 119 ( 1986). 
214 
Frebbe, L. M., and Bralley-Mullen, H. lmmuno potentiating effects of the 
adjuvants SGP and Quii-A. II. Identification of responding cell populations. 99; 
128(1986). 
Freund, J. The mode of action of immunologic adjuvants. Adv. Turbec. Res. 7: 
130-48 (1956). 
Furrie, E., Smith, R. E., Turner, M. W., Strobel, S., and Mowat, A M. Induction of 
local innate immune responses and modulation of antigen uptake as 
mechanisms underlying the mucosal adjuvant properties of immune stimulating 
complexes (ISCOMS).Vaccine. May 22;20(17-18):2254-62 (2002). 
Garuda International, Inc. Quillaja Extract Powder. [On-line] Available: 
http:/www.moocalium. com/dquil.htm (1999). 
Gaunt, I. F., Grasso, P., and Gangoli, S.D. Short term toxicity of quillaia extract 
in rats. Food Cosmet. Toxico., 12:641-650 (1974). 
Gebara, V. C., Petricevich, V. L., Raw, I. and da Silva, W. D. Effect of saponin 
from Quillaja saponaria (Molina) on antibody, tumour necrosis factor and 
interferon-gamma production. Biotechnol. Appl. Biochem. 21: 31-7 (1995). 
215 
George, A. J. Legal status and toxicity of saponins. Food Cosmet. Toxicol. 3: 
85-91 (1965). 
Gerwig G. J., Kamerling J. P., and Vliegenthart J. F., Determination of the D and 
L configuration of neutral monosaccharides by high resolution capillary g.l.c. 
Carbohydr. Res.62:349-357 (1978). 
Gerwig G. J., Kamerling J. P., and Vliegenthart J. F., Determination of the 
absolute configuration of mono-saccharides in complex carbohydrates by 
capillary G.L.C. Carbohydr. Res.Dec;77:10-7 (1979). 
Ghazi, H. 0., Erturk, M., Stannard, L. M., Faulkner, M., Potter, C. W., and 
Jennings, R. lmmunogenicity of influenza and HSV-1 mixed antigen ISCOMs in 
mice. Arch Virol.140(6):1015-31 (1995). 
Ghosh, S., Singh, N. K., and Rawat, P. Comparative immunopotentiating 
properties of saponin and incomplete Freund's adjuvant coupled to affinity 
purified larval antigen of Hyalomma anatolicum anatolicum. Indian J Exp Bioi. 
40(9): 1026-31 (2002). 
216 
Gizurason, S. Optimal Delivery of Vaccines: Clinical Pharmacokinetic 
Considerations. Clinic. Pharmacokinet., 30: 1-5 (1996). 
Goldsby, Richard A, Kindt, Thomas J., Osborne, Barbara, A, and Kuby, Janis. 
Kuby Immunology, Fourth edition, W.H. Freeman and Company. New York. 
USA, 303-327 (2000). 
Grieve, M.; Soap Tree. [On-line] Available:http:/www.botanical.com/botanical/mg 
mh/s/soaptr60.html (1995). 
Gregoriadis, G. Genetic Vaccines: Strategies for Optimization. Pharmaceutical 
Research, 15 (5): 661-70 (1998). 
Gu, L. C., Erdos, E. A, Chiang, H. S. Caldewood, T., Tsai, K., Visor, G. C., 
Duffy, J., Hsu, W. C. and Foster, L. C. Stability of interleukin 1 beta (IL-1 beta) in 
aqueous solution: Analytical methods, kinetics, products, and solution 
formulation implications. Pharm. Res. 8: 485-490 (1991 ). 
Guan, X. J., Guan, X. J, Wu, Y. Z., Jia, Z. C, Shi, T. D, and Tang, Y. 
Construction and characterization of an experimental ISCOMS-based hepatitis B 
polypeptide vaccine. World J Gastroenterol. Apr;8(2):294-7 (2002). 
217 
Guo, S., Kenne, L., Lundgren, L. N., Ronnberg, B., and Sundquist, B. G. 
Triterpenoid Saponins from Quilajja saponaria. Phytochemistry, 48 (1 ): 175-80 
(1998). 
Gupta, R. K., Relyveld, H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., and 
Gupta, C. K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 
11 (3): 293-306 (1993). 
Gupta, R. K. and Siber, G. R. Adjuvants for human vaccines-current status, 
problems and future prospects. Vaccine, 13: 1263-76 (1995). 
Hakomori, S. A rapid permethylation of glycolipids and polysaccharides 
catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide. J. Biochem. (Tokyo). 
Feb; 55: 205-208 (1964). 
Hancock, G. E., Speelman, D. J., Frenchick, P. A, Mineo-Kuhn, M. M., Baggs, 
R. B., and Hahn, D. J. Formation of the purified fusion protein of respiratory 
syncytial virus with the saponin QS-21 induces protective immune responses in 
Balb/c mice that are similar to those generated by experimental infection. 
Vaccine, 13 (4): 391-400 (1995). 
218 
Hancock, G. E., Heers, K. M., and Smith, J. D. QS-21 synergizes with 
recombinant interleukin-12 to create a potent adjuvant formulation for the fusion 
protein of respiratory syncytial virus. Viral lmmunol.13(4):503-9 (2000). 
Harrison, G. B., Shakes, T. R., Robinson, C. M., Lawrence, S. B., Heath, D. D., 
Dempster, R. P., Lightowlers, M. W., and Rickard, M. D. Duration of immunity, 
efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated 
with saponin or selected adjuvants. Vet lmmunol lmmunopathol. Sep 
20;70(3-4):161-72 (1999). 
Hassan, Y., Brewer, J. M., Alexander, J., and Jennings, R.; Immune responses in 
mice induced by HSV-1 glycoproteins presented as ISCOMs or NISV delivery 
systems. Vaccine, 14 (17/18): 1581-90 (1996). 
Herbert, W. J. Methods for the preparation of water-in-oil, and multiple, 
emulsions for the use as antigen adjuvants: and motes on their use in 
immunization procedures. In: Handbook of experimental Immunology. Weir, D. 
M. (ed.). Blackwell Scientific Publication. 1207-12 (1967). 
Highuchi, R., Tokimitsu, Y., Fujioka, T., Komori, T., Kawsaki, T., and Oakenful, 
D. G. Structure of Desacylsaponin Obtained from the Bark of Quillaja saponaria. 
Phytochemistry, 26 (1 ): 229-35 (1987). 
219 
Highuchi, R., Tokimitsu, Y. and Komori, T. An Acylated Saponin rom Quillaja 
saponaria. Pytochemistry, 27 (4): 1165-8 (1988). 
Hogland, S., Dalsgaard, K., Lovgren, K., Sundquist, B., Osterhaus, A, and 
Morein, B. lscoms and immunostimulation with viral antigen In: Subcellular 
Biochemistry. Harris J. R. (ed.) Plenium, N.Y. 39-68 (1989). 
Hoogerhout, P., Doners, E. M. L. M., van Gaans-van den Brink, J. A M., 
Kuipers, B., Brugghe, H. F., van Unen, L. M. A, Timmermans, H. A M., ten 
Hove, G. J., Jong, A P . J . M., Peters, C. C. A M., Wiertz, E. J. H. J., and 
Poolman, J. T. Conjugates of Synthetic Cyclic Peptides Elici Bactericidal 
Antibodies against a Conformational Epitope on a Class 1 Outer Membrane 
Protein of Neisseria meningitis. Infection and Immunity, 63 (9): 3473-8 (1995). 
Hora, M. S., Rana, R. K., Wilcox C. L., Katre, N. V., Hirtzer, P. Wolfe, S. M. N., 
and Thomson, J. W. Development of lyophilised formulation of interleukin-2. 
Dev. Bioi. Stand. 7 4: 295-303 (1992). 
Hoshi, S., Uchino, A, Saito, N., Kusanagi, K., lhara, T., and Ueda, S. 
Comparison of adjuvants with respect to serum lgG antibody response in orally 
immunized chickens. Comparative Immunology, Microbiology and Infectious 
Diseases, 22: 63-9 (1999). 
220 
Hostettmann, K. and Marston, A; Saponins: Chemistry and Pharmacology of 
Natural Products. Cambridge University Press. Cambridge, U. K. 327-29 (1995). 
Hu, K. F., Elvander, M., Merza., M., A kerblom, L., M Branderburg, A, and 
Morain, B. The immunostimulating complex (ISCOM) is an efficient mucosal 
delivery system for respiratory syncytial virus (RSV) envelope antigens inducing 
high local and systemic antibody responses. Clin. Exp. lmmunol.113:235 (1998). 
Hu, K. F., Chen, M., Abusugra, 1., Monaco, F., and Morain, B. Different 
respiratory syncytial virus and Quillaja saponin formulations induce murine 
peritoneal cells to express different proinflammatory cytokine profiles. FEMS 
lmmunol Med Microbial. Aug;31 (2): 105-12 (2001 ). 
Huber, M., Baier, W., Bessler, W. G., and Heinevetter, L. Modulation of the 
Th1/Th2 bias by lipopeptide and saponin adjuvants in orally immunized mice. 
lmmunobiology. Mar;205(1 ):61-73 (2002). 
losef, C., Van Nguyen, T., Jeong, K., Bengtsson, K., Morain, B., Kim, Y., Chang, 
K. 0., Azevedo, M. S., Yuan, L., Nielsen, P., and Saif, L. J. Systemic and 
intestinal antibody secreting cell responses and protection in gnotobiotic pigs 
immunized orally with attenuated Wa human rotavirus and Wa 
221 
2/6-rotavirus-like-particles associated with immunostimulating complexes. 
Vaccine. 2002 Mar 15;20(13-14):1741-53 (2002). 
lsconova, Innovative Vaccine Technology Development at lsconova AB. [Onine] 
Available: http://www. wnrc. com/busi nessbriefing/pdf/1 ifesciene2002/technology/l S 
CONOVA.pdf Printed July 9, (2003). 
Jacobsen, N. E., Fairbrother, W. J., Kensil, C. R., Lim, A., Wheeler, D. A., and 
Powell, M. F. Structure of the saponin adjuvant and its base-catalysed 
isomerization product by 1H and natural abundance 13C NMR spectroscopy. 
Carbohyd. Res. 280: 1-14 (1996). 
Jansson, P. E., Kenne, L., leigren, H., Lindberg, B., and Lonngren, J. A practical 
guide to methylation analysis of carbohydrates. Chem. Commmmun. 8: 1-75 
(1976). 
Jennemann, R., Bauer, B. 1., Bertalanfy, H., Selmer, T., and Wiegandt, H. 
Basidiolipids from Agaricus are Novel Immune Adjuvants. lmmunobiology, 200: 
277-89 (1999). 
222 
Jiang, B., Estes, M. K. Barone, C., Barniak, B., O'Neal, C. M., Attaino, A., 
Madore, H. P., and Conner, M. E. Hetertypic protection form rotavirus infection in 
mice vaccinated with virus-like particles. Vaccine, 17: 1005-13 (1999). 
Johansson, M. and Logren-Bengston, K.; lscoms with different Quillaja saponin 
components differ in their immunostimulating activities. Vaccine, 17 2894-2900 
(1999). 
Katayama, S., Oda, K., Ohgitani, T., Hirahara, T., and Shimizu, Y. Influence of 
antigenic forms and adjuvants on the lgG subclass antibody response to 
Aujeszky'S disease virus in mice. Vaccine, 17: 2733-39 (1999). 
Kensil, C. R., Patel, U., Lennik, M., and Marciani, D. Separation and 
Characterization of Saponins with Adjuvant Activity from Quillaja saponaria 
Molina Cortex. The Journal of Immunology, 146 (2): 431-7 (1991 ). 
Kensil, C. R., Soltysik, S., Patel, U., and Marciani, D. J. In Vaccines 92, Brown, 
F., Chancock, R. M. Ginsberg, H. S., and Lerner, R. A Eds., Cold Haber Spring 
Laboratory Press. New York, N.Y., pp 35-40 (1992). 
223 
Kensil, C. R., Wu, J-Y., and Soltysik, S. Structural and immunological 
characterization of the vaccine adjuvant QS-21. In: Vaccine Design: The Subunit 
Adjuvant Approach. Powell, M. F. and Newman, M. J. (eds.) Plenum Press, New 
York. Ch 22 (1995a). 
Kensil, C. R., Bedore, A, Cleland, J. L., Lim, A, Jacobsen, N., and Powell, M. F. 
Stability of QS-21 in aqueous solutions. Carbohydr. Res. (1995b). 
Kensil, C. R.; Saponins as Vaccine Adjuvants. Critical Review in Therapeutic 
Drug Carrier Systems. 13 (1-2) 1-55 (1996). 
Kensil, C ., Soltysik, S., Wheeler, D. A, and Wu, J-Y. Structure/Function Studies 
on QS-21. A Unique Immunological Adjuvant from Quillaja saponaria. Saponins 
used in Traditional and Modern Medicine. Edited by Walter and Yamasaki. 
Plenum Press. New York. 165-72 (1996). 
Kensil, C .R., Wu, J-Y., Anderson, C. A, and Wheeler, D. A QS-21 and QS-7: 
Purified Saponin Adjuvants. Brown, F. and Haahcim, L. R. (eds): Modulation of 
the Immune Response to Vaccine Antigens. Dev. Bioi. Stand. Basel, Karger, 92: 
41-7 (1998). 
224 
Kenny, J. S., Hughes, B. W., Masada, M. P., and Allison, A. C. Influence of 
adjuvants on the quantity, affinity, isotype and epitope specificity of murine 
antibodies. J. lmmunol. Meth. 12: 157-66 (1989). 
Kersten, G. F. and Crommelin, D. J. Liposomes and ISCOMs. Vaccine. Feb 
14;21(9-10): 915-20 (2003). 
Kersten, G. F. A., van De Put, A-M., Teerlink, T., Beuery, E. C., and Crommelin, 
D .J. A.; lmmunogenecity of Liposomes and lscoms Containing the major Outer 
Membrane Protein of Neisseri gonorrhea: Influence of Protein Content and 
Liposomal Bilayer composition. Infection and Immunity, 56 (6): 1661-4 ( 1988a). 
Kersten, G. F. A., Teerlink, T., Derks, H. J. G. M., Verkleij, A. J., van Wezel, T. 
L., Crommelin D. J. A., and Beuery, E. C. Incorporation of the major outer 
membrane protein of Neisseria gonorrhea in saponin lipid complexes (iscoms): 
chemical analysis, some structural features and comparison of their 
immunogenicity with three other antigen delivery systems. Infection and 
Immunity 56: 432-8 (1988b). 
Kersten, G. F. A., Spiekstra, A., Beuvery, E. C. and Crommelin D. J. A. On the 
structure of immune-simulating saponin- lipid complexes (iscoms). Biochimica et 
Biophysica Acta, 1062: 165-171 (1991 ). 
225 
Kim, Y. J. and Gin, D. Y., Synthesis of the trisaccharide portion of the 
immunologic adjuvant QS-21A via sulfonium-mediated oxidative and dehydrative 
glycosylation. Org Lett. Jun 14;3(12): 1801-4 (2001 ). 
Konnings, S., Copland, M. J,. Davies, N. M., and Rades, T. A method for the 
incorporation of ovalbumin into immune stimulating complexes prepared by the 
hydration method. lnt J Pharm. Jul 25;241 (2):385-9 (2002). 
Korbert, R. Saponins: Their Properties, Composition and Uses. The 
Pharmaceutical Journal and Pharmacist, 86: 244-5,293-4 (1911 ). 
Labriola, R. A and Deulofeu, V. A Structure of Prosapogenin from Quillaja 
Saponin. Experentia, 25 (2): 124-125 (1969). 
Leontein, K., Lindberg, B., and Lonnberg, J. Assignment of absolute 
configuration of sugars by g.l.c. of acetylated glycosides formed from chiral 
alcohols. Carbohydr. Res 62: 359-362 (1978). 
Leung, Y-M., Ou, Y-J., Kwan, C-Y., and Loh, T-T. Specific interaction between 
tetradine and Quillaja saponins in promoting permeabilization of plasma 
membrane in human leukemic HL-60 cells. Biochemica et Biophysica Acta, 
1325: 318-28 (1997). 
226 
Lipford, G. B., Wagner, H., and Heeg, K. Vaccination with immonodominant 
peptides ecapsulated in Quii-A-containing liposomes induces peptide- specific 
primary CDS+ cytotoxic T-cells. Vaccine. 12 (1 ): 73-80 (1993). 
Liu, G., Anderson, C., Scaltreto, H., Barbon, J., and Kensil, C. R. QS-21 
structure/function studies: effect of acylation on adjuvant activity.Vaccine. 
Jun21 ;20 (21-22): 2808-15 (2002). 
Livingston, P. 0., Adluri, S., Helling, F., Yao, T-J., Kensil, C. R., Newman, M. J., 
and Marciani, D. Phase I trial of the immunological adjuvant QS-21 with a GM2 
ganglioside-KLH conjugate vaccine in patients with malignant melanoma. 
Vaccine. 12: 1275-80 (1994). 
Lovgren, K. The serum antibody response distribution in subclass and isotypes 
after intra nasal and subcutaneous immunization with influenza virus 
immunostimulating complexes (iscoms). Scand J. lmmunol., 27: 241-5 (1988). 
Lovgren, K. and Morein, B. The requirement of lipids for the formation of 
immunostimulating complexes (lscoms). Biotechnol. Appl. Biochem. 10: 161-72 
(1988). 
227 
Lunden, A., Wright, S., Allen, J. E., and Buxton, D. Immunisation of mice against 
neosporosis. lnt J Parasitol. Jun 15;32(7):867-76 (2002). 
Maharaj, 1., Froh, K. J., and Campbell, J. B. Immune responses of mice to 
inactivated rabies vaccine administered orally: potentiation by Quillaja Saponin. 
Can. J. Microbial. 32: 414-420. (1986) 
Maillard., M. P. and Hosttettman, K., Determination of saponins in crude plant 
extracts by liquid chromatography- thermospray mass spectrometry. J. of 
Chromate. 647, 137-146 (1993). 
Makkar, H. P. S. and Becker, K. Effect of Quillaja saponin on In vitro Rumen 
Fermentation. Saponins used in Food and Agriculture. Edited by Walter and 
Yamasaki. Plenum Press. New York. (1996). 
Makkar, H. P. S. and Becker, K. Degradation of Quillaja saponins by mixed 
culture of rumen microbes. Letters in Applied Microbiology, 25: 243-5 (1997). 
Makkar, H. P. S., Sen, D., Blummel, M., and Becker, K. Effects of Fractions 
Containing Saponins from the Yucca Schidigeru, Quillaja saponaria and Acacia 
auriculiformis on Rumen Fermentation. J. Agric. Food Chem., 46: 4324-4328 
(1998). 
228 
Marchand, M., Punt, C. J,. Aamdal, S., Escudier, B., Kruit, W. H., Keilholz, U., 
Hakansson, L., van Baren, N., Humblet, Y., Mulders, P., Avril, M. F., Eggermon,t 
A. M., Scheibenbogen, C., Uiters, J., Wanders, J., Delire, M,. Boon, T., and 
Stater, G. Immunisation of metastatic cancer patients with MAGE-3 protein 
combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. Jan;39(1 ):70-7 
(2003). 
Marciani, D. J., Press, J. B., Reynolds, R. C., Pathak, A. K, Pathak, V., Gundy, L. 
E., Farmer, J. T., Koratich, M. S., and May, R. D. Development of semisynthetic 
triterpenoid saponin derivatives with immune stimulating activity. Vaccine. Jul 
15;18(27):3141-51 (2000). 
Marciani, D. J., Ptak, R. G., Voss, T. G., Reynolds, R. C., Pathak, A. K., 
Chamblin, T. L., Scholl, D. R., and May, R. D. Degradation of Quillaja saponaria 
Molina saponins: Loss of the protective effects of a herpes simplex virus 1 
subunit vaccine. lnt lmmunopharmacol. Nov;2(12): 1703-11 (2002a). 
Marciani, D. J., Pathak, A. K., and Reynolds, R. D. Quillaja saponin adjuvants: 
Derivatives formed under sub-optimal conditions. Vaccine. Sep 
1 0;20(27 -28):3237 -8 (2002b). 
229 
Martin, T. J., Enhanced immunogenicity of chiron bioline adjuvanted influenza 
vaccine in the elderly. In: Brown LE, Hampson AW, Webster RG, editors. 
Proceedings of the 3rd international Conference on Options for the control of 
Influenza 3. Amsterdam: Elsvier; p 647-52 (1996) 
McClintock, E. Trees of Golden Gate Park: Three from South America. The 
Journal of the Pacific Horticulture Foundation, 45 (1 ): 18-20 (1984). 
McCiuskie, M. J. and Weeratna, R. D. Novel adjuvant systems. Curr Drug 
Targets Infect Disord.Nov; 1 (3):263-71 (2001 ). 
Mcinerney, T. L., Brennan, F.R,. Jones, T. D., and Dimmock, N. J. Analysis of 
the ability of five adjuvants to enhance immune responses to a chimeric plant 
virus displaying an HIV-1 peptide. Vaccine. (1999) Mar 17; 17(11-12): 1359-68. 
McNeal, M. M., Rae, M. N., Conner, M. E., and Ward, R. L. Stimulation of local 
immunity and protection in mice by intramuscular immunization with triple- or 
double-layered rotavirus particles and QS-21.Virology. Mar 30; 243 (1 ): 158-66 
(1998). 
230 
McNeal, M. M., Rae, M. N., and Ward, R. L. Effects of different adjuvants on 
rotavirus antibody responses and protection in mice following intramuscular 
immunization with inactivated rotavirus. Vaccine. Mar 17;17(11-12):1573-80 
(1999). 
Meyer, V. R. Practical High-Performance Liquid Chromatography, 3rd Ed., 
Wiley, New York, (1999). 
Mimaki, Y., Yokosuka, A, Kuroda, M., and Sashida, Y. Cytotoxic activities and 
structure-cytotoxic relationships of steroidal saponins. Bioi. Pharm. Bull. 
Nov;24( 11 ): 1286-9 (2001 ). 
Mitra, S. and Dungan, S. R. Micellar Properties of Quillaja Saponin. 1. Effects of 
Temperature, Salt, and pH on Solution Properties. J. Agric. Food Chem., 45: 
1587-95 (1997). 
Molina, J. I. Essai sur L. Histoire Naturelle du Chili. Vol. ii. p.337 (1782). 
Moore, A, McCarthy, L., and Mills, K. H. The adjuvant combination 
monophosphoryl lipid A and QS21 switches T cell responses induced with a 
soluble recombinant HIV protein from Th2 to Th1. Vaccine. Jun 
4;17(20-21):2517-27 (1999). 
231 
More in, B., Sundquist, B., Hoglund, S., Daalsgaard, K., and Osterhaus, A., 
lscom, a novel structure for antigenic presentation of membrane proteins from 
enveloped viruses. Nature. Mar 29-Apr 4;308(5958):457-60 (1984). 
Morein, B., Villacre-Eriksson, M., and Lovgren-Bengston, K.; lscom, a Delivery 
System for Parenteral and Mucosal Vaccination. Dev. Bio. Stand, 92: 33-9 
(1998). 
Murray, R .. , Cohen, P., and Hardegree, M. C. Mineral oil adjuvants: Biological 
and chemical studies. Ann. Allergy 30: 146-51 (1972). 
Nakamura, T., Takeda, T., and Oghara, Y. Studies on the constituents of 
Calliandra anomala (Kunth) Macbr.ll. Structure elucidation of four acylated 
triterpenoidal saponins. Chem. Pharm. Bull 42: 1111-15 (1994). 
Nord, L. I. and Kenne, L. Separation and structural analysis of saponins in a bark 
extract from Quillaja saponaria Molina. Carbohyd. Res. 320: 70-81 (1999). 
Nyberg, N. T., Kenne, L.,Ronnberg, B., and Sundquist, B. G. Separation and 
structural analysis of some saponins in a bark extract from Quillaja saponaria 
Molina. Carbohydrate Research, 320: 70-81 (1999). 
232 
Oda, K., Matsuda, H., Murakami, T., Katayama, S., Ohgitani, T., and Yoshikawa, 
M. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and 
food plants.Biol Chem.Jan;381(1):67-74 (2000). 
Paykari H., Dalimi, A, and Madani, R. Immunization of sheep against Fasciola 
gigantica with glutathione S-transferase. Vet Parasitol. Apr 30; 1 05(2): 153-9 
(2002). 
Perret, C ., Wolfender, J. L., and Hostettmann, K. LC/ES-MS analysis of 
triterpene glycosides: Rapid Estimation of the saponin content of dried berries of 
Phytolacca dodecandra. Phytochemical analysis 10, 171-278 (1999). 
Phillips, J. C., Butterworth, K. R., Gaunt, . 1.. F., Evans, J. G., and Grasso, P. 
Long-term toxicity study of quillaja extract in mice. Food Cosmet. Toxicol., 17: 23-
27 (1979). 
Pietrobon, P. J. F. and Kanda, P. Lipopeptides and Their Effects on the Immune 
System- Uses as Vaccine Components. In: Vaccine Research and 
Developments. Koff, W. C. and Six, H. R. (eds.). Marcel Decker, Inc. New York, 
N. Y. USA 1: 3-42 (1992). 
233 
Pillion, D. J., Recchia, J., Wang, P., Marciani, D. J. and Kensil, C. R.; DS-1, a 
Modified Quillaja Saponin, Enhances Ocular and Nasal Absorption of Insulin. J. 
Pharm. Sci., 84 (11): 1276-9 (1995). 
Pillion, D. J., Amsden, J. A., Kensil, C. R. and Recchia, J. Structure-Function 
Relationship among Quillaja Sapoinns Serving as Excipients for Nasal and 
Ocular Delivery of Insulin. J. Pharm. Sci., 85 (5): 518-24 (1996). 
Potter, M. and Boyce, C. R. Induction of plasma cell neoplasm in strain BALB/c 
mice with mineral oil and mineral oil adjuvants. Nature 193: 1086-87 (1962). 
Potter, M. and MacCardle, R. C. Histology of developing plasma cell neoplasia 
induced by mineral oil in BALB/c mice. J. Natl. Cancer lnst.33: 497- 515 (1964). 
Prado, J. A., Peters, R. and Agiure, S. Biomass Equations for Quillay. (Quillaja 
saponaria Molina) in the Semiarid Region of Central Chile. Forest Ecology and 
Management, 16: 41-47 (1986). 
Price, K. R., Johnson, I. T. and Fenwick, G. R. The chemistry and biological 
significance of saponins in food and feeding stuff. CRC Crit. Rev. Food Sci. Nutr. 
26: 27-135 (1987). 
234 
Qiao, M., Murata, K., Davis, A. R., Jeong, S. H., and Liang, T. J. Hepatitis C 
virus-like particles combined with novel adjuvant systems enhance virus-specific 
immune responses. Hepatology. Jan;37(1 ):52-9 (2003). 
Ragupathi, G., Meyers, M,. Adluri, S., Howard, L., Musselli, C., and Livingston, P. 
0. Induction of antibodies against GD3 ganglioside in melanoma patients by 
vaccination with GD3-Iactone-KLH conjugate plus immunological adjuvant QS-21. 
Int. J. Cancer. Mar 1 ;85(5):659-66 (2000). 
Ramon, G. Precedes pour accroitre Ia production des antioxines. Ann. lnst. 
Pasteur 40: 1-10 (1926). 
Rao, A. V., and Gurfinkel, D. M. The bioactivity of saponins: triterpenoid and 
steroidal glycosides. Drug. Metabol. Drug. Interact. 17(1-4):211-35 (2000). 
Recchia, J., Lurantos, M. H. A., Amsden, J. A., Storey, J. and Kensil, C. R.; A 
Semisynthetic Quillaja Saponin as a Drug Delivery Agent for Amino Glycoside 
Antibiotics. Pharmaceuti. Res. 12 ( 12): 1917-23 ( 1995). 
Rimmelzwaan, G. F., Baars, M,. van Seek, R., van Amerongen, G., 
Lovgren-Bengtsson, K., Claas, E. C., and Osterhaus, A D. Induction of 
235 
protective immunity against influenza virus in a macaque model: comparison of 
conventional and iscom vaccines. J. Gen. Viral. Apr;78 ( Pt 4):757 -65 (1997). 
Rimmelzwaan, G. F., Claas, E. C., van Amerongen, G., de Jong, J. C., and 
Osterhaus, A D. ISCOM vaccine induced protection against a lethal challenge 
with a human H5N1 influenza virus. Vaccine. Mar 17; 17(11-12): 1355-8 (1999 ). 
Robson, N. C., Beacock-Sharp, H., Donachie, A M., and Mowat, A M. Dendritic 
cell maturation enhances CDS+ T-cell responses to exogenous antigen via a 
proteasome-independent mechanism of major histocompatibility complex class I 
loading. Immunology. Jul; 1 09(3):37 4-83 (2003). 
Rocher, Y. Isolation of saponins from Ficadia ranunculoides. Chemi. Abs. 64: 
6418a (1965). 
Ronnberg, B., Fekadu, M. and Morein, B.; Adjuvant activity of non-toxic Quillaja 
saponaria Molina components for use in ISCOM matrix. Vaccine, 13 (14): 
1375-82 (1995). 
Ronnberg, B., Fekadu, M., Behboudi, S., Kenne, L. and Morein, B.; Effects of 
carbohydrate modification of Quillaja saponaria Molina QH-B fraction on the 
236 
adjuvant activity, cholesterol-binding capacity and toxicity. Vaccine, 15 (17/18): 
1820-25 (1997). 
Rouessac, F. and Rouessac, A Chemical analysis : modern instrumental 
methods and techniques. English ed. Translated by Michel Bertrand and Karen 
Waldron. Chichester; Toronto; Wiley; 127-160 (2000). 
Sabbatini, P. J., Kudryashov, V., Ragupathi, G., Danishefsky, S. J., Livingston, P. 
0., Bornmann, W., Spassova, M., Zatorski, A, Spriggs, D., Aghajanian, C., 
Soignet, S., Peyton, M., O'Fiaherty, C., Curtin, J., and Lloyd, K. 0. Immunization 
of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a 
phase 1 trial. Int. J. Cancer. Jul 1 ;87 (1 ): 79-85 (2000). 
Santos, W. R., Bernardo, P. R., Pecanha, L. M., Palatnik, M., Parente, J. P. and 
de Sousa C. B. Hemolytic activities of plant saponins and adjuvants. Effects of 
periandra mediterranea saponin on the humoral response to the FML antigen of 
Leishmania donovani. Vaccine, 15: 1024-9 (1997). 
Sasaki, S., Sumino, K., Hamajima, K., Fukushima, J., Ishii, N., Kawamoto, S., 
Mohri, H., Kensil, C. R., and Okuda, K. Induction of systemic and mucosal 
immune responses to human immunodeficiency virus type 1 by a DNA vaccine 
237 
formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. 
J. Virol. Jun;72(6):4931-39 (1998). 
Schope, Th., Hiller, K. Wray, V. and Nimtz, M. Applications of MS-MS for the 
Rapid, Comparative Analysis of Saponin Mixture as Exemplified by the 
Deacylated and Partially deacylated Triterpenoid Saponins of Bellis annua. 
Planta Medica, 62; 336-40 (1996). 
Sen, S., Makkar, H. P. S.,Muetzel, S. and Becker, K. Effect of Quillaja saponaria 
saponins and Yucca schidiger plant extract on growth of Escherichia coli. Letters 
in Appl. Microbial. 27: 35-8 (1998). 
Shu, Q., Hillard, M. A, Bindon, B. M., Duan, E., Xu, Y., Bird, S. H, Rowe, J. B, 
Oddy, V. H., and Gill, H. S. Effects of various adjuvants on efficacy of a vaccine 
against Streptococcus bovis and Lactobacillus spp in cattle. Am. J. Vet. Res. 
Jul;61 (7): 839-43 (2000). 
Shu, Q., Bir, S. H., Gill, H. S, Duan, E., Xu, Y., Hiliard, and Rowe, J. B. Antibody 
response in sheep following immunization with Streptococcus bovis in different 
adjuvants. Vet. Res. Commun. Jan;25(1 ):43-54 (2001 ). 
238 
Simms, J. R., Heath, A. W., Richardson, V. J., and Jennings, R. Large scale 
comparison of adjuvant effects on immunogenicity and protection in a herpes 
simplex virus type1 vaccination model. Biochem Soc Trans May;25(2):272 
(1997). 
Simms, J. R., Heath, A. W., Richardson, V. J., and Jennings, R. Humoral 
response to HSV-1 subunit vaccines--a statistical analysis. Oev Bioi Stand., 92: 
335- 40 (1998). 
Simms, J. R., Heath, A. W., and Jennings, R. Use of herpes simplex virus (HSV) 
type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary 
and recurrent HSV-2 infection in guinea pigs. J Infect Dis. Apr; 181 (4): 1240-8 
(2000). 
Simms, J. R., Jennings, R., Richardson, V. J., and Heath, A. W., Large-scale 
comparison of experimental adjuvants with herpes simplex virus vaccine reveals 
a correlation of protection with lgG2a and lgG2b responses. J Med Viral. 
Sep;68(1 ):82-91 (2002). 
Simoes, C. M., Amoros, M., and Girre, L. Mechanism of antiviral activity of 
triterpenoid saponins. Phytother. Res. Jun;13(4):323-8 (1999). 
239 
Singh, M., and O'Hagan, D. T. Recent advances in vaccine adjuvants. Pharm. 
Res. Jun; 19(6):715-28 (2002). 
Sjolander, A., Lovgren-Bengston, K., Johansson, M. and Morain, B.; Kinetics, 
Localization and lsotype Profile of Antibody Responses to Immune Stimulating 
Complexes (lscoms) Containing human Influenza Virus Envelope Glycoproteins. 
Scan. J. lmmunol., 43: 164-72 (1996). 
Sjolander, A., Lovgren-Bengston, K. and Morain, B. Kinetics, localization and 
cytokine profile of T cell responses to immune stimulating complexes (iscoms) 
containing human influenza virus envelope glycoproteins. Vaccine, 15 (9): 
1030-8 (1997a). 
Sjolander, A., van't Land, B. and Lovgren-Bengston, K. lscoms Containing 
Purified Quilaja Saponins Upregulate both Th1-like and Th2-like Immune 
Responses. Cellular Immunology, 177: 69-76 (1997b). 
Sjolander, A., and Cox, J. C. Uptake and adjuvant activity of orally delivered 
saponin and ISCOM vaccines. Adv. Drug Deliv. Rev. Dec 1 ;34(2-3):321-338 
(1998). 
240 
Sjolander, A., Cox, J. C., and Bar,r I. G. ISCOMs: An adjuvant with multiple 
functions. J. Leukoc. Bioi. 1998 Dec;64(6):713-23.(1998a). 
Sjolander, A,. Ahlberg, N., Stahl, S., and Andersson, R. Characterization of 
immune responses to experimental polyvalent subunit vaccines assembled in 
iscoms. Mollmmunol. Feb;35(3):159-66 (1998b). 
Sjolander, S., Drane, B., Davis R., Beezum L., Pearse., and Cox, J. Intranasal 
immunization with influenza-ISCOM induces strong mucosal as well as systemic 
antibody and cytotoxic T -lymphocyte responses. Vaccine 19; 4072-80 (2001 ). 
Slingluff, C. L. Jr., Yamshchikov, G., Neese, P., Galavotti, H., Eastham, S., 
Engelhard, V. H., Kittlesen, D., Deacon, D., Hibbitts, S., Grosh, W. W., Petroni, 
G., Cohen, R., Wiernasz, C., Patterson, J. W., Conway, B. P., and Ross, W. G. 
Phase I trial of a melanoma vaccine with gp1 00(280-288) peptide and tetanus 
helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer. 
Res. Oct;7(1 0):3012-24 (2001 ). 
Smith, R. E., Donachie, A. M,. Grdic, D., Lycke, N., and Mowat, A. M. 
Immune-stimulating complexes induce an IL-12-dependent cascade of innate 
immune responses. J. lmmunol. May 1;162(9):5536-46 (1999). 
241 
Snyder, L. R., Glajch, J. L., & Kirkland, J. J. Practical High Performance Liquid 
Chromatography Method Development, Wiley, NY. (1988). 
Snyder, L. R., Kirkland, J. J., and Glajch, J. L. Practical HPLC Method 
Development, Wiley, NY. (1997). 
So, H-S., Yoon, H-S., Choi, D-Y., Kwon, Y-S., Sung, J-H., Lee. G. T., Park, E-S., 
Cho, H-S., Lee, B. M., Cho, J. M. and Ryu, W-S. Effects of a Novel Saponin 
Adjuvant Derived from Quillaja saponaria on the Immune response to 
Recombinant Hepatitis B Surface Antigen. Molecules and Cells 7 (2): 178-86 
(1997). 
Soltysik, S., Bedore, D. and Kensil, C. R. Adjuvant Activity of QS-21 Isomers. In: 
Specific immunotherapy of cancer with vaccine. Bijstijn, Ferrone and Livingston. 
(eds.) Annals New York Aca. Sci. 690: 392-5 (1993). 
Soltysik, S., Wu, J-Y., Rechhia, J., Wheeler, D. A, Coughlin, R. T. and Kensil, C. 
R. Structure/function studies of QS-21 adjuvant: assessment of triterpene 
aldehyde and glucoronic acid roles in adjuvant function. Vaccine, 13 (15): 
1403-1 0 ( 1 995). 
242 
Spickler AR, Roth JA Adjuvants in veterinary vaccines: modes of action and 
adverse effects. J Vet Intern Med., May-Jun; 17(3):273-81 (2003). 
Spiegelberg, H. L. Biological activities of immunoglobulins of different classes 
and subclasses. Advances in Immunology, 19: 259-94 (197 4). 
Steinbeck, C., Schneider, C., Rotscheidt, K., and Breitmaier, E. A 4-Methyl -7-
hydroxyphthalide Glycoside and other Constituents From Quillaja saponaria 
Molina. Phytochemistry, 40: 1313-15 (1995). 
Stittelaar, K. J., Boes, J., Kersten, G. F., Spiekstra, A, Mulder, P. G., de Vries, P., 
Roholl, P. J., Dalsgaard, K., van den Dobbelsteen, G., van Alphen, L., and 
Osterhaus, A D. In vivo antibody response and in vitro CTL activation induced by 
selected measles vaccine candidates, prepared with purified Quii-A components. 
Vaccine. May 22; 18(23):2482-93 (2000). 
Takamashi, H., Takishita, T., Morein, B. Putney, S., Germain, R. N. and Berzofky, 
J. A Induction of CD8+ cytotoxic cells by immunization with purified HIV-1 
envelope protein in ISCOMS. Nature, 344: 873-5 (1990). 
Tanaka, 0., Tamura, Y., Masuda, H. and Mizutani, K. Application of saponins in 
243 
foods and cosmetics: saponins of Yucca and Sapindus mukurossi. In: saponins 
used in food and agriculture. Walter and Yamakatsi (eds.).Pienum Press, New 
York. (1996). 
Taniyama, T., Yoshikawa, M .. , and Kitagawa, 1., Saponin and sapogenol. XLIV. 
Soya saponin composition in soybeans of various origins and soya saponin 
content in various organs of soybean . Structure of soya saponin V from soybean 
hypocotyl. Yakugaku Zashi, 108: 562-571 (1988). 
ten Hagen, T. L. M., Sulzer, A J., Kidd, M. R., Lal, A A and Hunter, R. L. Role of 
adjuvants in the modulation of antibody isotype, specificity and induction of 
protection by whole blood stage Plasmodium yeolii vaccines. J immunol. 151: 
7077-85 (1993). 
Thompson, A Isolation and structural characterization of a triterpenoid saponin 
from Quillaja saponaria Molina. Unpublished manuscript. Memorial University of 
Newfoundland, St Johns. N. L. Canada. (1998). 
Trease, G. E. and Evans, W. C. Pharmacognosy, 1Oth edn. Williams and Wilkins 
Company, Baltimore. U. S. A 435-6 (1972). 
Valensi, J-P. M., Carlson, J. R. and Van Nest, G. A Systemic Cytokine Profiles in 
BALB/c Mice lmmunised with trivalent Vaccine Containing MF59 Oil Emulsion 
244 
and other Advanced Adjuvants. The Journal of Immunology, 153: 4029--39 
(1994 ). 
van Binnendijk, R. S., van Baalem, C. A., Poelem, M. C., de Vries, P., Bees, J., 
Cerundolo, V., Osterhus, A. D. and UytdeHaag, F. G. Measles Virus 
Transmembrane Fusion Protein Synthesized De Novo or Presented in 
lmmunostimulating Complexes Is Endogenously Processed for HLA Class 1- and 
HLA Class !-restricted Cytotoxic T-cell Recognition. J. Exp. Med. 176: 119-28 
(1992). 
van Setten, D. C. and van de Werken, G. Monomer mapping a pc-based software 
tool facilitating the determination of monomer composition from mass 
spectrometric molecular weight data. Rapid Commun. Mass Spectrom. 8: 917-9 
(1994). 
van Setten, D. C., van de Werken, G., Zomer, G., and Kersten, G. F. A. Glycosyl 
Composition and Structural Characteristics of the Potential Immune-Adjuvant 
Active Saponins in Quil/ja saponaria Molina Extract Quii-A. Rapid 
Communications in Mass Spectrometry, 9: 660-66 (1995). 
van Setten, D. C. and van de Werken, G. Molecular Structure of Saponins from 
245 
Quillaja saponaria Molina. Saponins used in Traditional and Modern Medicine. 
Edited by Walter and Yamasaki. Plenum Press. New York. (1996). 
Varshney, I. P., Beg, M. F. A, and Sankaram, A V. B. Saponins and sapogenins 
from Quillaja saponaria. Fitoterapia56: 254-56 (1985). 
Verschoor, E. J., Mooij, P., Oostermeijer, H., van der Kolk, M., ten Haaft, P., 
Verstrepen, B., Sun, Y., Morein, B., Akerblom, L., Fuller, D. H., Barnett, S. W., 
and Heeney,. J. L. Comparison of immunity generated by nucleic acid-, MF59-, 
and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus 
macaques: evidence for viral clearance. J. Viral., Apr;73(4): 3292-300 (1999). 
Villacres-Eriksson, M. C., Bengstrom-Mollaouglu, M., Kaberg, H. and Morein, B. 
Involvement of interleukin-2 and interferon gamma in the immune response 
induced by influenza virus iscoms. Scand. J. lmmunol., 36: 421-6 (1992). 
Villacres-Eriksson, M. C., Bengstrom-Mollaouglu, M., Kaberg, H., Lovgren, K., 
and Morein, B. The induction of cell-associated and secreted intrleukin-1 by 
iscoms, matrix or micelles in murine splenic cells. Clin. Exp. immunol. 93: 120-5 
(1993). 
Villacres-Eriksson, M. C., Behboudi, S., Morgan, A. J., Trinchieri, G., and Morein, 
B. lmmunomodulation by Quillaja saponaria Adjuvant Formulations: In vivo 
246 
Stimulation of lnterleukin -12 and Its Effects on the Antibody Response. Cytokine, 
9 (2): 73-82 (1997). 
Vogel, F. R. and Powell, M. F. A compendium of vaccine adjuvants and excipi-
ents, In: Vaccines Design: The Subunit and Adjuvant Approach, Powell and 
Newman (eds.). Plenum Press, New York, 141 (1995). 
Vogel, F. R., Powell, M. F. And Alving, C. R A compendium of vaccine adjuvants 
and excipients. [on-line] Available;http://vrc.nih.gov/daids/vaccine/pdf/compeium. 
pdf 
Wallis, T. E. Textbook of Pharmacognosy, (5th edn.), J. & A. Churchill Ltd, 
London (1967). 
Watson, D., Watson, N., Fossum, C. Lovgren, K., and Morein, B. Interactions 
between immune stimulating complexes (iscoms) and peritoneal mononuclear 
leukocytes. Microbial. lmmunol., 35: 199-203 ( 1992). 
White, A. C., Cloutier, P., and Coughlin, R. T. A Purified Saponin Acts as an 
Adjuvant for T-lndependent Antigen. Advances in Experimental Medicine and 
Biology, 303: 207 210 (1991 ). 
Wolfender J. L., Maillard., M., and Hostettmann, K. Liquid chromatography -
Thermospray mass spectrometric analysis of crude plant extracts containing 
247 
phenolic and terpene glycosides. Journal of Chromatography. 647: 183-190 
(1993). 
Wu, B. Recent development of studies on traditional Chinese medicine in 
prophylaxis and treatment of AIDS. J Tradit Chin Med. Mar; 12(1 ): 10-20. (1992). 
York, W. S., darvill, A G., McNeil, M., Stevenson, T. T., and Albertsheim, P., 
Isolation and characterization of plant cell walls and cell wall components. In 
Methods in Enzymology. Vol. 118. Academic Press Inc., New York. NY (USA) 
pages 3-40 (1985). 
248 




